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Abstract
Traditionally atherosclerosis has been considered merely as a lipid storage disease. It has
been known that the excess lipid molecules accumulate in the artery walls, which
eventually leads to narrowing of the lumen. Nowadays it is also known that
atherosclerosis is a chronic inflammatory process that will develop over decades of
human life. During that process the artery wall loses its normal function. The feared end-
points of atherosclerosis are cardiovascular diseases, which are the main reasons for
disability and mortality in the world. Typical atherosclerotic risk factors have been
known for decades: age, male sex, smoking, diabetes, high blood pressure and high
cholesterol values. In addition to these traditional risk factors many inflammatory
parameters have been shown to be increased in cardiovascular disease patients as well in
people who had atherosclerotic changes in the arteries. The C-reactive protein (CRP)
especially has been shown to be a significant independent biomarker. It has also been
shown that preventive treatment for patients with increased CRP values is beneficial.
Many other inflammatory markers or immunity mediators have been related to
atherosclerosis and cardiovascular disease risk. However, only limited information exists
about the role of these factors in healthy people and whether they can be considered as
independent risk factors for early atherosclerosis.
Data from two large Finnish cohorts were used in this dissertation. The Cardiovascular
Risk in Young Finns Study, an ongoing follow-up study involving participants between
24 and 39 years of age in the 21-year follow-up conducted in 2001 (n=2,283).
Inflammatory markers, CRP and serum amyloid A (SAA), as well as cytomegalovirus
(CMV) antibodies were measured from the participants of the Cardiovascular Risk in
Young Finns Study. In the data analysis we found that CRP levels were significantly
higher in those women who used combined oral contraceptives. Triglyceride levels were
also elevated in combined oral contraceptive users and triglyceride levels were associated
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with elevated CRP levels. Additionally, the effect of oral contraceptive use on CRP levels
was so decisive that it overwhelmed the effect of CRP genetics on CRP values. Increased
SAA concentrations were also associated with use of combined oral contraceptives.
Interestingly, the use of an intrauterine device was associated with decreased SAA
values. SAA levels were also associated directly with body mass index, leptin (a hormone
secreted by adipose tissue) and with HDL cholesterol or its surface apoliprotein-A1. SAA
levels correlated with early vascular changes but these associations were not independent
in multivariate models. Decrease in heart rate variability has been shown to be a marker
of dysregulation of the autonomic nervous system. We demonstrated that heart rate
variability is independently associated with CRP but not with SAA levels. High CMV
antibody titers was shown to be related with blood pressure values and inversely with
endothelial function in men. These relations were not seen in women.
The Health 2000 Study included 1,867 participants between 46 to 76 years of age. PTX3
levels were measured from the participants of the Health 2000 Study. PTX3 levels were
associated with atherosclerotic risk factors, including LDL cholesterol levels, pulse
pressure and indoleamine 2,3 dioxygenase levels. There was no relation between early
vascular changes and PTX3 values.
In conclusion, measured inflammatory markers were related to several atherosclerotic
risk factors such as metabolic and blood pressure values. However, only high CMV
antibody levels were independently associated with unfavourable changes in vascular
function.
12
Tiivistelmä
Perinteisesti ateroskleroosin ajateltiin olevan ainoastaan rasva-aineenvaihdunnan häiriö,
jossa rasvamolekyylit kertyvät ylimäärin valtimoseinämään aiheuttaen valtimon seinämän
paksuuntumisen. Nykytiedon valossa ateroskleroosin tärkeänä osana on myös hidas
vuosikymmeniä kestävä tulehduksellinen prosessi, jonka aikana normaali valtimoseinämä
menettää vähitellen luonnollisen toimintakykynsä. Sen pelätyt seuraukset ovat sydän- ja
verisuonitaudit, mitkä ovat suurin syy toimintakyvyttömyydelle ja kuolleisuudelle
maailmassa. Ateroskleroosin tyypilliset riskitekijät ovat olleet tiedossa vuosikymmenien
ajan: korkea ikä, mies sukupuoli, tupakointi, diabetes, korkeat verenpainearvot ja
kohonneet kolesteroliarvot. Näiden perinteisten riskitekijöiden lisäksi monien
tulehdusmerkkiaineiden kohonneita pitoisuuksia on mitattu sydän- ja
verisuonitautipotilailta kuten henkilöiltä, joilla on ateroskleroottisia muutoksia
valtimoissa. Erityisesti C-reaktiivisen proteiinin (CRP) pitoisuuksien on osoitettu olevan
merkittävä itsenäinen riskitekijä. Lisäksi uusimmat tutkimukset ovat osoittaneet, että
ennaltaehkäisevä hoito on hyödyllistä henkilöille, joilla CRP pitoisuudet ovat koholla.
Monien muidenkin tulehdusmerkkiaineiden ja immuuniparametrien on osoitettu olevan
yhteydessä ateroskleroosiin ja sydän- ja verisuonitauteihin. Kuitenkin
tulehdusmerkkiaineista ja niiden itsenäisistä yhteyksistä varhaisiin valtimotaudin
muutoksiin on vain vähän tietoa nuorilla aikuisilla.
Tutkimuksissamme käytimme kahta laajaa suomalaista aineistoa. Lasten ja nuorten
sepelvaltimotaudin riskitekijät (LASERI) pitkittäistutkimuksen 21-vuotisseurantaan
osallistui yhteensä 2 283 henkilöä vuonna 2001. Tutkittavat henkilöt olivat tällöin iältään
24-39 vuotiaita. LASERI aineistosta mittasimme CRP, seerumin amyloidi A (SAA) ja
sytomegalovirus (CMV) vasta-aine pitoisuudet. Tutkimuksessamme huomasimme CRP
pitoisuuksien olevan selkeästi korkeammat niillä naisilla, jotka käyttivät
yhdistelmäehkäisyvalmisteita. Näillä naisilla oli lisäksi korkeammat
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triglyseridipitoisuudet ja ne olivat yhteydessä kohonneisiin CRP tasoihin. Lisäksi
yhdistelmäehkäisynvalmisteiden käyttöön yhteydessä ollut CRP tasojen nousun todettiin
olevan niin voimakas, että se pystyi peittämään CRP:n geneettisen säätelyn vaikutukset.
Seerumin SAA pitoisuuksien osoitettiin myös olevan korkeammat
yhdistelmäehkäisyvalmisteita käyttävillä naisilla, kun taas hormonikierukan käyttö liittyi
alentuneisiin SAA tasoihin. SAA tasojen osoitettiin olevan vahvasti yhteydessä
painoindeksin, rasva-aineenvaihduntaan liittyvän hormonin leptiinin ja HDL kolesterolin
tai sen pinnalla esiintyvän apoliproteiini-A1:n kanssa. SAA pitoisuudet korreloivat
varhaisten valtimotaudin muutosten kanssa, mutta monimuuttajamallissa yhteys ei
säilynyt itsenäisenä selittävänä tekijänä. Sydämen sykevaihtelun vähentymisen on
osoitettu olevan merkki autonomisen hermoston epätoiminnasta. LASERI aineistossa
pystyimme osoittamaan sydämen sykevaihtelun olevan itsenäisesti yhteydessä CRP
tasoihin, mutta SAA tasoihin itsenäistä yhteyttä emme havainneet. Lisäksi pystyimme
osoittamaan korkeiden CMV vasta-ainetasojen olevan yhteydessä kohonneisiin
verenpainetasoihin ja alentuneeseen verisuonen toimintakykyyn miehillä. Näitä yhteyksiä
emme kuitenkaan havainneet naisilla.
Toiseen käytössämme olleeseen aineistoon - Terveys 2000 tutkimukseen osallistui 1 867
henkilöä ja he olivat iältään 46-76 vuotiaita tutkimushetkellä. Terveys 2000 aineistosta
mittasimme pentraksiini-3 (PTX3) pitoisuudet. PTX3 tasojen osoitettiin olevan
yhteydessä valtimotaudin riskitekijöihin, erityisesti LDL kolesterolin tasoihin,
pulssipaineeseen ja indoliamiini 2,3-dioksigenaasin pitoisuuksiin. Varhaisten
valtimotaudin muutosten ja PTX3 tasojen välillä emme huomanneet yhteyttä.
Yhteenvetona voidaan todeta, että mittaamamme tulehdusmerkkiaineet olivat yhteyksissä
moniin tunnettuihin valtimotaudin riskitekijöihin, kuten rasva-aineenvaihduntaan ja
verenpainetasoihin. Kuitenkin vain CMV vasta-ainepitoisuuksilla pystyimme osoittamaan
olevan itsenäinen yhteys epäedullisiin muutoksiin valtimonseinämän toiminnassa.
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Introduction
Atherosclerosis is the main reason for mortality and disability in the industrialized
countries (Walt, 2004). Atherosclerosis is a tedious process that is probably ongoing in
some extent in the arteries of all people.  The atherosclerotic process can start already in
childhood (Oliveira et al., 2010). Atherosclerotic changes have been found one of six
teenagers and the prevalence increases with increasing age, with the prevalence over 85%
in people over 50 years old (Tuzcu et al., 2001). There are two important pathological
mechanisms at the beginning of this process: lipid accumulation in the arteries and
inflammation. Through these processes the artery loses its normal capacity to function
and the lumen is constricted. This eventually leads to inadequate blood flow in the artery
and the manifestation of cardiovascular diseases (CVD) including conditions like
coronary artery disease and stroke (Pearson et al., 2003). Decisive preventive measures
have been taken in order to decrease the incidence of these diseases. Recommendations
for healthier lifestyles have been given by the World Health Organization in order to
decrease CVD risk, including measures like decreasing smoking, increasing physical
activity, decreasing use of saturated fat and increasing use of vegetables and fruits (2007).
In addition, pharmacologic interventions with medications to lower elevated blood
pressure, fasting glucose and cholesterol levels have been shown to decrease the CVD
risk (2007). Therefore blood pressure, fasting glucose and cholesterol levels
measurements have established their role in the preventive examinations of CVD risk
patients. However, studies have shown that these so called traditional atherosclerotic risk
factors underestimate the risk of CVD in young adults (Akosah et al., 2000; Akosah et al.,
2003).
In recent decades, the new pathogenenic mechanism of atherosclerosis has emerged.
Inflammation has been shown to play a significant role in the pathogenesis of
atherosclerosis from the beginning to end (Libby et al., 2009). However, many details are
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still unknown. Although inflammation has an obvious role in the pathogenesis of
atherosclerosis, there is no single outstanding inflammatory marker that could reflect this
ongoing inflammation in the body. The C-reactive protein (CRP) is the most studied
inflammatory marker and increased CRP levels have been shown to be associated and
predict future CVD events (Kaptoge et al., 2010). However, there is still controversy
about the causal role of CRP and whether it will yield any additional benefit beyond the
traditional risk factor assessment (Zacho et al., 2008; Zacho et al., 2010). American
recommendations favour the CRP measurement in order to achieve more exact CVD risk
assessments but the European recommendation still favours only the measurement of
conservative risk factors (Graham et al., 2007; Pearson et al., 2003).
This dissertation focuses on the role of inflammation in the pathogenesis of the
atherosclerosis and the role of inflammatory markers in early atherosclerosis. The
subjects in the first, second, third and fifth studies were young adults participating in the
ongoing Cardiovascular Risk in Young Finns Study. The subjects in Study IV were the
subjects of the Finnish Health 2000 Study, including middle-aged and older individuals.
Inflammatory markers CRP, Serum amyloid A and pentraxin-3; and cytomegalovirus
antibodies, as a marker of past of present infection, were measured. All the markers were
determined from the young adults, except the pentraxin-3 levels which were measured
from the participants of the Health 2000 Study. In addition, other traditional
atherosclerotic risk factors were measured from all these subjects and early
atherosclerotic changes of arteries were measured with ultrasound examinations. We
aimed to resolve whether these inflammatory markers were related to the early vascular
changes and which traditional atherosclerotic risk factors are related to increased
inflammation parameters in healthy young adults and older middle-aged adults.
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Review of the literature
1. Inflammation and atherosclerosis
Atherosclerosis is a chronic process where the normal arterial wall is thickened and loses
its normal capability to function. Atherosclerosis manifests typically in bifurcations of
arteries and other places where blood flow is not laminar. The traditional risk factors for
atherosclerosis have been known for decades: smoking, overweight, hypertension,
diabetes, physical inactivity, saturated fat and cholesterol in the diet (2007).
Atherosclerosis pathogenesis includes a highly complex series of inflammatory,
metabolic, thrombotic and other known, possibly also some as yet unidentified
mechanisms. The feared endpoints of atherosclerosis are cardiovascular diseases (CVD)
which are the main causes of death and disability in developed countries (Walt, 2004).
Traditionally atherosclerosis has been thought to be solely a lipid accumulation disease in
the arteries (Ross and Glomset, 1976). The current view is that inflammation also plays a
substantial role in the development and aggravation of atherosclerosis (Libby et al.,
2009). There is no single inflammatory cascade behind atherosclerosis; instead all the
branches of the immune system are known to participate in the pathogenesis of
atherosclerosis.
1.1. Innate immunity in atherosclerosis
Innate immunity is the rapid and blunt arm of human immune defence against pathogens.
The elements involved in innate immunity, such as monocytes, dendritic cells, mast cells
and platelets have been shown to have a role in the pathogenesis of atherosclerosis (Libby
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et al., 2009). The first step of the inflammatory process in atherosclerosis is the
recruitment of non-activated monocytes from the arterial lumen to intima. The
recruitment involves the attachment of monocytes to activated endothelial cells by
leukocyte adhesion molecules (Rocha and Libby, 2009). There are several subtypes of
these adhesion molecules; vascular cell adhesion molecule-1 (VCAM-1) especially is
known to be important. It is still partly unclear which mediators stimulate the expression
of these adhesion molecules. For example, endothelial cells have been shown to express
VCAM-1 in response to cholesterol, modified lipoproteins, interleukins and shear stress
of haemodynamic flow (Nakashima et al., 1998). Another important mediator for
monocytes recruitment to the intima includes specialized cytokines – chemokines, which
can chemoattract attached monocytes to migrate into the intima. The most studied pair is
the monocyte chemoattractant protein 1 (MCP-1) and its receptor CC-receptor-2. In
experimental animal models deficiency in MCP-1 and CC-receptor-2 leads to reduced
burden of atheroclerosis (Boring et al., 1998). There are also other known chemokines
such as CC-chemokine ligand 5, its receptor CC-receptor 5 and CX3-chemokine receptor
1.
In the intima, monocytes are activated and become macrophages which lead to up-
regulation of pattern-recognition receptors, including scavenger receptors and toll-like
receptors (Janeway and Medzhitov, 2002; Peiser et al., 2002). These receptors recognize
a wide broad range of molecules, including bacterial endotoxins, apoptotic cell fragments
and oxidized low density lipoprotein (LDL) particles. Recognization of these particles is
followed by the phagocytosis of these particles, especially LDL particles, in
atherosclerosis. Eventually, if the macrophages internalize enough lipid particles they
transform into lipid rich foam cells. These activated macrophages release growth factors
and cytokines which further aggravates inflammation (Hansson, 2005). This migration of
monocytes and activation continues even in established atherosclerotic lesions and not
just in the initial stages of lesion formation (Swirski et al., 2006).
Monocytes in atherosclerosis have heterogeneity (Libby et al., 2008). In mice, the
monocytes that are more proinflammatory are distinguished by the presence of high
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levels of Ly6C marker. The less inflammatory monocytes are known for the low levels of
Ly6C, but have major surveillance function in homeostasis. Hyperlipidemia stimulates
the enrichment of high Ly6C monocytes in mice and the number of high Ly6C
monocytes is increased in atherosclerosis (Swirski et al., 2007). These high Ly6C
monocytes express high levels of proinflammatory cytokines and other macrophage
mediators, including matrix metalloproteinases (Libby et al., 2009). In humans, there is
also equivalent distribution of macrophages to proinflammatory and homeostatic. These
proinflammatory macrophages are classically activated (M1) and rest alternatively
activated (M2). M1 are associated with higher levels of atherosclerosis but this bisection
is only a simplification from a larger heterogeneity (Johnson and Newby, 2009).
Mast cells are only a minor fraction of the leukocyte population in the arteries. However,
mast cells release many mediators e.g. histamine, leukotrienes, certain serine proteinases
and heparin. These factors have many potentially harmful actions. These substances have
vasoactive effects, they may act as growth factors and stimulate angiogenesis. In mice
models, mast cells have been shown to participate in atherogenesis (Sun et al., 2007).
However, the role of mast cells in human atherosclerosis is still uncertain, although there
is evidence that mast cells may participate also in human atherosclerosis and CVD
especially abdominal aorta aneurysm formation (Kovanen, 2009; Swedenborg et al.,
2011).
1.2. Adaptive immunity in atherosclerosis
Active T-cell infiltration is present in atherosclerotic lesions. CD4+ T cells or helper T-
cells are a prominent subclass in the inflammation of atherosclerosis. Known antigens for
T-cells include oxidized LDL particles, heat-shock proteins and microbial surface
proteins (Rocha and Libby, 2009). Four subtypes of helper T-cells are currently known:
Th1, Th2, Th17 and Treg cells. Th1 response is aggravated in atherosclerosis and leads to
increased secretion of proinflammatory cytokines such as interferon-? (IFN-?) and tumor
necrosis factor-? (TNF-?). These cytokines augment the production of many
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inflammatory and cytotoxic molecules in macrophages and vascular cells, further
promoting atherosclerosis (Hansson, 2005). The role of Th2 cells is still controversial
(Libby et al., 2009). Th2 cells release interleukin-4 (IL-4) and IL-13 cytokines which
have been shown to have anti-inflammatory effects by attenuating the deleterious effects
induced by IFN-?. However, some studies suggest that Th2 responses may promote
aneurysm formation by inducing elastolytic enzymes (Shimizu et al., 2004). More
recently discovered T-cell subtypes, Th17 and Treg cells are probably also involved in
the pathogenesis of atherosclerosis. Th17 cells probably drive proinflammatory effects in
atherosclerotic lesions, although opposite reports have also been presented (Chen et al.,
2010). Treg cells possess anti-inflammatory nature in atherosclerosis. Treg cells can
suppress the functions of proinflammatory helper T-cells and produce anti-inflammatory
cytokines – IL-10 and transforming growth factor-? (Rocha and Libby, 2009).
Transfusion of Treg cells to atherosclerosis susceptible mice has been shown to reduce
lesion burden (Ait-Oufella et al., 2006).
One third of T-cells found in human atherosclerotic lesions are CD8+ T-cells (Libby et
al., 2009).  These cells have the capability to recognize viral antigens and destroy cells
with cell-cell contact. Activation of CD8+ T-cells in a mouse model have been shown to
cause destruction of smooth muscle cells and macrophages in arteries, further
accelerating atherosclerosis (Ludewig et al., 2000). A minor proportion of T-cells in early
atherosclerotic lesions are natural killer T-cells. In contrast to other T-cells which
recognize protein antigens, the natural killer T-cells’ activation is dependent on lipid
antigens (Tupin et al., 2004). The activation of natural killer T-cells leads to the
production of proinflammatory cytokines and promotion of atherosclerosis.
1.3. Humoral immunity in atherosclerosis
B lymphocytes can secrete antibodies that recognize numerous antigens e.g. pathogens’
membrane structures. B cells are responsible for humoral immunity. The current evidence
indicates that humoral immunity has a protective role in atherosclerosis. B-cells produced
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in spleen have anti-atherogenetic effects and splenectomy has been shown to increase the
risk of vascular disease (Caligiuri et al., 2002; Witztum, 2002). This phenomenon is
probably due to the result of the similarities in epitopes of oxidized LDL and
pneumococcal antigen (Binder et al., 2003). These epitopes are phospholipids such as 1-
palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine (Shaw et al., 2000).
Immunization of rabbits with oxidized LDL has been shown to attenuate atherosclerosis.
Also autoantibodies against LDL surface molecule, apolipoprotein B (apoB), epitopes are
associated with less atherosclerosis and CVD events in humans (Sjogren et al., 2008).
Currently vaccines are developed for humans. It has been shown that Treg stimulation
might be one possible mechanism behind these favourable effects of humoral
immunization (Wigren et al., 2011).
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2. Inflammatory markers
2.1 C-reactive protein
2.1.1. Function of C-reactive protein
C-reactive protein (CRP) is a classic short pentraxin protein (Bottazzi et al., 2006). CRP
molecule consists of a five noncovalently associated identical subunits that are arranged
symmetrically in a cyclic configuration around a central pore, with the total molecular
weight of a 23 kDa (Oliveira et al., 1979). CRP can also be categorized as an acute-phase
reactant based on its biological properties. It is produced basically in response to any kind
of inflammatory stimulus e.g. during infections, acute injuries, autoimmune inflammatory
diseases and malignancies (Wilson et al., 2006). CRP is produced mainly by liver in
response to inflammatory signals, most prominently IL-6 and IL-1?. The most important
cells that secrete IL-6 and IL-1? are stimulated monocytes and macrophages, endothelial
cells, fibroblast cells and plasma cells (Kato et al., 1990; Shearer, 1995; Tocci, 1997).
CRP can also be directly synthesized by the cells at the site of inflammation e.g.
monocytes, endothelial cells, fibroblasts and adipocytes (Morley and Kushner, 1982).
The function of CRP is to recognize non-familiar particles i.e. antigens. Due to its
properties, CRP is categorized as a part of innate immunity (Janeway and Medzhitov,
2002). CRP recognizes particles that express phospocholine (Volanakis and Kaplan,
1971). This molecule can be found in numerous pathogens, including Streptococcus
pneumoniae, Clostridium spp., Lactococcus spp., Bacillus spp., Haemofilus influenzae,
Neisseria meningitidis and N. gonorrhoeae. In humans phospocholine is located between
phospholipids in cell membranes and in normal conditions it is coated so that CRP cannot
interact with it. However, in situations when the cell membrane is damaged, CRP is able
to interact with the phospocholine and initiate inflammatory response. This could be an
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important mechanism in the apoptotic and necrotic cells elimination. In addition, CRP
can be bound to nuclear material i.e. histones, chromatins and ribonucleic acid particles.
In light of all these interactions it has been suggested that the function of CRP could be
the removal of disposable materials and thereby possibly prevent the development of
autoimmune diseases (Szalai, 2004).
CRP is capable of activating innate immune response via activating complement cascade.
C1q is one of the binding sites of CRP (Siegel et al., 1974). CRP stimulates early phases
of complement cascade (C1, C2 and C4) without leading to the formation of membrane
attack complex C5b-9 (Berman et al., 1986). This is enabled by the presence of a factor
H, a molecule that controls complement activation. Factor H is located on the surface of
the cell membrane and is able to bind with CRP thereby preventing the further activation
of complement. This mechanism enables CRP to conserve late factors of complement and
reduce inflammation (Mold et al., 1999).
CRP and phagocytic cells interact via Fc? receptors. There are four subclasses of Fc?
receptors but only two of them are able to bind with CRP – Fc?RI and Fc?II (subtypes a
and b). These receptors are found on the surface of neutrophils, monocytes and
macrophages (Nimmerjahn and Ravetch, 2006). It has been demonstrated that there is
allele-specific variation between individuals in these receptors’ genomes and their
functional differences have been illustrated (Stein et al., 2000). The activation of
monocytes and neutrophils via Fc? receptors leads to the phagocytosis of CRP bound
particles and the expression of proinflammatory cytokines (Ballou and Lozanski, 1992).
The strength of this activation depends on the number of receptors activated (Mold et al.,
1999).
2.1.2. CRP genetics
In twin studies, CRP concentrations were shown to be up to 40 percent hereditary
(MacGregor et al., 2004). Human CRP gene is located on 1q23.2 and consists of 2 exons
and 1 intron. The gene is polymorphic and contains at least 31 SNPs, of which five have
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been a subject of greater interest (Carlson et al., 2005). These five SNPs, -717 A/G, -286
C/T/A, +1059 G/C, +1444 C/T and +1846 G/A; have been shown to associate with CRP
concentrations (Ben-Assayag et al., 2007; Eklund et al., 2008; Kovacs et al., 2005). In
modern genome-wide association studies (GWAS) considerably more SNPs have been
identified as possible genetic regulators of CRP levels. The following loci have been
associated with CPR levels: genes encoding CRP, leptin receptor, IL-6 receptor,
glucokinase regulator, hepatic nuclear factor 1-?, apolipoprotein E, achaete-scute
complex homolog 1, pyrin domain containing 3, IL-1 family member 10, protein
phosphatase 1, regulatory subunit 3B, hepatocyte nuclear factor 4-?, RAR-related orphan
receptor A, Sal-like 1, poly(A) binding protein, cytoplasmic 4, B-cell chronic
lymphocytic leukemia/lymphoma 7B, proteasome assembly chaperone 1, protein tyrosine
phosphatase, nonreceptor type 2, G protein-coupled receptor family C group 6 member A
and interferon regulatory factor 1 (Dehghan et al., 2011). All in all, these results indicate
a wide interplay between genes involving the immune system, metabolism and chronic
inflammation on CRP levels regulation. Additionally, genetic studies have shown that
CRP gene polymorphisms associated with increased CRP levels are not associated with
increased CVD risk (Wensley et al., 2011; Zacho et al., 2008).
2.1.3. Role of CRP in diseases
Under physiological conditions, normal human CRP concentration is approximately 0.8
mg/l (Shine et al., 1981). CRP levels can increase up to 1,000-fold in 24-72 hours in
infectious and non-infectious conditions, e.g. tissue damage, sepsis and gout. It has been
used widely by physicians as a marker of acute inflammation and values <10 mg/l have
been considered “negative” and values over 10 mg/l have been considered as an
implication of ongoing inflammation in the body. However, e.g. modern high-sensitive
latex turbidometric immunoassay methods can also precisely measure these “negative”
CRP levels. Measurements have revealed that only a minority of people have CRP
concentrations in physiological levels. In fact, one third of Americans have CRP
concentrations over 3 mg/l (Kushner et al., 2006).
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These slightly increased CRP concentrations have been associated with various clinical
conditions, including: diabetes mellitus, metabolic syndrome, obesity, cancers,
Alzheimer’s disease, acute myocardial infarction and stroke (Lavie et al., 2009). The use
of CRP as a predictor of CVD has especially been the subject of a wide range of research
and it has been shown in numerous publications that increased levels of CRP are a strong
biomarker for CVD indices (Kaptoge et al., 2010; Pearson et al., 2003), although
criticism has been voiced about the quality of these publications (Hemingway et al.,
2010). It is hypothesized that increased levels of CRP indicate an ongoing low grade
inflammation in the body and that this could aggravate pathologies such as
atherosclerosis.  CRP levels can be stratified into values <1 mg/l (low risk), 1-3 mg/l
(intermediate risk) and >3 mg/l (high risk) for cardiovascular diseases. It has been
suggested that CRP could offer advantage for physicians to categorize intermediate risk
patients according to traditional risk factors to either high risk or low risk individuals for
CVD (Lavie et al., 2009). Adding CRP value as an additional risk marker into the
traditional CVD risk model, the Framingham algorithm, with other risk factors such as
age, sex, cholesterol levels and blood pressure values yields more exact predictions
(Ridker et al., 2007; Ridker et al., 2008b). Despite the usefulness of CRP in CVD risk
prediction, the current view is that CRP is  unlikely to be causally related to
atherosclerosis and increased CVD risk (Nordestgaard, 2009).
The usefulness of CRP values is not limited to risk prediction. Therapeutic intervention
studies with statins have shown that patients whose cholesterol and CRP levels were
reduced by therapy were at lower risk of having CVD outcomes when compared to those
whose cholesterol levels, but not CRP levels, were reduced (Ridker et al., 2005a; Ridker
et al., 2005b). These findings and other evidence have suggested that statins have a
dualistic effect; lipid lowering and anti-inflammatory (Libby et al., 2009). The obvious
next step was to test the possibility of using statins to lower the CVD risk for those
individuals with normal cholesterol levels but increased CRP levels. This indicates that
there is likely to be ongoing low-grade inflammation and development of atherosclerosis
in these individuals. In a large prospective epidemiological setup, subjects with increased
CRP levels (?2 mg/l) but normal LDL cholesterol levels (<130 mg/dl) were randomized
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to take either rosuvastatin 20 mg daily or placebo (Ridker et al., 2008a). During follow-
up, the intervention group achieved 44% reduction in CVD end-points compared to those
taking placebo. Although it is fair to point out that there was also a significant reduction
on LDL cholesterol values in the intervention group. In later analysis it was estimated the
number needed to treat value for statin therapy to CVD prevention in 5 years would be 25
(Ridker et al., 2009).
2.2. Pentraxin-3
2.2.1. Function of Pentraxin-3
Pentraxin-3 (PTX3) is a protein belonging to a long pentraxin family. It was first
discovered in the 1990s in guinea pig apexin in spermatozoa (Noland et al., 1994). PTX3
is a 45 kDa molecule that assembles to form high molecular weight multimers linked by
interchain disulphide bounds (Bottazzi et al., 1997). The C-terminal domain of PTX3
contains homology with classic short pentraxins (e.g. CRP), whereas the N-terminal
domain does not show any significant homology (Mantovani et al., 2008). PTX3 has
remained highly conserved during evolution, unlike CRP. In humans, the serum levels of
PTX3 vary from undetectable levels to 800 ng/ml during infections and inflammatory
conditions (Muller et al., 2001). While CRP is mainly produced in the liver, PTX3 is
produced and released in situ by many different cell types, including dendritic cells,
macrophages, fibroblasts, endothelial cells, renal cells and neutrophils (Bassi et al.,
2009). PTX3 production is stimulated by lipopolysaccharides (LPS), IL-1, IL-10 and
TNF-?. IFN-? has been shown to have an inhibitory effect or no effect on PTX3
expression and interestingly IL-6 seems to have no effect on PTX3 production (Bassi et
al., 2009). Genetic polymorphism of PTX3 genome has also been identified and SNP
rs6788044 especially is associated with higher PTX3 levels as well as with increased
fertility (May et al., 2010). No GWAS on PTX3 has been performed.
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PTX3 has been shown to have a role in immunity and inflammation, extracellular matrix
construction and female fertility (Mantovani et al., 2008). As a member of innate
immunity, the major task of PTX3 is to recognize microbial pathogens, activate
complement cascade and stimulate the uptake of pathogens by phagocytes. In vitro, after
preincubation of apoptotic cells, PTX3 has been shown to interact with complement C1q
and to activate complement cascade (Nauta et al., 2003). On the other hand, fluid-phase
binding of PTX3 has been shown to inhibit complement activation, giving rise to the idea
that PTX3 has a dual role in complement activation. PTX3 can also interact with factor H
(Deban et al., 2008). PTX3 binds to apoptotic cells and inhibits their removal via
dendritic cells (van Rossum et al., 2004). PTX3 may affect plaque stability by binding to
fibroblast growth factor, which plays a major role in the induction, proliferation,
migration and survival of vascular smooth muscle cells (Mantovani et al., 2008). PTX3
has also been shown to increase tissue factor expression in mononuclear cells and
endothelial cells, and this way PTX3 may promote coagulation (Napoleone et al., 2002;
Napoleone et al., 2004).
2.2.2. Role of PTX3 in diseases
PTX3 behaves as an acute phase protein. Under normal conditions PTX3 plasma levels
are <2 ng/ml in humans but may rise up to 200-800 ng/ml within 6-8 hours during
inflammatory and infectious conditions (Mantovani et al., 2008). PTX3 values correlate
with disease severity and have prognostic value in various infectious diseases, such as
sepsis, septic shock, tuberculosis and dengue (Huttunen et al., 2011; Muller et al., 2001).
PTX3 is also associated with CVD. PTX3 molecules have been identified in human
atherosclerotic plaques (Rolph et al., 2002). Plasma levels of PTX3 rise rapidly during
acute myocardial infarction and PTX3 levels have been shown to predict mortality in ST
elevation myocardial infarction (Latini et al., 2004; Peri et al., 2000). Also, PTX3 levels
have been shown to have elevated in non-acute conditions. For example, in patients with
unstable angina pectoris, PTX3 levels were three times higher compared to normal range
(Inoue et al., 2007). After hospitalization for unstable angina or non ST elevation
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myocardial infarction, PTX3 levels have also been shown to predict future CVD events
(Matsui et al., 2010). In a cohort of elderly CVD-free subjects, increased PTX3 levels
were shown to predict future CVD and all cause deaths independent of CRP and other
traditional risk factors (Jenny et al., 2009). PTX3 has been shown to correlate with the
presence of heart failure and aortic valve stenosis (Matsubara et al., 2011; Naito et al.,
2010). In addition, PTX3 genetics has been linked with the tissue ischaemia-reperfusion
injury and systemic inflammatory response after cardiac bypass surgery (Liangos et al.,
2010).
Elevated PTX3 levels have also been identified in some autoimmune diseases, e.g. small
vessel vasculitis and rheumatoid arthritis (Fazzini et al., 2001; Luchetti et al., 2000).
Chronic kidney disease patients have been shown to have increased PTX3 concentrations
and this was associated with increased mortality in these patients (Tong et al., 2007).
Thus PTX3 has plausible prognostic values in chronic kidney disease patients. Levels of
PTX3 have been shown also to be associated with pregnancy related diseases such as pre-
eclampsia (Cetin et al., 2006), excessive maternal inflammatory response and placental
vasculopathy (Assi et al., 2007).
2.3. Serum amyloid A
2.3.1. Function of serum amyloid A
Serum amyloid A (SAA) is a group of acute phase proteins that were originally described
for their role in AA amyloidosis. Human SAA consists of 104 amino acids (Parmelee et
al., 1982). Four SAA genes have been discovered in humans. SAA1 and SAA2 are acute
phase SAA and these levels may increase over 1,000 times during inflammation e.g.
infections, trauma, tumours and tissue damage. SAA3 is probably a pseudogene. SAA4 is
constitutively expressed and is constant but minor component of high density lipoprotein
(HDL) (Kisilevsky and Tam, 2002). Previously liver was thought to be the most
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important secretion site of SAA. However, it is now known that in nonacute-phase
conditions adipose tissue is the major site of SAA production (Poitou et al., 2006;
Sjoholm et al., 2005; Yang et al., 2006). It has been also shown that macrophages,
vascular smooth muscle cells and endothelial cells can express SAA locally (Meek et al.,
1994).
Proinflammatory cytokines (IL-1, IL-6, TNF-?) induce SAA gene expression (Thorn et
al., 2004). The role of IL-6 is the most critical because of its synergistic induction of SAA
gene when stimulated with other proinflammatory cytokines (Hagihara et al., 2004). The
precise mechanism is not known, but it involves steroids as co-stimulators. Oxidized
LDL also induces SAA expression (Ray et al., 1999). Conversely, SAA treatment of
vascular endothelial cells and monocytes markedly increased the production of IL-6, IL-
8, TNF-? and MCP-1 (Yang et al., 2006), indicating that there may well be a positive
feedback mechanism between these inflammatory markers. A recent GWAS has
identified two genetic loci for SAA: SAA1 and leptin receptor (Marzi et al., 2010),
suggesting that there is a close interplay between the genetic regulations of leptin and
SAA. A specific SAA receptor has not been identified, but it has been shown that SAA
can interact with following receptors: Toll-like receptors 2 and 4, CD36, class B
scavenger receptor and G-protein-coupled receptor formyl peptide receptor like 1/lipoxin
A4 receptor (King et al., 2011).
SAA has the features of an apolipoprotein. It is produced and it forms a heterogeneous
fraction of HDL at normal levels, containing SAA and predominantly apolipoprotein A1
(apoA1). At elevated levels of SAA, it displaces apoA1 from HDL to become the
dominant apolipoprotein of HDL (Kisilevsky and Tam, 2002). ApoA1 has a key role in
reverse cholesterol transport. This change leads to impaired cholesterol transport from
periphery to liver. HDL antioxidative properties are also impaired and this leads to the
suggestion that HDL-SAA is a proinflammatory molecule (O'Brien and Chait, 2006).
Furthermore, in obese mice, SAA molecules has been detected on apoB-containing
lipoproteins VLDL and LDL (King et al., 2011). LDL/SAA complex has also been
shown to be associated with obesity, metabolic syndrome and CVD events in Japanese
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populations (Kotani et al., 2009; Ogasawara et al., 2004). SAA molecules also exist as a
lipid free form in circulation (Malle and De Beer, 1996).
2.3.2. Role of SAA in diseases
Elevated serum SAA levels have been found to be associated with body mass index
(BMI), obesity and body fat percentage in adults and also in children and adolescents
(Gomez-Ambrosi et al., 2008; Yang et al., 2006; Zhao et al., 2010). SAA is said to be a
possible direct link between obesity and inflammatory diseases like atherosclerosis and
metabolic syndrome (Yang et al., 2006). Weight loss was found to significantly decrease
SAA levels in obese individuals. The insulin sensitivity after weight loss correlated
significantly with the decrease in SAA levels (Yang et al., 2006).
SAA is an independent predictor of CVD comparable to CRP or even better (Johnson et
al., 2004; Kosuge et al., 2007; Ridker et al., 2000). SAA levels are also elevated in
patients who have had myocardial infarctions (Bausserman et al., 1989). SAA is thought
to be a prothrombotic and proinflammatory mediator in CVD. SAA has been shown to
alter vascular proteoglycans and stimulate the production of proinflammatory mediators
in endothelial cells and monocytes (Song et al., 2009; Wilson et al., 2008).
Atherosclerotic plaques have been shown to contain SAA deposits (Maier et al., 2005).
SAA is also associated with insulin resistance and diabetes. Serum SAA concentrations
are elevated in type 2 diabetics and high SAA concentrations have been shown to predict
the development of diabetes (Herder et al., 2006). Tanis is a novel protein that is a
possible link between inflammation, diabetes and SAA. Tanis is increasingly expressed in
the liver of diabetic rats and diabetes has been shown to lead to dysregulation of Tanis
(Walder et al., 2002). Further it was demonstrated that SAA is one ligand of the Tanis
receptor. In type 2 diabetic humans Tanis messenger ribonucleic acid (mRNA)
expression in skeletal muscle and adipose tissue is positively associated with circulating
SAA levels (Karlsson et al., 2004). SAA has also been shown to down-regulate genes
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associated with insulin sensitivity (Scheja et al., 2008) and treatment of adipocytes with
SAA has been shown to decrease cellular insulin sensitivity (Ye et al., 2009).
Table 1.
Summary of different inflammatory markers features.
C-reactive protein Pentraxin-3 Serum amyloid A
Structure Pentraxin Pentraxin Group of proteins
with features of an
apoliprotein
Main
expression
site
liver in situ adipose tissue
Expression
stimulators
IL-1?, IL-6 lipopolysacharide,
IL-1, IL-10, TNF-?
IL-1, IL-6, TNF-?,
oxidized-LDL
Main
function
pathogen
recognization and
opzonization,
activation of
complement, binding
to apoptotic and
necrotic cells
pathogen recognization and
activation of complement,
stimulation of extracellular
matrix construction and
promote fertility
mainly unknown,
has features of an
apolipoprotein and is
a constituent of HDL
cholesterol
Related
diseases
Diabetes, metabolic
syndrome, obesity,
cancers, Alzheimer’s
disease and
cardiovascular
diseases
Heart failure, vasculitis,
rheumatoid arthritis,
chronic kidney disease,
pre-eclampsia, placental
vasculopathy and
cardiovascular diseases
Amyloidosis,
obesity, metabolic
syndrome, diabetes,
insulin resistance
and cardiovascular
diseases
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2.4. Determinants of inflammatory markers
Measuring low concentrations of inflammatory markers and interpretation these results is
challenging because many known internal and external atherosclerotic risk factors are
associated with these inflammatory markers. The main determinants of CRP, PTX3 and
SAA are summarized in Table 2.
Table 2.
Reported effects on inflammatory marker levels of presence or increase of various
determinants.  Reference numbers in parentheses.
CRP PTX3 SAA
Age ? (1) ? (2,3,4) ? / - (5,6,7,8,9,10,11)
Male sex - (1,12,13,14) ? / ? / - (3,4,15) ? / - (9,16,17)
BMI / waist circumference ? (1,18) ? / ? / - (3,19,20,21) ? (16,22,23)
Leptin ? (18) ? ? (16)
Lipids ? (1) ? / ? (3,20,24) ? (9,10)
Blood pressure ? (1,25) (-) (15,24,26) - (9,11,27)
Glucose ? (1) ? / - (15,26) (-) (9)
Insulin ? (1) ? / - (15,26) (-) (9)
Metabolic syndrome ? (1) ??) (24) ? (16,28,29)
Diabetes ? (1) ? ? (28)
COCs or ERT usage ? (13,14,30) ? ? (31,32)
Physical activity ? (1) ? ? (33)
Smoking ? (1) ? (34) ? (35)
Alcohol consumption ? (1) ? - (36)
CRP ? (4,15) ? (23)
SAA ? (23) ?
References:
1. Kushner et al., 2006; 2. Matsui et al., 2010; 3. Yamasaki et al., 2009; 4. Jenny et al., 2009; 5. Lannergard
et al., 2005; 6. Wu et al., 2007b; 7. Pertovaara et al., 2009; 8. Sondergaard et al., 2004; 9. Gomez-Ambrosi
et al., 2008; 10. Johnson et al., 2004; 11. Delanghe et al., 2002; 12. Imhof et al., 2003; 13. Raitakari et al.,
2005; 14. Williams et al., 2004; 15. Suliman et al., 2008a+b; 16. Lappalainen et al., 2008; 17. Sjoholm et
al., 2005; 18. Viikari et al., 2007; 19. Miyaki et al., 2010; 20. Ogawa et al., 2010; 21. Shim et al., 2010; 22.
Meyers et al., 2008; 23. van Dielen et al., 2001; 24. Zanetti et al., 2009; 25. Virdis et al., 2007; 26. Alberti
et al., 2009; 27. Danesh et al., 1999; 28. Walder et al., 2002; 29. Yang et al., 2006; 30. Kluft et al., 2002;
31. Abbas et al., 2004; 32. van Rooijen et al., 2006; 33. Bergmann and Siekmeier 2009; 34. Dubin et al.,
2010; 35. Rothenbacher et al., 2003; 36. De Bacquer et al., 2006
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Deleterious effects on immune system are seen during aging. A direct correlation
between age and CRP concentrations has been shown in various populations and in
different age cohorts (Kushner et al., 2006). A direct correlation between age and PTX3
has been found in various adult cohorts. High PTX3 levels were associated with
increased age in Japanese cohorts consisting of myocardial infarct patients (Matsui et al.,
2010) and healthy adults (Yamasaki et al., 2009). In a CVD-free elder Caucasian cohort,
there was a significant correlation between age and PTX3 levels (Jenny et al., 2009).
Contradictory findings have been published about the correlation between age and SAA.
In Swedish and Chinese cohorts with a wide range of subjects of all ages, SAA levels
were shown to increase with increasing age (Lannergard et al., 2005; Wu et al., 2007b).
In Sjögren’s syndrome patients, SAA has also been shown to correlate with age
(Pertovaara et al., 2009). On the other hand, in a young Iraqi refugee cohort, SAA levels
did not correlate with age (Sondergaard et al., 2004) or in a cohort consisting Spanish
children and adolescents (Gomez-Ambrosi et al., 2008). In a large middle-aged
Caucasian female cohort with an increased risk of CVD, SAA levels did not correlate
with age (Johnson et al., 2004), nor was any correlation seen in another CVD risk cohort
(Delanghe et al., 2002). In a different approach, the SAA mRNA expression in adipocytes
was not associated with age in obese women (Poitou et al., 2005). One possible
explanation for these contradictory results is that age differences in SAA levels can only
be detected between persons with a decisive age difference.
Originally it was thought that woman had higher CRP levels than men (Kushner et al.,
2006). However, this idea has been questioned after the discovery that women who do
not use oral contraceptives or hormone replacement therapy have similar CRP levels to
those of men (Imhof et al., 2003; Raitakari et al., 2005; Williams et al., 2004).
Contradictory results have been reported for PTX3 and sex based difference. PTX3 levels
were higher in women than men in a healthy Japanese cohort (Yamasaki et al., 2009),
whereas in CVD-free older American population, PTX3 levels were higher in men (Jenny
et al., 2009). In a Swedish haemodialysis patient cohort no significant difference between
sexes was observed (Suliman et al., 2008a). Women have been shown to have higher
serum SAA levels than men (Lappalainen et al., 2008) and SAA mRNA levels have been
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shown to be higher in women (Lappalainen et al., 2008; Sjoholm et al., 2005), whereas in
Spanish children and adolescent there were no sex difference (Gomez-Ambrosi et al.,
2008). All in all it is still controversial whether there are any sex-based differences in
these inflammatory marker levels.
BMI, waist circumference, leptin and other markers to evaluate the composition and
function of the body’s adipose tissue have been shown to correlate closely with CRP and
SAA. Direct associations between CRP and BMI have been seen in all ages and leptin
levels especially seem to correlate closely with CRP levels (Kushner et al., 2006; Viikari
et al., 2007). SAA levels have also been shown to be directly associated with BMI and
leptin (Lappalainen et al., 2008; Meyers et al., 2008; van Dielen et al., 2001), while in the
case of PTX3, the results are polarized. Obesity has been associated with both increased
(Miyaki et al., 2010) and decreased PTX3 levels (Ogawa et al., 2010; Yamasaki et al.,
2009). Variation in these results could be explained by the finding that PTX3 was
positively associated with visceral fat but not with BMI (Shim et al., 2010). In any case it
has been shown that human adipose tissue releases PTX3 (Alberti et al. 2009). Similar
results have been reported between lipids and inflammatory markers. CRP and SAA have
been shown to correlate directly with atherogenic lipid profile, with the exception that
SAA levels correlate positively with HDL cholesterol (Johnson et al. 2004; Kushner et al.
2006; Gomez-Ambrosi et al. 2008), while in the case of PTX3, inverse correlations
between PTX3 and triglyceride levels have been reported (Ogawa et al.; Yamasaki et al.
2009) and contradictory reports have again been presented (Zanetti et al., 2009).
Increased CRP concentrations are related to hypertension, arterial stiffness and increased
blood pressure (Kushner et al., 2006; Virdis et al., 2007). However, after adjustment for
life course confounding factors in a Mendelian randomization approach, elevated CRP
levels are not associated with increased blood pressure values (Davey Smith et al., 2005),
while in the case of SAA, there is a relation with hypertension but not with arterial
stiffness (Pietri et al., 2006). At population level no correlation was found between SAA
and blood pressure (Danesh et al., 1999; Delanghe et al., 2002; Gomez-Ambrosi et al.,
2008). The current knowledge on a relation between PTX3 and blood pressure is scarce.
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However, some studies have reported non-significant correlations (Suliman et al. 2008a;
Alberti et al. 2009; Zanetti et al. 2009).
Glucose and insulin metabolism are also closely related to inflammation and
atherosclerosis. CRP levels are associated with increased fasting glucose and insulin
levels, insulin resistance, metabolic syndrome and diabetes (Devaraj et al. 2004; Kushner
et al. 2006). SAA levels have been shown to be associated with insulin sensitivity and
type 2 diabetes (Walder et al. 2002; Yang et al. 2006). However, negative correlations
have been reported between SAA and fasting glucose and insulin levels in obese children
and adolescents (Gomez-Ambrosi et al., 2008). Weight loss achieved by surgery has been
shown to decrease abdominal tissue SAA mRNA expression but this decrease was not
associated with glucose and insulin levels (Poitou et al. 2006), whereas in another study,
SAA levels correlated with insulin sensitivity in obese women but not in men
(Lappalainen et al. 2008). All in all, the relation between SAA, glucose and insulin
metabolism is still under debate. PTX3 expression in visceral adipose tissue was shown
not to correlate with fasting glucose and insulin levels (Alberti et al. 2009). PTX3
concentrations in plasma had no correlation between fasting glucose and insulin in
chronic kidney disease patients (Suliman et al. 2008). However, it seems that PTX3
levels are higher in patients suffering from metabolic syndrome (Zanetti et al. 2009).
However, this association is probably due the visceral fat component of metabolic
syndrome (Shim et al., 2010).
Use of combined oral contraceptives (COCs) has been shown to markedly increase CRP
levels in healthy premenopausal women (Raitakari et al., 2005; Williams et al., 2004).
However, this increase occurs without the increase of IL-6 levels, indicating that the
COCs stimulate CRP synthesis directly in the liver (van Rooijen et al. 2006). The
mechanism is probably due to the estrogen component of COCs because pills containing
only progestagen do not elevate CRP levels (Williams et al. 2004) and in postmenopausal
women estrogen replacement therapy (ERT) containing only estrogen elevates CRP
levels (Kluft et al., 2002). However, there is evidence that this progestagen component in
COCs may also affect CRP levels (Buchbinder et al., 2008; Kluft et al., 2002; Skouby et
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al., 2002). In postmenopausal women oral estrogen use significantly raises levels of SAA,
HDL and HDL-SAA, while transdermal estrogen reduces SAA and HDL-SAA levels
(Abbas et al., 2004). In premenopausal women, COCs use has been found to increase
SAA levels slightly (van Rooijen et al. 2006). It is not known how COCs or ERT use
affects PTX3 levels, but one study has shown that PTX3 mRNA expression in human
endometrial stromal cells is regulated by progesterone and estrogen (Popovici et al.,
2008).
Unfavorably habits like low physical activity, smoking and alcohol consumption have
been associated with increased CRP levels (Kushner et al., 2006). Physical activity and
smoking have also been related to SAA levels (Bergmann and Siekmeier, 2009;
Rothenbacher et al., 2003) but not alcohol consumption (De Bacquer et al., 2006). PTX3
levels have been associated with smoking (Dubin et al., 2010) but no data are available
about a relation to physical activity or alcohol consumption. Other habits have also been
shown to affect inflammatory markers, including factors like diet, education and stress
(Kushner et al., 2006). However, it is appropriate to mention that the independent effect
of these variables is partly unknown.
In addition to the correlations presented above, these inflammatory factors have been
shown to intercorrelate. SAA concentrations have been reported to correlate closely with
CRP (van Dielen et al. 2001). PTX3 levels also correlate with CRP but not as closely as
SAA and CRP (Suliman et al. 2008; Jenny et al. 2009). No correlation between PTX3
and SAA has been reported.
2.5. Early vascular changes and inflammatory markers
Modern ultrasound examinations are capable of detecting atherosclerotic changes in
arteries well before any clinical symptoms and these early vascular changes have been
linked with increased CVD incidence and mortality in later years (Blacher et al., 1998;
Bots et al., 1997; Chambless et al., 1997; Chan et al., 2003). Most of the studies have
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investigated the relation between CRP levels and early vascular changes and many of
them have shown an association between CRP and impaired vascular function. CRP
concentrations have been associated with increased carotid artery intima-media thickness
(IMT) (Hulthe et al., 2001; Juonala et al., 2006) but a Mendelian randomization study did
not support the causality of this relation (Kivimaki et al., 2007). CRP levels haven been
associated with endothelial dysfunction and inversely with brachial artery flow-mediated
dilation (FMD) (De Haro et al., 2008; Fichtlscherer and Zeiher, 2000; Juonala et al.,
2005; Yudkin et al., 1999). In addition, genetic polymorphisms of CRP have been
associated with increased carotid artery distensibility (Cdist) in young adults (Eklund et
al., 2008). The term carotid artery compliance (CAC) has also been used in addition to
carotid artery distensibility. The latter term is nowadays recommended in order to avoid
confusion with coronary artery calcification, which also can be abbreviated as CAC.
Only few studies have investigated the relation between early vascular changes and SAA.
In a cohort consisting of elderly Swedish men, there was no correlation between IMT and
SAA (Wohlin et al. 2007), whereas in a Finnish cohort consisting of type 2 diabetics,
SAA levels correlated with IMT, but were not an independent determinant for IMT in a
multivariate model (Leinonen et al., 2004). In a small Japanese cohort SAA values also
correlated with IMT, but these results were not adjusted for all the typical atherosclerotic
risk factors (Uurtuya et al., 2009). In a genetic approach, polymorphisms of SAA gene
have been associated with IMT values (Xie et al.; Carty et al. 2009). However there was
significant ethnic variation in these reports. There are no studies available about an
association between SAA, Cdist and FMD. However, in an animal model SAA has been
related to endothelial dysfunction (Wang et al., 2008).
In chronic kidney disease patients PTX3 levels have been shown to correlate directly with
IMT and inversely with FMD (Suliman et al. 2008). It was further shown that an
association between PTX3 and FMD remained after adjustment for typical atherosclerotic
risk factors such as age, blood pressure, insulin sensitivity index and CRP levels. These
results were confirmed in another chronic kidney disease cohort in the case of FMD but
not IMT (Yilmaz et al., 2011). A direct correlation between IMT and PTX3 was also
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observed in elderly hypertensive patients (Yano et al., 2010). In a study consisting of
metabolic syndrome patients, PTX3 levels correlated with IMT but had no independent
effect in the multivariate model (Zanetti et al. 2009).
2.6. Inflammatory mediators in the pathogenesis of atherosclerosis
2.6.1. C-reactive protein
Various mechanisms have been proposed for how inflammatory mediators contribute to
the pathogenesis of atherosclerosis. In vitro CRP can bind to modified LDL cholesterol,
especially to non-esterified LDL (Taskinen et al., 2002). CRP may function as a
chemotactic substance for monocytes to infiltrate into the intima (Torzewski et al., 2000).
CRP may lead to endothelial dysfunction via upregulation of cellular adhesion molecules,
decrease in nitrix oxide expression, increase in endothelin-1 release and upregulation of
Lectin-like oxidized LDL receptor-1 (Li et al., 2004; Pasceri et al., 2000; Verma et al.,
2002). Additionally CRP may be involved in atherothombosis by increasing plasminogen
activator inhibitor-1 availability and stability in endothelium (Devaraj et al., 2004).
However, overexpression of CRP in human and animal models has not been shown to
aggravate atherosclerosis (O'Brien and Chait, 2006).
2.6.2. Serum Amyloid A
In vitro SAA mediates HDL cholesterol binding to differentiated macrophages and
endothelial cells (Hayat and Raynes, 2000; Kisilevsky and Tam, 2002). HDL bound SAA
impairs the capacity of HDL to promote cholesterol efflux from macrophages (Artl et al.,
2000). SAA may also play a role in HDL cholesterol retention in atherosclerotic lesions
(O'Brien et al., 2005). In addition, SAA can stimulate the expression of matrix-degrading
metalloproteinases and promote chemotaxis and adhesion of monocytes and lymphocytes
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(O'Brien and Chait, 2006). SAA may also induce the expression of IL-1? in tissues
(Niemi et al., 2011).
2.6.3. Pentraxin-3
PTX3 probably has a dualistic effect on atherosclerosis. On the other hand, there is
evidence that PTX3 is expressed in atherosclerotic plaques, and PTX3 positive
neutrophils can infiltrate into atherosclerotic plaques (Rolph et al., 2002; Savchenko et
al., 2008). On the other hand, PTX3 may have cardioprotective functions by inhibiting
inflammatory responses and macrophage accumulation (Norata et al., 2009). PTX3 can
also bind to activated circulating platelets and impair platelets proinflammatory and
prothrombotic actions (Maugeri et al., 2011). In addition, PTX3 can inhibit angiogenesis
and promote restenosis (Camozzi et al., 2005; Inforzato et al., 2011).
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3. Inflammation and adipose tissue
3.1. Obesity and inflammation in adipose tissue
Excess gain of nutrition compared to energy consumption leads to weight gain. The
World Health Organization defines obesity as having of a body mass index ?30 kg/m². In
addition persons with waist circumference greater than 102 cm for men and 88 cm for
women can be considered obese (2002). It is estimated that 300 million adults in the
world meet these criteria of obesity. In men the fat accumulates typically centrally and in
women accumulation is typically gluteal and femoral. This distribution difference is due
to sex steroid hormones. The central or upper fat accumulation is the greatest health risk
(Canoy, 2008). This excess nutrition is stored in adipose tissue in the form of lipids.
Traditionally adipose tissue was considered merely as a lipid deposit organ. However,
nowadays it is known that adipocytes have a more complex role (Attie and Scherer,
2009). One could say that adipose tissue is an endocrine organ with the capability to
produce numerous inflammatory mediators.
Adipose tissue contains adipocytes and macrophages. In obese people, these
macrophages are activated and produce cytokines such as IL-1, IL-6, TNF-?. In obese
people, these cytokines are released into the circulation and elevated cytokine levels have
been found in them (Wang and Nakayama, 2010). Cytokines further stimulate the hepatic
production of CRP leading to chronic systemic inflammation i.e. systemic low grade
inflammation. It has been shown that even the number of macrophages in adipose tissue
is increased in obesity (Weisberg et al., 2003). Other unfavorable substances are also
produced in adipose tissue: a procoagulant substance like plasminogen activator
inhibitor-1, vasoactive substances like angiotensinogen and endothelin. Visceral fat
especially has been shown to express significant amounts of cytokines and other
deleterious substances (Rodriguez et al., 2007).
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Macrophages in adipose tissue have the same characteristics as macrophages in
atherosclerotic lesions in regulation and impression. Active and resident (alternatively
activated) macrophages, i.e. more and less inflammatory, can be distinguished from each
other and chemokines may also have a role in macrophage infiltration and expression in
adipose tissue (Rocha and Libby, 2009). One intriguing finding was the discovery of
peroxisome proliferator-activated receptor ? (PPAR?) – a nuclear receptor required for
maturation of alternatively activated macrophages. Deficiency of PPAR? in mouse
models has led to increased obesity and insulin resistance (Odegaard et al., 2007). Th2
cell derived anti-inflammatory cytokines IL-4 and IL-13 induce PPAR? activation (Kang
et al., 2008). Glitazones, drugs designed to stimulate PPAR? activation, have been shown
to decrease glucose levels as well as decrease systemic inflammation in humans (Rocha
and Libby, 2009). T lymphocytes are present in adipose tissue and their number is
increased in obesity (Wu et al., 2007a). T cell accumulation appears even earlier than
macrophage accumulation (Kintscher et al., 2008). Th1-activated adaptive immunity is
probably involved in obesity, leading to excess TNF-? and IFN-? production (Rocha and
Libby, 2009).
3.2. Metabolic syndrome
The term metabolic syndrome describes the group of disturbances including glucose
intolerance, central obesity, dyslipidemia and hypertension. Metabolic syndrome is a
growing problem in western lifestyle countries and is mainly due the high energy diet,
low physical activity and stress (Monteiro and Azevedo, 2010). People who have
metabolic syndrome have an increased risk of developing CVD, type 2 diabetes and
cancer (Monteiro and Azevedo, 2010). Different exact definitions for metabolic
syndrome have been proposed. The initial definition by the World Health Organization
stated that a patient must have either diabetes mellitus, impaired glucose tolerance,
impaired fasting glucose or insulin resistance; and additionally two of the following:
elevated blood pressure, dyslipidemia, central obesity, or microalbuminuria (Alberti and
Zimmet, 1998; Balkau and Charles, 1999). The International Diabetes Foundation has
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stated that patient must have central obesity and two of the following: raised
triglycerides, low HDL cholesterol, hypertension, raised fasting plasma glucose. The
United States National Cholesterol Education Program stated that diagnose requires at
least three of the following: central obesity, raised triglycerides, low HDL cholesterol,
blood pressure and increased fasting plasma glucose (2001). Other definitions have also
been presented. Probably the most useful definition for the future is the recent joint
statement from different institutes (Alberti et al., 2009a). Criteria include at least three of
the five of the following: population specific waist circumference limits,
hypertriglyceridemia (?1.7 mmol/L), reduced HDL cholesterol (males: <1.0 mmol/L,
females: <1.3 mmol/L), hypertension (systolic blood pressure ?130 mmHg and diastolic
blood pressure ?85 mmHg) and hyperglycaemia (fasting blood glucose ?100 mg/dL).
Central obesity and especially visceral fat has been shown to be highly predictive of
metabolic syndrome, insulin resistance and other deleterious conditions associated with
obesity (Elks and Francis, 2010). Systemic low-grade inflammation is an obvious feature
of metabolic syndrome. Increased inflammatory parameters, including CRP levels, have
been measured from these patients (Nakamura et al., 2008).
3.3. Adipokines
Adipose tissue is an endocrine organ that secretes bioactive peptides and proteins, which
are collectively named adipokines. These substances have a substantial role in energy and
vascular homeostasis. Many of the currently identified adipokines are dysregulated in
people with obesity, metabolic syndrome or type 2 diabetes (Maury and Brichard, 2010).
Adipokines have been shown to modulate the function of the cardiovascular system,
insulin sensitivity, insulin secretion, inflammation and fat mass (Maury and Brichard,
2010). For example, adipokines called leptin, adiponectin, resistin, visfatin, chemerin,
omentin, apelin and retinol-binding protein have been shown to be associated with these
modulations (Maury and Brichard, 2010). Only the first two are discussed in more details
in the scope of this dissertation.
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3.3.1. Leptin
Leptin is a 16 kDa hormone secreted by adipocytes. Typically obese people have higher
levels of leptin and signs of leptin resistance. In addition, leptin levels correlate with
adipose tissue mass and decrease in body weight is related to decreased leptin values
(Ahima, 2008). The current view is that leptin is a hormone that signals energy defiance
in the body, and not signaling to lose weight as was initially thought (Maury and
Brichard, 2010). Leptin acts in various organs, e.g. hypothalamus, cortex, limbic area,
pancreas, liver and the immune system. The main action of leptin is to regulate energy
homeostasis and reproductive functions in hypothalamus (Badman and Flier, 2007).
There leptin stimulates the secretion of anorexigenic peptides and decreases the secretion
of oroxigenic peptides, thereby leading to decreased food intake (Ahima, 2008). In a
common form of obesity it has been shown that the hypothalamus becomes resistant to
the action of leptin which prevents these favourable effects (Maury and Brichard, 2010).
In the periphery, leptin further stimulates fatty acid oxidation, glucose uptake and
prevents lipid accumulation in adipose and other tissues (Maury and Brichard, 2010).
Administration of leptin to obese people in order to cure obesity initially yielded
disappointing results (Heymsfield et al., 1999). This was probably due to the leptin
resistance seen in obese people. However, more recent studies have combined leptin
administration with medications that sensitize the body to the actions of leptin and this
approach has yielded more promising tentative results (Ozcan et al., 2009; Roth et al.,
2008).
3.3.2. Adiponectin
Adiponectin is a 30 kDa hormone that is produced in adipose tissue. In contrast to leptin,
adiponectin levels are decreased in obesity and correlate negatively with BMI (Arita et
al., 1999). Adiponectin levels are also decreased in type 2 diabetes and low adiponectin
levels are associated with CVD (Ouchi and Walsh, 2007). Adiponectin receptors are
expressed at least in muscles and liver. Adiponectin exhibits insulin sensitizing, fat
burning, anti-atherogenic, anti-inflammatory and anti-oxidant properties (Maury and
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Brichard, 2010). These features make adiponectin differ from leptin and it is one
plausible therapeutic target in order to achieve favourable effects in the body.
Interestingly, glitazones have been shown to increase adiponectin levels (Kubota et al.,
2006).
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4. Autonomic nervous system and inflammation
Traditional wisdom says that the mind has control over the body. This is also a valid
expression in the regulation of inflammation in the body. It has become evident that a
vagus nerve related inflammatory reflex mechanism regulates inflammatory responses
(Huston and Tracey, 2011). The vagus nerve innervates the organs of the
reticuloendothelial system which includes heart, lungs, liver, spleen and gastrointestinal
tract, of which the spleen is the most critical (Thayer, 2009).  Vagus nerve stimulation
leads to the release of neurochemical mediators, acetylcholine molecules, which interact
with alpha 7 nicotinic acetylcholine receptors (?7nAChR) on monocytes and
macrophages (Wang et al., 2003). This activation leads to the inhibition of
proinflammatory cytokines but not anti-inflammatory cytokines such as IL-10. The
autonomic nervous system’s control over the immune system has been termed the
cholinergic anti-inflammatory pathway (Tracey, 2002).
Under normal body homeostasis, the cholinergic anti-inflammatory pathway exerts a
tonic inhibitory impulse on innate immune responses. Interference with this pathway, by
either damaging the vagus nerve or knocking out the gene of ?7nAChR, leads to excess
proinflammatory cytokine response and exaggerate response to bacterial products and
injuries (Borovikova et al., 2000; Wang et al., 2003). The signal transduction mechanism
involving the ?7nAChR is not fully understood. The current view is that ?7nAChR ligand
interaction activates JAK-STAT dependent inhibition of the nuclear translocation of
nuclear factor –?B, which leads to decreased transcription of cytokine genes (de Jonge et
al., 2005; Huston and Tracey, 2011). A few mechanisms by which the cholinergic anti-
inflammatory pathway alleviates inflammation have been identified. Vagus nerve
stimulation significantly decreases TNF-? synthesis in spleen and this way the systemic
inflammation is decreased (Huston et al., 2006). Vagus nerve stimulation also
downregulates circulating neutrophil activation by attenuating the expression of CD11b, a
surface molecule required for cell adhesion and chemotaxis (Huston et al., 2009).
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The most widely used method to assess this vagus nerve activity in humans is to measure
heart rate variability (HRV). Control of the heart rate is under the influence of the
autonomic nervous system with the vagus nerve being the most important
parasympathetic mediator. Under resting conditions, the parasympathetic nervous system
is a more potent regulator of heart rate and during exercise the sympathetic nervous
system is more important. The heart rate is not constant even at rest. Fluctuations
between successive R waves can be recorded in electrocardiogram (ECG) tracings. From
these recordings HRV can be assessed either with reference to time (time domain
analysis) or frequency (frequency domain analysis). From time domains the following
variables can be derived: the standard deviation of R-R intervals (SDNN), the square root
of the mean squared difference of successive R-Rs (RMSSD), the number of pairs of
successive R-Rs that differ by more than 50 ms (NN50) and the proportion of NN50
divided by total number of R-Rs (pNN50). From frequency domains the following
variables can be derived: ultra-low frequency (ULF), very low frequency (VLF), low
frequency (LF), high frequency (HF) and total power (TP). Profound mathematics is
behind all these variables, which is beyond the scope of the study at hand, and computer
based analysing software is used to derive these variables.
Indices of HRV have been associated with increased morbidity and mortality in various
diseases (Huston and Tracey, 2011). Decreased HRV is associated with increased risk of
CVD events (Dekker et al., 2000), diabetes (Urbancic-Rovan et al., 2007) and
hypertension (Mussalo et al., 2001). HRV is also associated with autoimmune diseases
like rheumatoid arthritis (Bruchfeld et al., 2010) and interestingly with depression (Kemp
et al., 2010). This is thought to be one plausible mechanism behind unfavourable changes
in immune parameters among depressed patients.  Many studies have shown an
association between decreased HRV and increased low-grade systemic inflammation
measured as CRP, IL-6 or TNF levels (Haensel et al., 2008; Lampert et al., 2008;
Sajadieh et al., 2004). Interestingly one study has shown a synergistic effect of reduced
HRV and increased CRP on the risk for CVD (Sajadieh et al., 2006).
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5. Infections and atherosclerosis
In the late 1980’s a Finnish research group found evidence that seropositivity to
Chlamydia pneumoniae infection was associated with increased CVD risk (Saikku et al.,
1988). Since then numerous microbes have been investigated as possible risk factors for
CVD, including hepatitis A, Epstein-Barr, herpes simplex viruses, cytomegalovirus,
Mycoplasma pneumoniae, Helicobacter pylor, some dental bacteria and many others, as
well (Leinonen and Saikku, 2002). Currently, no consensus on the matter has been
reached whether microbe infections are a risk factor for CVD indices; both positive and
negative associations have been reported (Danesh et al., 1997). Therefore, instead of
studying single pathogens, the total infectious burdens of these pathogens have been also
studied. The total infectious burden has been shown to be associated with CVD more
strongly than the single pathogens (Smieja et al., 2003). In addition to these known
pathogenic microbes with a tendency to cause chronic infections, there is increasing
evidence that bacteria of the normal human gut, oral cavity and airways are related to
obesity and atherosclerosis (Caesar et al., 2010). Adenoviruses and some other viruses
have also been associated with obesity (Pasarica and Dhurandhar, 2007).
5.1. Cytomegalovirus
Cytomegalovirus (CMV) is a widespread virus in human populations. CMV is a member
of the herpes family of viruses and contains double-stranded deoxyribonucleic acid
(DNA) as their genome. Evidence of CMV infection has been found in all the world’s
populations examined (Soderberg-Naucler, 2006).  The infection is typically acquired
during childhood, with an incidence of 30-40% within the first year of life. Incidence
rises over the lifespan and in cohorts of elderly people over 90% are seropositive to the
virus (Roberts et al., 2010).  Typically CMV infection is mild or even asymptomatic in
healthy individuals and after the initial immune response, the virus becomes latent and
resides in the cells of myeloid lineage (Taylor-Wiedeman et al., 1991). However, it seems
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that CMV is not merely a silent and latent virus in the body after primary infection, but
rather persists in the body with features of a chronic productive infection or as a latent
infection with periodic reactivations. Evidence of CMV shedding was detected in the
urine and plasma samples of the majority of healthy seropositive young women during a
30-month follow-up (Arora et al., 2010). In the same study cohort, one-third of the
seropositive women also showed evidence of CMV reinfection with new CMV strains,
which were identified by the appearance of new antibodies specific for CMV envelope
glycoproteins (Ross et al., 2010). CMV shedding was observed in women with evidence
of reinfection and in those without it (Arora et al., 2010). Additionally, shedding of CMV
into urine has been associated with increased plasma CMV antibody titers in astronauts
(Mehta et al., 2000).
CMV has an established role in many diseases and the possible role of CMV as a
mediator in other disease has also been hypothesized. In immunocompromised people,
the CMV infection causes significant symptoms. Patients may encounter symptoms such
as spiking fever, leucopenia, malaise, hepatitis, interstitial pneumonia, gastrointestinal
disease and retinitis. Typical risk groups are organ transplant patients and HIV-infected
patients (Bailey et al., 1995; Soderberg-Naucler, 2006). The foetus is at risk of having
birth defects, typically hearing loss and mental retardation, if CMV infection occurs
during pregnancy (Fowler et al., 1992). In addition to these established pathologies, CMV
has been associated with other chronic inflammatory diseases. The virus has been
detected in many autoimmune diseases, psoriatic plaques, lesions of inflammatory bowel
disease, rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s syndrome
(Soderberg-Naucler, 2006). The virus has also been detected in different kinds of cancers,
tumours of colon and prostate, and glioblastomas (Soderberg-Naucler, 2006).
In addition to all the other implications, there is a notable relation between CMV,
atherosclerosis and CVD. CMV can infect human endothelial cells and it has been shown
to aggravate the development of atherosclerosis (Cheng et al., 2009; Vliegen et al., 2004).
CMV infection leads to neutrophil transendothelial migration, smooth muscle cell
migration, intracellular adhesion molecule expression, leukocyte and thrombocyte
48
adhesion, CXC chemokine expression and cytokine secretion (Soderberg-Naucler, 2006).
In addition CMV infection has been shown to cause increased blood pressure values in
mice via stimulating renin synthesis (Cheng et al., 2009). In humans CMV DNA copy
number and CMV related microRNA expression has been associated with hypertension
(Li et al., 2011). In heart transplant patients the CMV infection has been shown to lead to
higher incidence of graft rejection and cardiac allograft vascular disease (Grattan et al.,
1989). The use of antiviral treatment with ganciclovir has been shown to decrease
rejection and allograft vascular disease risk in CMV infected transplant patients (Potena
et al., 2006). In immunocompromised people the role of CMV as a risk factor for CVD is
controversial. Some studies have shown significant associations between CMV infection
and CVD, when other studies have reported non-significant results. (Adler et al., 1998;
Haider et al., 2002; Smieja et al., 2003; Sorlie et al., 2000). However, studies carried out
on elderly people have shown consistently that high levels of antibodies against CMV are
associated with increased cardiovascular and total mortality (Roberts et al., 2010;
Strandberg et al., 2009; Wang et al., 2010). CMV infection has also been related to early
vascular changes i.e. FMD and IMT (Grahame-Clarke et al., 2003; Nieto et al., 1996;
Simmonds et al., 2008). However, non-significant results have also been reported (Khairy
et al., 2003; Oshima et al., 2005).
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Aims of the study
The aim of the dissertation was to study the role of different inflammatory markers in
early atherosclerosis. The specific aims were to
1. Investigate the effect of combined oral contraceptives use on CRP levels,
determinants and genetic regulation in healthy young women.
2. Examine SAA level distribution, determinants and predictive value for early
atherosclerotic changes in healthy young adults.
3. Analyse the effect of cholinergic autonomic pathway estimated by short-term
HRV, on CRP and SAA levels in healthy young adults.
4. Investigate PTX3 concentrations distribution, determinants and associations with
early atherosclerotic changes in a middle aged cohort.
5. Study whether high CMV antibody titers are associated with early atherosclerotic
changes, blood pressure and other traditional atherosclerotic risk factors in healthy
young adults.
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Subjects and methods
1. Subjects
1.1. Studies I,II,III and V
The study population consisted of participants in the Cardiovascular Risk in Young Finns
Study, which is an ongoing multi-centre follow-up study involving five university
hospitals in Finland. The study began in 1980, when 3,596 participants between the ages
of 3 and 18 were randomly selected from the national population registers. The 21-year
follow-up was conducted in 2001, when 2,283 participants were between 24 and 39 years
of age. Cardiovascular risk factor measurements, including BMI, serum lipids, blood
pressure values, CRP, SAA, leptin, adiponectin, alcohol consumption and smoking
habits, were recorded during this follow-up.
1.2. Study IV
The study population was a subpopulation drawn from a Finnish cross-sectional health
examination survey, the Health 2000 Survey, carried out 2000-2001. The overall study
cohort was a two-stage stratified cluster sample (8,028 persons) representing the entire
Finnish population aged 30 years and above. In order to study cardiovascular risk and
diabetes more thoroughly, a supplementary study was carried out (sample size 1,867 and
participation rate 82%). The participants in the study consisted of those supplementary
study subjects from whom the data about the clinical and metabolic cardiovascular risk
factors were available. The study subjects (n=1,236; n=666 women, n=570 men) were
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between 46 and 76 years of age and the study was conducted in the catchment of the five
Finnish university hospitals.
2. Methods
2.1. Measurements of inflammation markers
In Studies I, II, III and V; CRP measurements were taken from fasting plasma. CRP
concentrations were analysed using a highly-sensitive latex turbidometric immunoassay
(Wako Chemicals GmbH, Neuss, Germany) with a detection limit of 0.06 mg/L. Serum
SAA concentrations were measured with an enzyme-linked immunosorbent assay
(ELISA) kit with a detection limit of <0.004 mg/L (Human SAA, Biosource
International, Camarillo, CA).
In Study IV, PTX3 concentrations were determined in EDTA-plasma using a commercial
ELISA kit according to the manufacturer’s instructions (Quantikine DPTX 30; R&D
Systems Inc., Minneapolis, USA). The mean detection limit for the assay was 0.025
ng/mL and the assay exhibited no cross-reactivity with either CRP or serum amyloid P.
Plasma CRP concentrations were determined using a chemiluminescent immunometric
assay (Immulite, Diagnostic Products Corporation, Los Angeles, CA, USA).
In Study V, CMV IgG antibody titers were analysed using a commercial enzyme
immunoassay (Enzygnost Anti-CMV/IgG, Siemens Healthcare Diagnostics Products
GmbH, Marburg, Germany). According to the manufacturer, the test sensitivity was
99.3% and the specificity was 98.2%. Seropositivity for CMV was defined as a serum
anti-CMV IgG titer of ?230.
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2.2. Analysis of CRP -717, -286, +1059, +1444 and +1846 genotypes
DNA was extracted from whole blood using a commercially available kit (Qiagen Inc.,
Hilden, Germany) in 2001. Genotyping of CRP gene polymorphisms -717A>G
(rs2794521), -286C>T>A (rs3091244), +1059G>C (rs1800947), +1444C>T (rs1130864)
and +1846G>A (rs1205) were performed using the ABI Prism 7900HT Sequence
Detection System for both PCR and allelic discrimination (Applied Biosystems, Foster
City, CA). For SNP +1059 a commercial kit from Applied Biosystems was used (Assay
On Demand, C_177490_10 CRP). The SNPs -717, +1444 and +1846 were genotyped
using Assays By Design from Applied Biosystems under standard conditions. The
triallelic tagSNP -286 was genotyped with designed primers and probes as previously
described (Carlson et al., 2005), except for the genotype calling, which was done
manually from the PCR run component tab.
2.3. Analysis of typical atherosclerotic risk factors
In Studies I,II,III and V, blood pressure measurements were taken using a random zero
sphygmomanometer (Hawksley & Sons Ltd, Lancing, UK) and the mean of three
measurements was used in the analysis. BMI was calculated from measured height and
weight values. Waist and hip circumferences were measured in standard positions and
waist-hip ratio was calculated from these measurements. CRP, SAA, leptin, insulin, HDL
cholesterol, triglyceride and total cholesterol levels were obtained from fasting blood
plasma samples. LDL-cholesterol was calculated with the Friedewald formula.
Homeostasis assessment of insulin resistance (HOMA-IR) was calculated according to
the formula: HOMA-IR = fasting glucose (mmol L-1) × fasting insulin (mU L-1) / 22.5.
Information on smoking habits, alcohol consumption, oral contraceptive use, type of oral
contraceptives used, medications used, physical activity, pregnancy and breastfeeding
were collected by administering a questionnaire.
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In Study IV, BMI and waist-hip ratio measurement were done as described in previous
paragraph. The blood pressure was measured with the automatic Omron M4 manometer
(Omron Matsusaka Co., Japan, Omron Healthcare Europe B.V., Hoofddrop, the
Netherlands) and the mean of three measurements was used in the analysis. Pulse
pressure was calculated as the difference between the mean systolic and the mean
diastolic pressure. Current smoking, CVD history and events were evaluated with a
questionnaire. Those who were current smokers were defined as smokers and the rest of
subjects as non-smokers. Venous blood samples were drawn after an overnight fast. HDL
cholesterol, total cholesterol, triglyceride and plasma glucose concentrations were
determined enzymatically with a clinical chemistry analyzer (Olympus, AU400,
Hamburg, Germany).
2.4. Ultrasound measurements of arteries
In Studies II and V, Carotid ultrasound measurements were performed with a Sequoia
512 high-resolution ultrasound system (Acuson, CA). Cdist, which shows the ability of
the large arteries to expand under cardiac pulse pressure, was assessed from the formula
Cdist=([Ds-Dd]/Dd)/(Ps-Pd), where Ds is the systolic diameter, Dd is the diastolic diameter,
Ps is the systolic blood pressure and Pd is the diastolic blood pressure. Mean IMT was
derived from a minimum of four measurements of the posterior wall of the left carotid
artery (at ~10mm proximal to the bifurcation). In Study V, the brachial FMD was also
measured. The left brachial artery diameter was measured both at rest and during reactive
hyperaemia. Increased flow was induced by inflation of a pneumatic tourniquet placed
around the forearm to a pressure of 250 mmHg for 4.5 minutes, followed by release.
Three measurements of arterial diameter were performed at end-diastole at a fixed
distance from an anatomic marker at rest and at 40, 60 and 80 seconds after cuff release.
The vessel diameter in scans after reactive hyperaemia was expressed as the percentage
relative to the resting scan. The average of three measurements at each time point was
used to derive the maximum FMD (the greatest value between 40 and 80 seconds)
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In Study IV, high-resolution B-mode carotid ultrasound examination of the right carotid
artery was performed according to a standardized protocol using a 7.5 MHz linear array
transducer. The examinations were performed by centrally trained and certified
sonographers at six study locations around Finland. Carotid IMT measurements were
performed off-line with automated imaging processing software and one reader was
responsible for reading all the ultrasound images. Three summary measures of the carotid
IMT were calculated: the mean of the three average IMTs of the common carotid artery
(mean CCA IMT), the mean of the three average IMTs of the carotid bulb (mean bulb
IMT), and the mean of these two means (mean IMT). Mean IMT was used in the study.
The mean Cdist in Study IV was assessed analogously compared to description on Cdist
measurements in Studies II and V.
2.5. Analysis of heart rate variability measurements
In Study III, a single-channel chest-lead ECG, 3 minutes in length, was recorded. Prior to
the recording, subjects were comfortably seated in supine positions for a minimum of 15
minutes during a vascular ultrasound scan. The signals were converted from analogue to
digital with a sampling rate of 200 Hz; the respective time-series of R-R intervals were
generated. ECG signals were manually revised. The stationary period was identified
during a 3-minute period of metronome controlled breathing at frequency of 0.25 Hz and
was used to compute the time and frequency-domain HRV indices. The study subjects
were trained for this procedure beforehand in order to avoid emotional arousal. The mean
duration of the stationary period was analysed 173 seconds and the mean number of
analysed R-peaks was 196. These indices were analysed using a commercial WinCPRS
program (Absolute Aliens, Turku, Finland).
The following parameters were identified from time and frequency-domain
measurements: HF (0.15-0.40 Hz), LF (0.04-0.14 HZ), TP, RMSSD, and SDNN. The
ratio between low frequency and high frequency oscillations (LF/HF × 100%) was
calculated. Under resting conditions vagal activity of cardiovascular autonomic
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regulation prevails (Levy, 1971). The vagal activity is the major contributor of the HF
component of spectral HRV (1996). The LF component may represent either sympathetic
modulation or combination of both sympathetic and vagal influences. LF/HF is
considered to reflect sympathovagal balance or sympathetic modulations (1996; Pagani et
al., 1986). RMSSD is considered as a marker of vagal function and correlates strongly
with HF.
Short-term HRV indices depend on the length of the time-series, and shorter time-series
may result in less variability; therefore, HRV indices were recollected from 75 subjects in
order to compare HRV indices on 3 and 5 minute ECG recordings. In addition, the
reproducibility of short-term HRV indices was assessed from 51 subjects after an average
of 4.4 months from the first measurement. Both the reproducibility and the comparability
of these measurements were satisfactory and no statistically significant differences were
observed in these measurements (Koskinen et al., 2009).
2.6. Statistical analyses
In all studies, the data was analysed by SPSS for Windows statistical software (versions
14.0, 15.0 and 17.0, SPSS Inc., Chicago, IL, USA). For non-parametric variables Mann-
Whitney’s test and Kruskall-Wallis test were used in statistical analyses. For normally
distributed variables t-test and one-way ANOVA were used. Correlation between skewed
variables was estimated with Spearman’s test and the correlation between normally
distributed variables was estimated using Pearson’s test. Comparisons of the variables
between sexes or according to COCs use were performed with Student’s t-test, Mann-
Whitney’s test and Chi-squared test as appropriate. For linear regression analysis and for
analysis of covariance (ANCOVA) the non-parametric values were log transformed prior
to analysis. In all analyses, the level of p<0.05 was considered statistically significant.
In Study I, the haplotypes were constructed from the five CRP SNPs using the PHASE
v2.0.2. program. It calculates from the genotype data the most probable haplotype pairs
for each individual using a Bayesian statistical method.
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2.7. Ethics
In Studies I, II, III and V; the study was approved by local ethics committees and was
conducted following the guidelines of the Declaration of Helsinki. All participants also
gave their written informed consent. In Study IV, the protocol was approved by the
Epidemiology Ethics Committee of the Helsinki and Uusimaa Hospital District. All
participants also gave their signed informed consent.
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Results
1. Effect of using different COCs on CRP determinants and genetic
regulation
It was previously known that COCs use has a marked effect on women’s CRP levels. In
this study we aimed to find out if COCs use alters the usually seen determinants of CRP
in women and if these changes are somehow related to different COCs used. In
multivariate linear regression model, it was shown that in women who use COCs, CRP
levels were related to BMI (B=0.020, SE=0.009, p=0.029), leptin (B=0.524, SE=0.124,
p<0.001) and triglyceride (B=0.358, SE=0.156, p=0.023) levels, while in non-users CRP
levels were only related to BMI (B=0.028, SE=0.005, p<0.001) and leptin (B=0.557,
SE=0.080, p<0.001). Further it was seen that the relation of CRP and triglycerides in
COC users was associated with use of high dosage of progestagen or cyproterone.
Interestingly, the genetic haplotypes previously shown to associate with CRP levels in
this cohort had an effect on CRP levels only in those women who did not use COCs.
2. SAA values in young adults
In Study II, the aim was to ascertain the distribution of SAA levels in healthy young
adults and identify associations between SAA, atherosclerotic risk factors and early
vascular changes. Distributions of SAA concentrations in healthy young women and men
are presented in Figure 1. At baseline women had higher SAA levels (p<0.001) but this
association was attenuated to null when the analysis was adjusted with leptin, adiponectin
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or ApoA1. Women using COCs had higher SAA levels than non-users (median 13.60
mg/L vs. 10.70 mg/L, p<0.001). Whereas in women using a levonorgestrel-releasing
intrauterine device (IUD) had lower SAA values compared to non-users (median 8.75
mg/L vs. 10.7 mg/L, p=0.034). SAA levels correlated directly with indices of adipose
tissue mass (BMI, waist circumference), lipid, blood pressure, insulin, HOMA-IR, leptin
and CRP values in both sexes. Interestingly many of these associations diminished after
adjustment for BMI.
In multivariate regression model, independent determinants for SAA were CRP (women:
B=0.479, SE=0.028, p<0.001; men: B=0.610, SE=0.025, p<0.001), leptin (women:
B=0.121, SE=0.048, p=0.012; men: B=0.112, SE=0.041, p=0.007) and ApoA1 (B=0.270,
SE=0.054, p<0.001) in women and HDL cholesterol (B=0.097, SE=0.040, p=0.017) in
men. We also did alternative multivariate models without CRP. In that model
independent determinants for SAA were leptin (B=0.424, SE=0.070, p<0.001), ApoA1
(B=0.270, SE=0.054, p<0.001) and BMI (B=0.011, SE=0.004, p=0.013) in women; and
leptin (B=0.340, SE=0.071, p<0.001) and waist circumference (B=0.001, SE=0.001,
p=0.006) in men. Serum SAA concentrations correlated significantly with early vascular
changes i.e. IMT and Cdist (termed as carotid artery compliance in the original
publication). However, in multivariate model, SAA levels had no independent effect on
these variables.
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Figure 1. Distribution of serum SAA levels in healthy young women and men.
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3. HRV measurements and inflammatory markers in young adults
HRV indices and inflammatory markers, CRP and SAA, were measured from 1,601
subjects after the exclusion criteria. We aimed to ascertain the relations of these
inflammatory markers and HRV indices. CRP levels correlated with the following HRV
indices: heart rate (r=0.112, p<0.001), LF (r=-0.065, p<0.01), TP (r=-0.074, p<0.01),
SDNN (r=-0.080, p<0.01) and RMSSD (r=-0.072, p<0.01). SAA levels correlated with
heart rate (r=0.113, p<0.001), HF (r=-0.049, p<0.005), LF (r=-0.057, p<0.05), TP (r=-
0.054 p<0.01), SDNN (r=-0.070, p<0.01) and RMSSD (r=-0.075, p<0.01). Multivariate
regression models were created to assess the independent effect of HRV indices on
inflammatory markers. Heart rate (B=0.006, SE=0.003, p=0.040), LF (B=-0.070,
SE=0.031, p=0.024), TP (B=-0.087, SE=0.032, p=0.007), SDNN (B=-0.186, SE=0.066,
p=0.005) and RMSSD (B=-0.108, SE=0.048, p=0.024) remained independent
determinants for CRP after adjustment with typical atherosclerotic risk factors including
leptin. However, none of the HRV indices were associated independently with SAA
levels.
4. PTX3 levels determinants and associations with early
atherosclerotic markers
Aim of Study IV was to ascertain the distribution and determinants of PTX3 values, and
its relation to early vascular changes. PTX3 levels did not differ between men and women
(median 1.04 ng/L vs. 0.98 ng/L, p=0.107). Considering all the subjects in Study IV,
PTX3 levels correlated significantly (p<0.05) with age, systolic and diastolic blood
pressure, pulse pressure, total cholesterol (inverse), LDL-cholesterol (inverse), glucose,
insulin, HOMA-IR, indoleamine 2,3-dioxygenase (IDO), IMT and Cdist (inverse) (Table
1). In stepwise linear regression model, LDL-cholesterol (B=-0.038, SE=0.011, p=0.001),
pulse pressure (B=0.002, SE=0.001, p=0.004) and IDO (B=0.003, SE=0.001, p=0.017)
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were independent determinants of PTX3 levels. In multivariate analysis, PTX3 had no
independent effect on IMT (p=0.659) nor Cdist (p=0.878).
However, earlier studies have yielded different results on PTX3 determinants among
people with various clinical conditions. In order to homogenize our study groups,
subjects were divided in four subclasses: insulin-resistant, hypercholesterolaemic,
hypertensive and healthy subjects. In insulin-resistant subjects, PTX3 levels correlated
directly with age, pulse pressure and IDO, and correlated inversely with total and LDL
cholesterol. In hypercholesterolaemic subjects, PTX3 levels correlated directly with HDL
cholesterol, systolic blood pressure and pulse pressure. In hypertensive subjects, PTX3
levels correlated directly with systolic blood pressure, pulse pressure and IDO. No
significant correlations were observed in healthy subjects. After the subclass division,
there were no significant correlations between PTX3 and early vascular changes. In
multivariate regression model, LDL cholesterol (B=-0.054, SE=0.019, p=0.005) and IDO
(B=0.004, SE=0.002, p=0.015) were independently associated with PTX3 levels in
insulin-resistant subjects. In hypercholesterolaemic and hypertensive subjects only pulse
pressure was independently associated with PTX3 levels.
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Table 1. Pearson’s correlations for PTX3 in Health 2000 study subjects.
r p
Age (years) 0.116 <0.001
Body mass index (kg/m2) -0.032 0.272
Waist circumference (cm) 0.010 0.739
Hip circumference (cm) 0.003 0.917
Waist-hip ratio 0.010 0.724
Heart rate (beats/min) 0.010 0.731
HDL-cholesterol (mmol/l) 0.014 0.628
LDL-cholesterol (mmol/l) -0.084 0.004
Total cholesterol (mmol/l) -0.064 0.026
(log)Triglycerides (mmol/l) 0.011 0.713
Glucose (mmol/l) 0.063 0.029
(log)Insulin (mmol/l) 0.086 0.003
(log)HOMA-IR 0.091 0.002
Systolic blood pressure (mmHg) 0.123 <0.001
Diastolic blood pressure (mmHg) 0.067 0.020
Pulse pressure (mmHg) 0.132 <0.001
(log)CRP (mg/l) 0.023 0.430
IDO 0.114 0.002
Carotid IMT (mm) 0.073 0.012
Cdist (%/10mmHg) -0.076 0.012
5. Relation of high CMV antibody titers to atherosclerotic risk
factors, blood pressure and early vascular changes
In Study V, we aimed to ascertain if CMV antibody titers were associated with typical
atherosclerotic risk factors, blood pressure and early vascular changes. CMV antibody
titers were significantly higher in women than in men. There were significantly (p<0.001)
more women with CMV antibody titers over 14,000 than men (72.5% vs. 27.5%). In
men, high CMV antibody titers were directly associated with age (p<0.001), systolic
(p=0.053) and diastolic (p=0.002) blood pressure elevation, and inversely associated with
flow-mediated dilation (p=0.015). In women, CMV antibody titers were not associated
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with any of the parameters analysed. In a multivariate regression model, which included
traditional atherosclerotic risk factors, CMV antibody titers were independent
determinants for systolic (p=0.030) and diastolic (p=0.004) blood pressure elevation and
flow-mediated dilation (p=0.015) in men. These findings were also repeatable in a
subgroup consisting solely of seropositive subjects.
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Discussion and conclusions
1. COCs use alters metabolic determinants and genetic regulation
of CRP
In Study I, we investigated the effect of COCs use on CRP determinants and genetic
regulation. It was shown that triglycerides were an independent determinant of CRP only
in women who used COCs. This association especially was related to use of high dosage
of progestagen or cyproterone. However, CRP levels were not significantly different in
these groups compared to users of other progestagens. These findings raise the possibility
that lipids and CRP are not related in all women as has been thought. The relation
between CRP and triglycerides could be a result of simultaneous expression of these
substances in liver stimulated by COCs usage. This hypothesis is supported by the
finding that COCs use increase CRP levels without increase in IL-6 levels (van Rooijen
et al., 2006), indicating that COCs stimulate hepatocytes directly.
Another important finding in Study I was that CRP genetic polymorphisms seem to have
an effect on CRP levels only in those women who do not use COCs. This finding
highlights the importance of thorough adjustment with known internal and external
factors affecting CRP levels, for example in genetic studies. The mechanism by which
COCs induce CRP production in liver is unknown. No obvious steroid hormone binding
site has been identified in CRP gene.
The risk of CVD events is slightly increased in women who use COCs (Battaglioli and
Martinelli, 2007; Tanis et al., 2001). CVD risk is also associated with the increased levels
of CRP (Kaptoge et al., 2010; Pearson et al., 2003; Ridker et al., 2000). We conclude that
use of COCs is associated with higher CRP and triglyceride levels. Additionally known
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genetic regulation of CRP levels can be overwhelmed by the strong COCs effect. Further
studies are still needed to ascertain whether there is cell based interplay between these
factors. It is a clinically relevant question so that women can have even safer and more
efficient means of contraception in the future.
2. SAA concentrations are associated with cardiometabolic risk
factors but not with early vascular changes
In Study II, we demonstrated that SAA levels were associated with several
cardiometabolic risk factors. Although in multivariate model only few variables had
independent associations with SAA. Predictably indices of adipose tissue i.e. BMI, waist
circumference and leptin were closely related to SAA levels. This supports the hypothesis
that SAA is expressed mainly in adipose tissue and hence could be a possible link
between obesity and inflammation (Yang et al., 2006). Additionally HDL cholesterol in
men and ApoA1 in women were independently associated with SAA levels. These
findings were expected because of the capability of SAA to displace ApoA1 on the
surface of HDL particles (Kisilevsky and Tam, 2002). SAA levels were also associated
with insulin levels and with insulin sensitivity index, although these associations were
adjusted to null in multivariate models. Our results therefore indicate that insulin
sensitivity has no independent relation to SAA.
Our results do not support the role of SAA as an independent predictor of early
atherosclerotic changes. SAA levels correlated with IMT and CAC indices but had no
independent predictive value for these early vascular changes. Despite these results, the
relation between SAA and vascular changes remains controversial. Our results and the
results by Wohlin et al. support the notion that SAA is not an independent predictor of
IMT in European populations (Wohlin et al., 2007). In cohorts consisting of Asian or
African-American subjects there is evidence that SAA levels and SAA genetics may be
associated with IMT (Carty et al., 2009; Uurtuya et al., 2009; Xie et al., 2010). Thus there
66
may be some ethnic diversity in relation of SAA and CVD risk that needs to be more
thoroughly investigated in the future.
We were also able to demonstrate that SAA levels are increased among COCs using
healthy young women and decreased in those women using IUD. The association
between COCs use and increased SAA levels has also been seen in one other study (van
Rooijen et al., 2006). Another study showed there was positive association between ERT
use and SAA levels in postmenopausal women (Miller et al., 2004), but this association
may be diminished by oral administration of an androgenic progestin,
medroxyprogesterone acetate (Wakatsuki et al., 2002). The association between IUD use
and decreased SAA levels is a novel finding that has not been reported elsewhere. It has
previously been shown that transdermal administration of ERT reduces SAA levels
(Abbas et al., 2004). The mechanism by which transdermal ERT reduces SAA levels is
unknown but it may be related to anti-inflammatory effects of estrogen because
subcutaneous estradiol administration has been shown to reduce leukocyte infiltration
into injured vessels in animals (Miller et al. 2004). This mechanism could partly explain
the inverse association between IUD use and SAA levels, but IUDs do not release
estrogen. It is possible that progestagen may also have some unknown anti-inflammatory
mechanism.
In conclusion, serum SAA levels are associated with indices related to adipose tissue
mass. However, SAA levels had no independent effect on early vascular changes. Further
studies are still needed to determine whether early SAA measurements can have
prognostic value on future CVD events. It is important to concede that only free SAA
levels of serum were measured. Therefore these results may only give a limited view of
the meaning of SAA in early atherosclerosis. Thus other forms of SAA may be more
relevant i.e. locally produced SAA, HDL bound SAA or LDL-SAA complex.
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3. HRV is independently associated with CRP but not with SAA
In Study III, we measured HRV, a way to assess autonomic nervous system function, and
inflammatory markers CRP and SAA in healthy young adults. The CRP and SAA levels
correlated significantly with the most of the HRV indices. However, in multivariate
regression model, only the association between CRP and HRV indices remained
significant while the association between SAA and HRV was attenuated to null after
adjustment for typical atherosclerotic risk factors, including leptin. It has been previously
been shown that leptin levels correlate significantly with HRV indices and there is a
strong relation between leptin and inflammatory markers (Paolisso et al., 2000; Viikari et
al., 2007). None of the previous studies had taken all these three aspects into
consideration; hence we could conclude for the first time that the known association
between CRP and HRV indices is independent of leptin. However, there were no
independent associations between SAA and HRV. One plausible explanation for this
difference could be the different sites of expression. In normal conditions the majority of
circulating SAA is expressed in adipose tissue while in the case of CRP the main source
is liver (Sjoholm et al., 2005; Yang et al., 2006). The liver is under the innervation of the
vagus nerve but this is not the case with adipose tissue. Therefore it is plausible that the
autonomic nervous system can only regulate CRP production but not SAA expression.
Our findings support the link between abnormalities in autonomic nervous system
function and changes in inflammatory parameters. This further supports the hypothesis
that the cholinergic anti-inflammatory pathway may be involved in the pathogenesis of
chronic inflammatory diseases such as CVD.
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4. PTX3 levels are related to atherosclerotic risk factors but not to
subclinical atherosclerosis in middle-aged individuals with high
risk for CVD
In Study IV, we demonstrated that PTX3 levels were associated with atherosclerotic risk
factors among middle-aged subjects with high risk for CVD. After categorizing these
people into three subgroups: insulin-resistant, hypercholesterolemic and hypertensive
subjects; not all of these associations were seen in the whole population remained. In
multivariate models done either in whole population or in these high CVD risk
subgroups, the same determinants were seen: LDL cholesterol, pulse pressure and IDO.
However, all these associations were rather weak and these factors could explain only
1.1-5.7% of the variation in PTX3 values. Additionally no correlations between PTX3
and markers of subclinical atherosclerosis were seen in high CVD risk subgroups or in
the multivariate model of whole population. Therefore it is plausible that PTX3
represents some unknown aspect of atherosclerosis. PTX3 has a possible dualistic role; in
mouse models, PTX3 has been shown to have a cardioprotective function (Norata et al.,
2009; Salio et al., 2008). Our finding of a positive relation between PTX3 and IDO also
supports this idea. IDO is a known immunoinflammatory downregulator of Th1 cell
responses (Xu et al., 2008).  Hence it is plausible that PTX3 is expressed by cells in order
to achieve a protective physiological response. Further studies are still needed to ascertain
the PTX3 possible cardioprotective role in atherosclerosis and CVD.
Contradictory results have been reported about the determinants of PTX3. Our results
support a correlation between PTX3, age, and cholesterol and blood pressure values. The
direct correlation between PTX3 and age is seen quite unanimously (Jenny et al., 2009;
Matsui et al., 2010; Yamasaki et al., 2009). Differing results have been reported about the
correlation between PTX3 and cholesterol values (Ogawa et al., 2010; Yamasaki et al.,
2009; Zanetti et al., 2009). Our results indicate that there may be an inverse relation
between these variables. Further studies are needed to clarify this discrepancy. Earlier
studies have reported non-significant correlations between PTX3 and blood pressure
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(Alberti et al., 2009b; Suliman et al., 2008b; Zanetti et al., 2009). Our study was the first
also to take pulse pressure into consideration and had decidedly more subjects than in
these earlier studies. Therefore the relation of PTX3 and blood pressure may have not
been seen in them. However, further studies are still needed to confirm our results and to
determine the factors involved in the regulation of PTX3.
5. CMV IgG antibodies titers are directly associated with blood
pressure and inversely with FMD in healthy young men
In Study V, we discovered that CMV IgG antibodies titers were associated with increased
blood pressure values and inversely with FMD values in young men. These results were
not seen in women. However, women had significantly higher CMV titers than men.
Cheng et al. showed in mice that CMV infection increased blood pressure values in a
dose dependent manner (Cheng et al., 2009).  They could also demonstrate that CMV
infection stimulates renin synthesis in cell cultures and increased renin values were
measured from these mice after CMV infection. In Chinese cohort, hypertension were
shown to associate with increased CMV DNA copy number in plasma (Li et al., 2011).
Our results were the first to demonstrate that high CMV antibody titers are associated
with increased blood pressure in humans. The relation between CMV titers and blood
pressure is a new mechanism which could explain the deleterious effects of CMV. High
CMV antibody levels as well as seropositivity indicating past or present CMV infection
are known to be associated with mortality (Roberts et al., 2010; Simanek et al., 2011;
Strandberg et al., 2009; Wang et al., 2010).
The inverse association between CMV titers and FMD is another possibly deleterious
mechanism caused by CMV. In vitro, CMV infection has been shown to stimulate the
P38-MAPK signalling pathway and upregulate phosphatase and tensin homolog
substances (Shen et al., 2006; Weis et al., 2004). Via this pathway, endothelial nitric
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oxide synthase is inhibited and reduced nitric oxide production leads to endothelial
dysfunction (Petrakopoulou et al., 2004). The association between CMV and endothelial
dysfunction has been further hypothesised to be a possible pathologic mechanism of
hypertension (Zhang et al., 2011). This mechanism is one possible explanation for the
demonstrated association between CMV titers and reduced FMD in our study, and it is
also a possible alternative explanation for the demonstrated association between CMV
titers and increased blood pressure. Despite these promising novel results, further studies
are still needed to confirm these results and longitudinal studies are needed to show if
there is a causal relation between CMV infection, blood pressure and endothelial
function.
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Summary and limitations
In this dissertation we found that measured inflammatory parameters were related to
various metabolic, lifestyle and physical findings. These factors appeared to relate with
each other in a rather complex way, which well accords with the current understanding of
many pathological mechanisms linking inflammation and atherosclerosis. Our results also
support the existence of such multiple relations in healthy young adults and middle-aged
subjects. However, we could only show that CMV antibody levels were independently
associated with early vascular changes. It is still important to realize that we measured
only a few of the hundreds of known inflammatory parameters in humans (Cytokines &
Cells Online Pathfinder Encyclopedia, www.copewithcytokines.org). In the future, it will
be important to continue the research on inflammatory parameters, also in people without
apparent atherosclerotic manifestations, in order to detect markers of ongoing
atherosclerotic inflammation in the body.
There were limitations in these studies. First of all, we must concede that despite a wide
range of studies affirming the relation between inflammation and atherosclerosis, the
causality of these two events has not been confirmed in humans. Also, inflammation in
atherosclerosis is not limited merely to the early phases of atherosclerosis. The
inflammatory process continues from the initial lesion to the plaque rupture. Within the
limits of this dissertation, it was only possible to discuss the inflammation in the early
phase of atherosclerosis. This setup also limits the generalizability of these results. The
cross-sectional natures of these studies do not allow us to investigate the causality.
Therefore it is possible that measured inflammatory marker levels in these early stages of
atherosclerosis may have no relation to late atherosclerotic indices or they might equally
have an even more significant relation to them. Eventually only the lifelong longitudinal
follow-up of the young Finns Study will reveal the true significance of these findings.
Finally, there are also many other pathological mechanisms that play a substantial part in
atherosclerosis, such as coagulation, lipid accumulation, fibrosis and calcification.
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Therefore this dissertation cannot be considered a comprehensive presentation of the
pathogenesis of atherosclerosis.
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Use of combined oral contraceptives alters metabolic determinants and genetic regulation
of C-reactive protein. The Cardiovascular Risk in Young Finns Study
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Background. Use of combined oral contraceptives (COCs) is known to increase concentrations of C-reactive
protein (CRP), an important predictor of cardiovascular disease. The inflammatory nature of the disease is well
acknowledged. The aim of this study was to find out whether the metabolic, lifestyle and genetic determinants of
CRP differ between women who use COCs and those who do not use any hormonal contraceptives (non-users).
Material and methods. A total of 1,257 women (24–39 years) participated in the ongoing Cardiovascular Risk in
Young Finns Study, a population based cross-sectional follow-up study. Use of hormonal contraceptives was
determined by questionnaire. Plasma CRP and other cardiovascular risk factors were measured; five CRP gene
polymorphisms were genotyped (2717AwG, 2286CwTwA, +1059GwC, +1444CwT and +1846GwA) and
CRP haplotypes were constructed. Results. Multivariate regression analysis revealed that BMI and leptin were
the main determinants of CRP in non-users, whereas in COC users the main determinants were BMI, leptin and
triglycerides. The median CRP and triglyceride values were significantly higher in COC users than in non-users.
The correlations between triglyceride and CRP were tested separately in different COC users in accordance with
progestagen content and dosage, the analysis revealing significant association only in women using a high dosage
of progestagen or cyproterone. The haplotypes of CRP gene had no significant association with CRP
concentration in COC users, while independent effects on CRP were found in non-users. Conclusion. Our study
suggests that use of COCs alters the metabolic determinants and genetic regulation of CRP.
Keywords: Body mass index; haplotypes; leptin; progestins; triglycerides
Introduction
C-reactive protein (CRP) is an acute phase protein
that has been widely used as a marker of acute
inflammation. It is now known that even a minor
elevation of CRP, i.e. low-grade inflammation, is
associated with an increased risk of cardiovascular
disease (CVD) morbidity and mortality [1,2]. Many
demographic, social, metabolic and lifestyle factors
are known to have an effect on CRP concentration,
e.g. age, sex, ethnicity, socio-economic status, birth-
weight, dietary pattern, physical activity, alcohol
consumption, diabetes mellitus, insulin concentra-
tions, glucose concentrations, blood pressure, body
mass index (BMI), HDL-cholesterol, triglycerides
and oestrogen/progestogen use [3,4].
Genetics plays a part in determination of CRP
concentration. Twin studies suggest that CRP plasma
concentrations are over 40 % heritable, and there is
an increasing amount of evidence showing an
association between CRP genetics and CRP concen-
tration [5,6]. For example, in an American popula-
tion, haplotypes constructed from seven selected
CRP gene SNPs have been associated with different
CRP concentrations [7]. In Finns, data from the
ongoing Cardiovascular Risk in Young Finns Study,
the population used in the present study, have shown
that at least five CRP SNPs are associated with
different CRP concentrations [8]. Haplotypes based
on those five SNPs have been associated with life-
long differences in average CRP concentrations, and
seem to explain about 5 % of circulating CRP
concentrations [9].
Combined oral contraceptives (COCs) have been
widely used as a safe and efficient method for
preventing unwanted pregnancies. Over the years,
the amounts of oestrogen and progestagen in COCs
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have been decreased and chemical formations have
been modified in order to reduce the risk of
thrombosis. The progestagens can be divided into
second-generation (norgestrel, levonorgestrel, norges-
trione) and third-generation (desogestrel, gestodene)
compounds. Some progestagens are not classifiable
into second or third generation (e.g. cyproterone,
norgestimate). Despite these developments, with use
of COCs there is still an increased the risk of
developing myocardial infarction, especially in
women with other cardiovascular risk factors [10].
Similarly, the risk of thromboembolic disease is still
increased [11].
We have previously shown in this population that
women using oral contraceptives have higher CRP
concentrations than non-users [12]. It is usually
considered that increased CRP is mostly due the
oestrogen component in COCs, although there are
some studies suggesting that CRP concentration
might also depend on progestagen content in COCs
[13–15]. In the present analysis, our aim was to find
out whether the metabolic, lifestyle and genetic
determinants of CRP differ between women who
use COCs and those who do not use any hormonal
contraceptives.
Methods
Subjects
The subjects in the study were participants in the
ongoing Cardiovascular Risk in Young Finns Study,
a five-centre follow-up study involving five university
hospital cities in Finland. The study began in 1980,
when 3,596 participants aged 3, 6, 9, 12, 15 and 18
were randomly selected for the study [16]. The most
recent follow-up was conducted in 2001, when 1,257
women and 1,026 men were 24–39 years of age.
Cardiovascular risk factors, including serum lipids,
BMI, blood pressure values, CRP, alcohol consump-
tion, diabetes and smoking habits were recorded [17].
The study was approved by local ethics committees.
Clinical and chemical analyses
BMI was calculated from measured height and
weight. A random zero sphygmomanometer
(Hawksley & Sons Ltd, Lancinn UK) was used to
measure blood pressure and a mean of three
measurements was used in the analysis. From fasting
plasma sample CRP, insulin, leptin, total cholesterol,
HDL-cholesterol and triglyceride concentrations
were drawn. LDL-cholesterol concentration was
calculated using the Friedewald formula (detailed
description in [17,18]). Smoking habits, alcohol
consumption, hormonal contraceptive use, physical
activity [19], history of recent infection, diabetes
and chronic rheumatic disease were elicited by
questionnaire.
The study included women who did not use any
hormonal contraceptives (non-users) (n5811) and
those who used COCs (COC users) (n5305), proges-
tin only pills (n512), intrauterine devices (n5119) or
subcutaneous capsules (n53). This data was unavail-
able in 7 subjects. The COCs contained the following
substances: ethinylestradiol (n5291), oestradiol vale-
rate (n514), gestodene (n5136), desogestrel (n578),
cyproterone (n550), levonorgestrel (n547), norethis-
terone (n54), lynestrenol (n52). All intrauterine
devices released levonorgestrel.
Fasting plasma CRP concentrations were ana-
lysed using a high-sensitive latex turbidometric
immunoassay (Wako Chemicals GmbH, Neuss,
Germany); detection limit 0.06 mg/L. DNA was
extracted from whole blood using a commercially
available kit (Qiagen Inc., Hilden, Germany) in 2001.
CRP gene polymorphisms 2717AwG (rs2794521),
2286CwTwA (rs3091244), +1059GwC (rs1800947),
+1444CwT (rs1130864) and +1846GwA (rs1205)
were genotyped using the ABI Prism 7900HT
Sequence Detection System for both PCR and allelic
discrimination (Applied Biosystems, Foster City,
Calif., USA). For SNP +1059, a commercial kit from
Applied Biosystems was used (Assay On Demand,
C_177490_10 CRP). The SNPs 2717, +1444 and
+1846 were genotyped using Assays By Design from
Applied Biosystems under standard conditions. The
triallelic tagSNP 2286 was genotyped as previously
described [7], except for genotype calling, which was
done manually from the PCR run component tab.
Statistical analyses
The haplotypes were constructed using the PHASE v.
2.0.2 program [20] from the five CRP SNPs. This
program calculates from the genotype data the most
likely haplotype pairs for each individual using a
Bayesian statistical method. The haplotypes are
shown in the order 2717, 2286, +1059, +1444 and
+1846. The three most common haplotypes (fre-
quency w0.10) in this cohort were: A-T-G-T-G
(frequency 0.350), A-C-G-C-A (0.301), G-C-G-C-G
(0.207) (previously published in [8]).
The data were analysed with SPSS for Windows
statistical software (versions 14.0 and 15.0; SPSS Inc.,
Chicago, IL., USA). We excluded subjects whose
CRP concentrations were above 10 mg/L (n551),
triglycerides above 4 mmol/L (n54), who had a
history of recent infections (n583), diabetes (n511)
or chronic rheumatic disease (n525), who were
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pregnant (n562) or lactating (n554). Haplotyping
was unsuccessful in four subjects. No separate
analyses were performed for subjects using pills
containing progestin only, subcutaneous capsules,
oestradiol valerate, norethisterone or lynestrenol,
because the number of subjects in these groups was
low (nv10). As even vaginal administration of
hormones can affect protein synthesis of hepatocytes
[21], the intrauterine device users were excluded from
the non-user group. The total number of subjects
after the exclusions was 841.
Since the distributions of CRP, insulin, leptin
and triglyceride values were skewed, the non-
parametric Mann-Whitney test was used in statis-
tical analysis. For linear regression analysis and
for analysis of covariance (ANCOVA), the values
were log-transformed prior to analysis. Correlation
between skewed variables was estimated with
Spearman’s test. For normally distributed variables,
the t-test for independent samples was used to detect
differences in mean values among different groups.
The effects of metabolic and lifestyle factors on
CRP concentration were analysed using a linear
regression model, and therefore scale variables or
dummy variables were used. The regression model
for logarithmic CRP was constructed from the
following variables: BMI, waist circumference, age,
HDL-cholesterol, LDL-cholesterol, (log)triglycer-
ides, diastolic blood pressure, systolic blood pres-
sure, (log)insulin, glucose, (log)leptin, physical
activity index, alcohol consumption and smoking.
The variables were tested in a univariate model and
values that were associated with the dependent
variable (pv0.15) were selected for the multivariate
model. From co-linear variables (e.g. BMI and waist
circumference) only the one that showed a stronger
association with (log)CRP was selected for the
model. All non-significant variables (pw0.05) were
excluded one by one from the multivariate model,
starting from the least significant.
The effects of the haplotypes on CRP concentra-
tion were compared between carriers and non-
carriers using the Mann-Whitney test. The difference
between groups after adjustment by the variables
showing significance in the regression model
(pv0.05) was calculated with the ANCOVA method.
Results
Characteristics of the study subjects are given in
Table I. Women using COCs had higher median CRP
concentrations (pv0.001), triglyceride concentrations
(pv0.001), insulin concentrations (p50.032), mean
BMI (p50.002) and HDL-cholesterol (pv0.001) than
non-users. The COC users also had significantly lower
waist circumference (pv0.001), LDL-cholesterol
concentrations (pv0.001), glucose concentrations
(p50.009) and were significantly younger (pv0.001).
The intrauterine device users did not differ signifi-
cantly from the non-users according to the parameters
in data characteristics (data not shown).
To determine whether metabolic and lifestyle
determinants of CRP differ between non-users and
COC users, we built separate linear regression models
for these groups (Table II). In the multivariate
analysis of non-users, variables that remained sig-
nificant in the model were BMI and (log)leptin. In the
Table I. Characteristics of study subjects.
Variable
Non-users (n5591) COC users (n5250)
p for difference*Mean SD Mean SD
Body mass index (kg/m2) 24.21 ¡4.49 26.21 ¡3.32 0.002
Waist circumference (cm) 79.37 ¡11.65 75.67 ¡8.62 v0.001
Age (years) 32.17 ¡4.99 29.36 ¡4.73 v0.001
HDL-cholesterol (mmol/L) 1.34 ¡0.28 1.54 ¡0.30 v0.001
LDL-cholesterol (mmol/L) 3.19 ¡0.75 2.93 ¡0.71 v0.001
Systolic blood pressure (mmHg) 116.13 ¡12.71 118.03 ¡12.49 0.053
Diastolic blood pressure (mmHg) 71.85 ¡8.74 72.52 ¡8.79 0.318
Glucose (mmol/L) 4.93 ¡0.43 4.84 ¡0.42 0.009
Physical activity index 16.50 ¡14.75 17.90 ¡14.05 0.258
Smoking (daily) (%) 20.07 % 20.99 %
Median Quartiles Median Quartiles p for difference**
CRP (mg/L) 0.54 0.26–1.33 1.66 0.81–3.30 v0.001
Triglycerides (mmol/L) 0.90 0.70–1.20 1.20 1.00–1.60 v0.001
Insulin (mU/L) 6.00 5.00–9.00 7.00 5.00–9.00 0.032
Leptin (mU/L) 12.59 7.59–19.95 12.88 8.66–19.50 0.538
*T-test for difference between non-users and COC users. **Mann-Whitney test for difference between non-users and COC users.
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multivariate analysis of COC users, variables that
remained significant were BMI, (log)leptin and
(log)triglycerides. To find out whether the effect
of triglycerides was dependent on a certain proges-
tagen formulation in COCs, we calculated correla-
tion between triglycerides and CRP inside different
progestagen-containing subgroups (Table III). The
correlation was significant only in subjects using
cyproterone (r50.508, p50.001). To assess the
progestagen dosage effect, we calculated the corre-
lation in women using continuous COCs with low
dosages of progestagen (v3150 mg/month) and in
women using continuous COCs with high dosages
of progestagen (>3150 mg/month). Cyproterone
users were not included in this analysis. The
correlation was significant only in women using
continuous high dosages of progestagen (r50.298,
p50.012). Differences in median CRP values
between different progestagen users did not reach
statistical significance.
The effects of the haplotypes on CRP concentra-
tions were analysed separately in women according
to contraceptive use before and after adjustment of
metabolic and lifestyle factors. The results are
presented in Table IV (ANCOVA). In non-users,
all haplotypes had significant effects on CRP
Table II. Univariates and adjusted multiple linear regression model of (log)CRP in women without hormonal contraceptives
and with COCs.
Variable
Non-users (n5591) COC users (n5250)
Univariate Multivariate Univariate Multivariate
B SE p B SE p B SE p B SE p
Body mass index
(kg/m2)
0.053 ¡0.004 v0.001 0.028 0.005 v0.001 0.048 ¡0.008 v0.001 0.020 0.009 0.029
Waist circumference
(cm)
0.002 ¡0.001 v0.001 0.002 ¡0.001 v0.001
Age (years) 0.002 ¡0.004 0.542 0.000 ¡0.006 0.956
HDL-cholesterol
(mmol/L)
20.294 ¡0.070 v0.001 20.040 ¡0.097 0.680
LDL-cholesterol
(mmol/L)
0.101 ¡0.026 v0.001 0.014 ¡0.042 0.742
(log) Triglycerides
(mmol/L)
0.797 ¡0.107 v0.001 0.666 ¡0.169 v0.001 0.358 0.156 0.023
Systolic blood
pressure (mmHg)
0.007 ¡0.002 v0.001 0.006 ¡0.002 0.006
Diastolic blood
pressure (mmHg)
0.010 ¡0.002 v0.001 0.009 ¡0.003 0.003
(log) Insulin (mU/L) 0.697 ¡0.081 v0.001 0.440 ¡0.128 0.001
Glucose (mmol/L) 0.163 ¡0.045 v0.001 0.063 ¡0.065 0.331
(log) Leptin (mU/L) 0.869 ¡0.058 v0.001 0.557 0.080 v0.001 0.760 ¡0.101 v0.001 0.524 0.124 v0.001
Physical activity
index
20.004 ¡0.001 0.003 20.005 ¡0.002 0.050
Smoking (daily) 20.007 ¡0.046 0.879 20.123 ¡0.069 0.076
Alcohol
(drinks per week)
20.001 ¡0.003 0.863 20.007 ¡0.005 0.214
R250.309 R250.225
Table III. Median CRP and triglycerides levels compared to the type of progestagen included in the COCs.
Progestagen compound n
CRP Triglycerides Correlation*
Median Quartiles Median Quartiles r p
Gestodene 116 1.56 0.89–3.33 1.20 1.00–1.40 0.128 0.171
Desogestrel 60 1.90 0.79–3.26 1.30 1.00–1.70 0.210 0.106
Levonorgestrel 37 1.29 0.54–2.34 1.10 0.90–1.50 0.290 0.082
Cyproterone 41 2.00 0.52–4.06 1.60 0.90–2.00 0.508 0.001
Low-dosage continuous 96 1.56 0.89–3.31 1.20 1.00–1.50 0.042 0.686
High-dosage continuous
(without cyproterone)
71 2.02 0.82–3.43 1.30 1.00–1.80 0.298 0.012
*Spearman’s test for correlation between CRP and triglycerides.
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concentrations, the p-values ranging fromv0.001 to
0.041. In COC users, the haplotypes had no signi-
ficant effects on CRP concentration. Further analy-
sis in relation to progestagen/oestrogen content or
dosage did not change the result.
Discussion
CRP has various roles in the development of
atherosclerosis. It can bind to modified LDL-
cholesterol particles, especially to the non-esterified
cholesterol in LDL [22], after which CRP-opsonized
LDL can be taken up by macrophages via CRP
receptor CD32 [23]. This can lead to increased foam-
cell formation in atherosclerotic plaques. CRP can
also induce the expression of adhesion molecules [24]
and inhibit nitric oxide expression in the human
endothelial cells [25], both of which facilitate the
atherosclerosis processes further. In addition, CRP
promotes apoptosis of endothelial progenitor cells
that are responsible for vascular regenerative poten-
tial [26].
Although the risk of both myocardial infarction
(MI) and venous thromboembolism (VTE) is gen-
erally low in young women, COC use is known to
increase the risk of both. This is especially true in the
case of women who have other cardiovascular risk
factors – environmental and genetic. However, the
risk of MI might be lower in women who use third-
generation oral contraceptives [10], while the risk of
VTE diseases might be higher in women who use
third-generation COCs [11]. Because CRP is one
possible pathological agent behind CVD, and COC
usage affects CRP levels, we assessed the effects of
COC usage and the different progestagen effects on
CRP in young Finnish women.
The data shown in this report demonstrate that
CRP and triglyceride levels are higher in COC users
than in non-users. Also, the determinants of plasma
CRP concentration are different in COC users than in
non-users. The most striking difference was seen in
triglycerides, i.e. in COC users there was a positive
association between triglyceride and CRP concen-
trations, while in non-users there was no association
at all. In COC users, the association was found only
in users of COCs containing cyproterone or other
high progestagen dosage COCs. To the best of our
knowledge, these findings are now described for the
first time.
It has previously been shown that COC use
increases both plasma triglyceride concentrations
[21,27] and CRP concentrations [28]; this was also
observed in the present study. It is known that COCs
increases CRP concentrations without increasing IL-
6 concentrations [29], suggesting that COCs stimu-
lates hepatocytes directly to synthesize CRP, and not
via IL-6-mediated inflammation. The mechanism of
how COCs stimulates hepatocytes protein synthesis is
still not known. However, the role of oestrogen might
be more important than that of progestagen, because
studies in postmenopausal women have shown that
oestrogen alone can induce CRP concentrations
[14,30], and in premenopausal women it has been
observed that pills containing only progestagen do
not elevate CRP concentrations [28]. The role of
progestagens on CRP concentration is still unclear.
Studies comparing different progestagen effects on
CRP suggest that the effect might depend on specific
progestaten content [13–15]. Our findings support the
idea that progestagens do have a role in CRP
regulation. In particular, the amount of progestagen
seems to be important. Although there were differ-
ences in correlation between CRP and triglycerides
depending on the progestagens that had been used,
there were no significant differences in CRP concen-
trations. The cyproterones are usually prescribed to
women with androgen excess, e.g. polycystic ovary
syndrome. This underlying disorder affects the CRP
[31] and triglyceride [32] levels, so we cannot rule out
that correlation between triglycerides and CRP
Table IV. Effect of CRP haplotype carriage on CRP levels before and after adjustment of metabolic and lifestyle factors.
Carriage of
haplotype
Non-users COC users
n Median Quartiles p* Adjusted p** n Median Quartiles p* Adjusted p**
ATGTG+ 308 0.59 0.28–1.36 124 1.65 0.72–3.44
ATGTG2 210 0.43 0.23–0.96 0.008 0.004 94 1.71 0.82–3.27 0.776 0.688
ACGCA+ 261 0.48 0.24–1.05 103 1.67 0.80–3.33
ACGCA2 257 0.56 0.28–1.35 0.131 0.041 115 1.67 0.89–3.25 0.572 0.391
GCGCG+ 195 0.41 0.20–0.86 87 1.87 0.89–3.18
GCGCG2 323 0.66 0.28–1.49 v0.001 v0.001 131 1.54 0.79–3.33 0.584 0.419
Haplotypes are composed of SNPs 2717AwG, 2286CwTwA, +1059GwC, +1444CwT, 1846GwA. **Mann-Whitney test for
difference between carrier and non-carrier. *ANCOVA test with (log)CRP values: Non-users after adjustment of BMI, (log)leptin. COC
users after adjustment of BMI, (log)triglycerides, (log)leptin.
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among cyproterone users is due to the underlying
disorder, because its frequency is unknown in this
cohort. To avoid this bias, all the analyses were also
performed without cyproterone users, but it did not
change the results. The other significant determinants
of plasma CRP in our data were BMI and leptin.
They had similar effects on CRP in COC users and
non-users, so it seems that the IL-6 mediated
stimulation of CRP by BMI [33] and leptin [34] is
not affected by COC use.
In addition to the changes in the role of metabolic
factors in the regulation of CRP concentrations, we
found that the contribution of genetic control on
CRP concentrations was entirely different between
COC users and non-users. Haplotypes of the CRP
gene were associated with CRP concentrations in
non-users, but not in COC users. At present, the
molecular background of this is not known.
However, hepatic induction of CRP gene via IL-6
and without IL-6 is different; the CRP gene IL-6
responsive elements are probably involved in the
former but not in the latter. In other words, the CRP
production induced or enhanced by COCs is pre-
sumably regulated by different transcription factors
from the IL-6 mediated CRP production. Of the 5
SNPs used for construction of the haplotypes, two
are promoter region polymorphisms (2717 and
2286), one is exonic (+1059) and two are in the
39UTR region (+1444 and +1846), and there is no
obvious steroid receptor binding sequences in these
positions. Therefore, understanding the molecular
mechanism of this observed difference requires a
more thorough analysis of the transcriptional control
of this gene. The haplotypes analysed can explain
only about 5 % of the circulating CRP [9], so it is
possible that the genetic effect is overwhelmed by the
strong COC effect.
The most limiting factor in this study was its
cross-sectional design. There was a relatively large
variation in the use of different COCs with different
contents and amounts of oestrogen and progestagens,
which made it difficult to create comparable and
representative subgroups in relation to COC usage.
In order to keep comparison clear and representative
in both groups, the main comparison was done
between COC users and non-users. There were also
other disadvantages. The use of contraceptives was
elicited only by questionnaire; COC users and non-
users might not be comparable in every respect. For
example, there might be some infertile women who
do not need COCs and also women wishing to
become pregnant and therefore not using COCs.
There could also be other reasons possibly altering
the use of COCs that we could not account for,
such as temporary intermission due to broken
relationships, inconstant use of COCs (time and
brand, etc.). Unfortunately we were not able to
analyse all of these confounders, but still we believe
that these cases are low in number and do not affect
our results. Despite these limitations, we believe that
this study included a relatively large and representa-
tive number of young women (n5841) and that our
conclusions are valid.
In conclusion, our findings support a direct role
for COCs in CRP determination by affecting its
metabolic and genetic regulation. These findings
highlight the importance of thorough adjustment of
CRP concentration with confounding variables in
the analysis of genetic polymorphism, i.e. COC
usage diminishes the effect of CRP genetics on CRP
concentration. Future research of COC usage-
related changes in CRP determination and genetic
regulation are needed, especially random controlled
trials, and the clinical relevance of the findings has to
be seen.
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Serum amyloid A is independently associated with
metabolic risk factors but not with early atherosclerosis:
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Abstract. Jylha¨va¨ J, Haarala A, Eklund C, Pertovaara
M, Ka¨ho¨nen M, Hutri-Ka¨ho¨nen N, Levula M, Le-
htima¨ki T, Huupponen R, Jula A, Juonala M, Viikari
J, Raitakari O, Hurme M (University of Tampere and
Tampere University Hospital, Tampere; and Univer-
sity of Turku, Health Care District of Southwest
Finland and National Public Health Institute, Turku;
Finland). Serum amyloid A is independently
associated with metabolic risk factors but not with
early atherosclerosis: the Cardiovascular Risk in
Young Finns Study. J Intern Med 2009; 266: 286–
295.
Background. Serum amyloid A (SAA) is a sensitive
marker of inﬂammation and its elevation has been
implicated in obesity and in cardiovascular disease,
yet data on its regulation in young adults or on its
role in early atherosclerosis is scarce. We investigated
which factors explain the variation in SAA and analy-
sed whether SAA could be associated with preclinical
atherosclerosis.
Methods. Serum amyloid A levels were measured in
participants of the Cardiovascular Risk in Young
Finns Study (n = 2280, n = 1254 women, n = 1026
men). Correlates and determinants of SAA were anal-
ysed and the effect of SAA on subclinical atheroscle-
rosis, measured as intima-media thickness (IMT) and
carotid artery compliance, was evaluated with risk-
factor adjusted models.
Results. Serum amyloid A correlated directly and inde-
pendently of BMI with C-reactive protein (CRP),
waist circumference and leptin in both sexes, with
total cholesterol, LDL cholesterol and Apolipoprotein-
A1 (ApoA1) in women and with triglycerides, insulin
levels and insulin resistance in men. Use of combined
oral contraceptives and intrauterine device was also
associated with SAA levels. Determinants for SAA
included CRP, leptin and ApoA1 in women, and CRP,
leptin and HDL cholesterol in men. SAA levels
correlated with carotid compliance in both sexes and
with IMT in men, yet SAA had no independent
effect on IMT or carotid compliance in multivariable
analysis.
Conclusions. Serum amyloid A was associated with sev-
eral metabolic risk factors but was not an independent
predictor of IMT or carotid artery compliance. Further
longitudinal studies will show whether SAA holds a
prognostic value as a risk marker, analogously to CRP.
Keywords: early atherosclerosis, low-grade inﬂamma-
tion, metabolic risk factors, serum amyloid A.
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Introduction
Inﬂammation has been proposed to have an essential
pathophysiological role in atherosclerosis, metabolic
syndrome and diabetes [1, 2]. The biochemical mea-
surements used to detect the low-grade inﬂammatory
state in these disorders has mainly focused on C-reac-
tive protein (CRP), which frequently – yet not consis-
tently – has been associated with severity or poorer
prognosis in these disorders [1–3]. Another acute
phase reactant, serum amyloid A (SAA), has also pro-
ven to be a suitable and sensitive indicator of the
inﬂammation involved in various stages of these dis-
eases [3, 4]. However, it is yet to be resolved whether
CRP and SAA can act as functional risk factors or if
they are merely risk markers, i.e. indicators of the
systemic nature of the low-grade inﬂammatory condi-
tions. Nevertheless, elevation in SAA has been shown
to predict cardiovascular events analogously with or
even better than CRP [5–7] and in this sense, it has
been speculated that SAA could be one of the links
or even a proatherogenic risk factor between the
inﬂammatory metabolic disorders and cardiovascular
disease (CVD) [8, 9].
The human genome encompasses four SAA genes, of
which three encode functional proteins [4]. SAA1 and
SAA2 are highly homologous reactants whose con-
centration can increase up to 1000-fold upon infection
or trauma, whereas SAA3 is a pseudogene and SAA4
is a constitutively expressed minor constituent of non-
acute-phase HDL [10]. During the acute phase, liver
is considered to be the major site of SAA synthesis,
whilst in nonacute low inﬂammatory conditions, such
as obesity, the role of adipocytes as the secretory site
of SAA has recently been ﬁrmly established [11–13].
Expression of SAA is induced in response to proin-
ﬂammatory cytokines such as IL-1b, IL-6 and TNF-a
and circulating SAA associates predominantly with
HDL particles, in which it displaces ApoA1 and thus
alters the reverse cholesterol transport [10].
Because of its established correlation with CRP, lep-
tin, body mass index (BMI) and other obesity indices
[9, 11, 14, 15] as well as with cardiovascular
events [5, 6], SAA has been a subject of several
recent studies focusing on subjects with chronic dis-
eases or obesity. However, little is known about its
baseline distribution and regulation in younger healthy
adults, likewise its association with early atherosclero-
sis. The aim of this study was therefore to establish
the correlates and determinants of SAA in ostensibly
healthy young adults as well as to evaluate the associ-
ations of SAA and CRP with early atherosclerosis.
Methods
Subjects
The study population consisted of participants of the
Cardiovascular Risk in Young Finns study, which is
an ongoing multicentre follow-up study on atheroscle-
rosis risk factors in Finnish children and young adults.
The ﬁrst study was conducted in 1980, when the
study was initiated and when the participants
(n = 3596), who were randomly chosen from the
national population registers of Helsinki, Tampere,
Turku, Oulu, Kuopio and their rural surroundings,
were 3, 6, 9, 12, 15 and 18 years of age. The study
design has been described in more detail elsewhere
[16, 17]. The follow-up, on which the data of the cur-
rent study is based, was carried out in 2001, when the
participants had reached 24, 27, 30, 33, 36 and
39 years of age. The parameters of early atherosclero-
sis, i.e. carotid artery compliance and intima-media
thickness (IMT), as well as serum lipids, proteins and
hormones, obesity indices, smoking habits, blood
pressure values, alcohol consumption, physical activ-
ity, the presence of diabetes and rheumatic diseases
were also recorded in this follow-up [18]. The study
was approved by the local ethics committees and was
conducted following the guidelines of the Declaration
of Helsinki. All participants gave their written
informed consent.
Clinical characteristics and biochemical measurements
Height and weight as well as waist and hip circumfer-
ences were measured and BMI and waist-hip ratio
were calculated. Blood pressure was measured using a
random zero sphygmomanometer and the mean of
three measurements was used in the analyses. Venous
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blood samples for the determination of SAA, leptin,
adiponectin, CRP, serum lipids (total cholesterol,
HDL cholesterol, LDL cholesterol, triglycerides
ApoA1 and ApoB), glucose and insulin were drawn
after 12 h fasting. Serum SAA concentrations were
measured with an ELISA kit with a detection limit of
<0.004 mg L)1 (Human SAA, Biosource Interna-
tional, Camarillo, CA, USA). The inter-assay coefﬁ-
cient of variation (CV) was 10.6% at a mean level of
0.5988 mg L)1 and 12.6% at a mean level of
0.0613 mg L)1 and the intra-assay coefﬁcient of vari-
ation was 5.8% at the mean level of 13.54 mg L)1.
Serum CRP was determined using a high-sensitivity
latex turbidometric immunoassay (Wako Chemicals
GmbH, Neuss, Germany) with a detection limit of
0.06 mg L)1. The CV for repeated measurements was
3.3% at the mean level of 1.52 mg L)1 and 2.65% at
the mean level of 2.52 mg L)1. Serum adiponectin
was measured with radioimmunoassay (Human
Adiponectin RIA kit; Linco Research, Inc., MO,
USA) with an inter-assay CV of 11.9%. More detailed
descriptions of the other analytical procedures and
physical examination have been reported previously
[18, 19]. Insulin resistance index was assessed with
homeostasis assessment of insulin resistance (HOMA-
IR), which was calculated based on fasting insulin
and glucose values according to the formula: HOMA-
IR = fasting glucose (mmol L)1) · fasting insulin
(mU L)1) ⁄22.5 [20]. Physical activity, alcohol con-
sumption, smoking habits, use of combined oral con-
traceptives (COCs) or intrauterine device (IUD),
rheumatic diseases, diabetes and recent infections
were elicited by questionnaire [18, 19].
Physical activity was assessed as a metabolic equiv-
alent (MET) index, in which one MET is the con-
sumption of 1 kcal of a person per weight kilogram
per hour in rest. MET was calculated from the
product of intensity · frequency · duration and
commuting physical activity. In the estimation of
the physical activity during commuting to work
place, the length of the journey and the means (i.e.
whether it was travelled by foot or by bicycle)
were taken into account. The coefﬁcients for the
variables were estimated from the previously estab-
lished tables [21].
Subjects with diabetes (n = 22, SAA median
17.90 mg L)1), chronic rheumatic disease (n = 34,
SAA 17.10 mg L)1), history of recent infection
(n = 113, SAA 12.10 mg L)1) as well as pregnant
women (n = 61, SAA 14.30 mg L)1) were excluded.
Lactating women (n = 41) were not excluded as their
plasma SAA (13.10 mg L)1) as well as CRP levels
(0.7 mg L)1) were comparable to the study popula-
tion (P = 0.090 for SAA and P = 0.849 for CRP).
Subjects with triglycerides above 4 mmol L)1
(n = 30, SAA 12.95 mg L)1) were also excluded
as the Friedwald formula used in LDL calculation
could not be applied. In addition, we excluded
women using COCs (n = 279, SAA 13.80 mg L)1)
or levonorgestrel-releasing IUD (n = 104, SAA
8.70 mg L)1) from the analyses concerning the cor-
relates, determinants and cardiovascular associations
of SAA, as their SAA values deviated markedly
(P < 0.001 and P = 0.03 respectively) from those
of the nonusers. Rest of the excluded subjects
(n = 128) were due to missing information in one or
several measured variables. After subtracting these
excluded individuals, we ended up with a population
of n = 1509 subjects (n = 618 women and n = 891
men) for which we analysed the population data
characteristics.
Carotid artery ultrasound measurements
Carotid ultrasound measurements were performed
with a Sequoia 512 high-resolution ultrasound sys-
tem (Acuson, CA, USA). Carotid artery compliance,
which depicts the ability of the large arteries to
expand under cardiac pulse pressure, was assessed
from the formula ([Ds)Dd] ⁄Dd) ⁄ (Ps)Pd), where Ds
is the systolic diameter, Dd is the diastolic diameter,
Ps is the systolic blood pressure and Pd is the dia-
stolic blood pressure [22]. Mean IMT, a structural
marker of vascular changes and a predictor of
future cardiovascular events, was derived from a
minimum of four measurements of the posterior
wall of the left carotid artery (at approximately
10 mm proximal to the bifurcation) [22]. Both caro-
tid compliance and IMT are continuous variables
and they followed the normal distribution in our
study population.
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Statistical analyses
Statistical analyses were performed using spss version
15.0 (SPSS Inc., Chicago, IL, USA). All the analyses
were carried out separately for men and women due
to their markedly deviating SAA values (P < 0.001).
Variables with skewed distribution (SAA, CRP, leptin,
adiponectin, insulin and triglycerides) were log-trans-
formed prior to analyses when normal distribution
was required. Comparisons of the variables between
sexes were performed with Student’s t-test, Mann–
Whitney’s test and Chi-squared test as appropriate. In
addition, Mann–Whitney’s test was used to test the
heterogeneity of SAA levels between smokers and
nonsmokers as well as between COC or IUD users
and nonusers. The correlations between (log)SAA and
clinical parameters as well as other serum markers
were assessed with Pearson’s correlation coefﬁcients,
additionally adjusted for BMI. Determinants, i.e. the
variables that explained the variation in SAA, were
analysed with stepwise multivariable regression analy-
sis in which all the variables that correlated signiﬁ-
cantly (P < 0.05) with SAA were included. Finally,
multivariable linear regression analysis was used to
evaluate whether SAA and CRP had an effect on pre-
clinical atherosclerosis markers, carotid compliance
and IMT. To exclude confounding effects, SAA and
CRP were entered into the model as an added factor
and the analysis was adjusted in a stepwise manner
with the established risk-factors of atherosclerosis, i.e.
age, BMI, LDL cholesterol, (log)triglycerides, glu-
cose, systolic blood pressure (only IMT), daily smok-
ing and physical activity. In all analyses, the level of
P < 0.05 was considered statistically signiﬁcant.
Results
Characteristics of the study population are shown in
Table 1. The majority of the risk factors differed sig-
niﬁcantly between men and women, the only vari-
ables not deviating were age, physical activity index,
insulin, insulin resistance index (HOMA-IR) and CRP
(Table 1). A signiﬁcant difference in SAA levels
between men and women was observed (P < 0.001),
but divergence in SAA levels was not, however,
attenuated (data not shown) when the analysis was
adjusted for leptin, adiponectin or ApoA1, which are
the factors more elevated in women than in men.
Median SAA levels of daily smokers and nonsmokers
did not differ amongst either sex (P = 0.546 for women
and P = 0.642 for men). Women using COCs had sig-
niﬁcantly higher SAA values than nonusers [SAA med-
ian 13.60 mg L)1, (IQR 7.67–25.90) vs. SAA median
10.70 mg L)1, (IQR 6.33–18.68), P < 0.001], whereas
women using levonorgestrel-releasing IUD had lower
SAA values than nonusers [SAA median 8.75 mg L)1,
(IQR 4.91–15.78) vs. 10.70 (IQR 6.33–18.68 mg L)1),
P = 0.034]. To examine whether the difference in SAA
levels could be attributed to the higher CRP concentra-
tion in COC using women [23], the analysis was
adjusted for plasma CRP. This adjustment, however,
did not abolish the observed differences.
SAA was found to correlate signiﬁcantly (P < 0.05)
and directly with BMI, waist circumference, waist-hip
ratio, total cholesterol, LDL cholesterol, triglycerides,
blood pressure, insulin, insulin resistance index
(HOMA-IR), leptin, CRP and ApoB in both genders.
However, signiﬁcant and direct correlation was
observed with glucose and physical activity index
only in men, whilst a direct correlation with ApoA1
and adiponectin was observed only in women. Vari-
ables not correlating with SAA were age, glucose, use
of alcohol, ApoB and homocysteine in women and
use of alcohol, ApoA1 and homocysteine in men. All
the signiﬁcant correlations (P < 0.05) were further
adjusted for BMI. Correlates that remained signiﬁcant
after BMI adjustment are presented in Table 2.
All variables correlating signiﬁcantly (P < 0.05) with
SAA were included in the multiple linear regression
model. According to the stepwise multivariable linear
regression analyses, the determinants for SAA in
women were CRP (B = 0.479, P < 0.001), ApoA1
(B = 0.270, P < 0.001) and leptin (B = 0.121,
P = 0.012) which together explained 44.9% of the
total variation in SAA (Table 3a). In men, the deter-
minants for SAA were CRP (B = 0.610, P < 0.001),
leptin (B = 0.112, P = 0.007) and HDL cholesterol
(B = 0.097, P = 0.017), together explaining 49.7% of
the
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variation in SAA (Table 3a). However, due to the
strong intercorrelation and similar proinﬂammatory
regulation of SAA and CRP we also wished to ana-
lyze the determinants of SAA without the effect of
CRP. In this model, the determinants for SAA in
women were leptin (B = 0.424, P < 0.001), ApoA1
(B = 0.270, P < 0.001) and body mass index
(B = 0.011, P = 0.013) and in men they were
leptin (B = 0.340, P < 0.001) and waist circumfer-
ence (B = 0.001, P = 0.006) (Table 3b). These
models, however, explained only 18.5% (in women)
and 12.6% (in men) of the variation in SAA.
Stepwise multiple linear regression analyses were
used to assess the effect of SAA and CRP on the
early atherosclerosis markers carotid compliance and
IMT. The effect of SAA and CRP was found to be
very similar, yet dependent on other risk factors,
mainly BMI and serum lipids (Table 4). In univariable
analysis (model 1, Table 4) both SAA and CRP corre-
lated inversely with carotid compliance in both sexes
and directly with IMT in men (Table 4). Neither
SAA, nor CRP correlated with IMT in females
(Table 4). A similar trend was also observable after
adjusting for age, smoking and physical activity
Table 1 Characteristics of the study population
Variable
Women (n = 618) Men (n = 891)
P for differenceMean SD Mean SD
Age (years) 32.05 4.94 31.66 5.02 0.134
BMI (kg m)2) 24.35 4.60 25.61 3.81 <0.001
Waist circumference (cm) 79.39 11.46 89.30 10.55 <0.001
Waist-hip ratio 0.80 0.06 0.89 0.06 <0.001
Systolic blood pressure (mmHg) 115.54 12.54 128.96 13.59 <0.001
Diastolic blood pressure (mmHg) 71.49 8.69 74.83 9.09 <0.001
Total cholesterol (mmol L)1) 5.01 0.89 5.24 1.00 <0.001
HDL cholesterol (mmol L)1) 1.35 0.27 1.17 0.28 <0.001
LDL cholesterol (mmol L)1) 3.19 0.77 3.43 0.89 <0.001
Triglycerides (mmol L)1)a 0.90 0.70–1.20 1.20 0.90–1.80 <0.001
ApoA1 (g L)1) 1.50 0.22 1.41 0.21 <0.001
ApoB (g L)1) 0.97 0.23 1.12 0.26 <0.001
Insulin (mU L)1)a 6.00 4.00–8.00 6.00 4.00–9.00 0.403
Glucose (g L)1) 4.91 0.41 5.15 0.41 <0.001
HOMA-IR 1.59 1.31 1.70 1.19 0.081
Leptin (ng mL)1)a 12.59 7.58–19.50 4.07 2.40–6.46 <0.001
Adiponectin (lg mL)1)a 10.00 7.80–13.50 6.80 5.10–9.20 <0.001
Homocysteine (lmol L)1) 9.27 3.57 10.79 3.89 <0.001
CRP (mg L))a 0.56 0.26–1.36 0.58 0.29–1.34 0.679
SAA (mg L)1)a 10.70 6.33–18.68 8.00 5.00–15.00 <0.001
Physical activity index 16.59 14.74 16.16 17.40 0.649
Alcohol (drinks per week) 3.72 6.44 8.76 10.40 <0.001
Smoking daily (% of total)b 20 29 <0.001
Carotid compliance (% ⁄ 10 mmHg) 2.34 0.78 2.02 0.66 <0.001
IMT (mm) 0.58 0.09 0.59 0.10 0.003
t-test for difference between groups.
aMedian values and interquartile range (IQR), Mann–Whitney’s test for difference between groups.
bChi-Squared test for difference between groups.
ApoA1, apolipoproteinA1; ApoB, apolipoproteinB; BMI, body mass index; CRP, C-reactive protein; HOMA-IR, homeostasis assessment of
insulin resistance; IMT, intima-media thickness; SAA, serum amyloid A.
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(model 2 in Table 4). However, after adjusting for
BMI, (log)triglycerides, glucose, LDL cholesterol and
systolic blood pressure (only for IMT), the effects of
SAA and CRP on carotid compliance and IMT were
attenuated to the null (model 3 in Table 4). Only the
association of CRP with carotid compliance in males
remained of borderline signiﬁcance (model 3 in
Table 4).
Discussion
The results of this large cross-sectional study demon-
strate as a novel ﬁnding that amongst ostensibly
healthy adults, SAA levels correlate directly with sev-
eral metabolic risk factors in women and in men, all
correlations being independent of BMI. CRP was
found to be the main determinant for SAA in both
sexes, yet the additional model, in which we assessed
the determinants for SAA without CRP, indicated that
we might actually lack the best biological regulator(s)
of SAA, as the additional model did not explain the
variation on SAA very well.
Our results concerning the correlation of SAA with
obesity indices, leptin and CRP corroborate earlier
reports, which have shown that SAA levels correlate
directly with CRP, leptin, obesity indices, body fat
percentage and adipocyte size [9, 11, 14, 15]. How-
ever, others have not consistently documented the
BMI-independent correlations between SAA and tri-
glycerides, ApoA1 and HDL cholesterol [11, 13, 15].
These divergences may be due to the fact that the
other studies have generally been performed on older
and obese individuals in smaller study populations, in
Table 2 Correlates of clinical and biochemical parameters with (log)SAA in women and men
Variable
Women (n = 618) Adjusted for BMI Men (n = 891) Adjusted for BMI
ra P ra P ra P ra P
Body mass index (BMI) 0.328 <0.001 0.281 <0.001
Waist circumference 0.334 <0.001 0.093 0.021 0.312 <0.001 0.138 <0.001
Waist-hip ratio 0.214 <0.001 0.034 0.405 0.250 <0.001 0.092 0.006
Age 0.025 0.732 0.074 0.028 0.026 0.434
Total cholesterol 0.189 <0.001 0.147 <0.001 0.099 0.003 0.032 0.348
HDL cholesterol 0.056 0.163 )0.066 0.049 0.010 0.776
LDL cholesterol 0.144 <0.001 0.094 0.021 0.071 0.035 0.010 0.766
(log)Triglycerides 0.170 <0.001 0.059 0.144 0.180 <0.001 0.077 0.022
ApoA1 0.121 <0.001 0.205 <0.001 0.010 0.766
ApoB 0.219 <0.001 0.066 0.152 0.165 <0.001 0.060 0.073
Systolic blood pressure 0.163 <0.001 0.048 0.235 0.080 0.017 )0.006 0.869
Diastolic blood pressure 0.157 <0.001 0.052 0.202 0.104 0.002 0.028 0.438
(log)Insulin 0.183 <0.001 0.014 0.765 0.206 <0.001 0.077 0.032
Glucose 0.022 0.593 0.068 0.042 0.024 0.512
(log)Leptin 0.390 <0.001 0.236 <0.001 0.342 <0.001 0.217 <0.001
HOMA-IR 0.191 <0.001 0.002 0.968 0.200 0.001 0.075 0.025
(log)Adiponectin 0.100 0.016 )0.021 0.611 )0.051 0.131
Homocysteine )0.009 0.830 0.023 0.492
Physical activity index )0.036 0.438 )0.072 0.043 )0.068 0.058
Alcohol )0.015 0.707 )0.001 0.978
(log)CRP 0.650 <0.001 0.585 <0.001 0.703 <0.001 0.672 <0.001
The signiﬁcant correlations were adjusted for BMI.
aPearson’s correlation.
ApoA1, apolipoproteinA1; ApoB, apolipoproteinB; BMI, body mass index; CRP, C-reactive protein; HOMA-IR, homeostasis assessment of
insulin resistance; SAA, serum amyloid A.
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which SAA levels have also fallen drastically, con-
comitantly with weight loss. The BMI-independent
correlations observed here therefore demonstrate that
SAA can be regarded as an indicator of the metabolic
status in lean and younger individuals as well. Along
these lines, as all the determinants for SAA in our
Table 4 Serum amyloid A (SAA) and C-reactive protein (CRP) as markers of IMT and carotid compliance in multivariable
stepwise regression model
Model 1 Model 2 Model 3
n B SE P n B SE P n B SE P
(log)SAA
Women IMT 609 )0.001 0.009 0.881 466 0.002 0.010 0.833 466 )0.008 0.010 0.427
Carotid compliance 609 )0.206 0.081 0.011 466 )0.227 0.092 0.014 466 )0.100 0.094 0.289
Men IMT 883 0.022 0.008 0.005 773 0.015 0.008 0.065 771 0.004 0.008 0.620
Carotid compliance 880 )0.170 0.051 0.001 771 )0.149 0.052 0.004 771 )0.071 0.053 0.177
(log)CRP
Women IMT 609 0.002 0.007 0.797 466 0.003 0.008 0.740 466 )0.012 0.009 0.172
Carotid compliance 609 )0.142 0.064 0.026 466 )0.163 0.072 0.023 466 0.014 0.081 0.861
Men IMT 883 0.027 0.007 <0.001 773 0.021 0.007 0.003 771 0.008 0.008 0.275
Carotid compliance 880 )0.215 0.045 <0.001 771 )0.199 0.046 <0.001 771 )0.100 0.050 0.045
Model 1. Only (log)SAA or (log)CRP as added factor.
Model 2. The effect of (log)SAA or (log)CRP adjusted for age, physical activity and smoking.
Model 3. The effect of (log)SAA or (log)CRP adjusted for age, physical activity, smoking, BMI, LDL cholesterol, glucose, systolic blood
pressure (only for IMT) and (log)triglycerides.
BMI, body mass index; IMT, intima-media thickness.
Table 3 Determinants for serum amyloid A (SAA) in adjusted multiple linear regression models in women and in men with (a)
and without (b) the effect of C-reactive protein (CRP)
Variable
Women (n = 618) Men (n = 891)
B SE P B SE P
(a)
(log)CRP 0.479 ±0.028 <0.001 0.610 ±0.025 <0.001
(log)Leptin 0.121 ±0.048 0.012 0.112 ±0.041 0.007
ApoA1 0.270 ±0.054 <0.001
HDL cholesterol 0.097 ±0.040 0.017
R2 = 0.449 R2 = 0.497
(b)
(log)Leptin 0.424 ±0.070 <0.001 0.340 ±0.071 <0.001
ApoA1 0.270 ±0.054 <0.001
BMI 0.011 ±0.004 0.013
Waist circumference 0.001 ±0.001 0.006
R2 = 0.185 R2 = 0.126
Variables correlating signiﬁcantly with (log)SAA (P < 0.05) were entered into the model in a stepwise manner.
Variables entered for women were BMI, waist circumference, waist-hip ratio, total cholesterol, LDL cholesterol, (log)triglycerides, systolic
blood pressure, diastolic blood pressure, (log)adiponectin, (log)insulin, glucose, insulin resistance (HOMA-IR), (log)leptin, (log)CRP (only in
model a), ApoA1 and ApoB. Variables entered for men were BMI, waist circumference, waist-hip ratio, age, total cholesterol, HDL cholesterol,
LDL cholesterol, (log)triglycerides, systolic blood pressure, diastolic blood pressure, (log)insulin, glucose, insulin resistance (HOMA-IR),
(log)leptin, physical activity index, (log)CRP (only in model a) and ApoB.
ApoA1, apolipoproteinA1; BMI, body mass index; CRP, C-reactive protein.
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cohort, i.e. CRP, leptin and ApoA1 ⁄HDL cholesterol
are related to lipid metabolism, we speculate that adi-
pose tissue, regardless of its extent, contributes to
SAA regulation via these factors. This hypothesis is
plausible in light of the knowledge that excess ⁄dys-
functional adipose tissue is a source of several pro-
inﬂammatory reactants and that SAA and CRP are
upregulated by pro-inﬂammatory stimuli, such as IL-
1b, TNF-a and IL-6 [1, 4]. On the other hand, SAA,
CRP and leptin can also induce pro-inﬂammatory
cytokines [1, 9, 24], suggesting a positive feedback
mechanism and a complex interconnection between
these three factors. In addition, SAA has been shown
to have a long-term effect in stimulating basal lipoly-
sis [9] thus perhaps contributing to insulin resistance
via increased release of free fatty acids into circula-
tion. Our results corroborate this ﬁnding as we
observed that in male subjects SAA correlates directly
with insulin resistance index and triglycerides, inde-
pendently of BMI. However, the molecular mecha-
nisms interconnecting obesity and inﬂammation are
still rather unknown and our data do not permit any
conclusions on the direction or causality of this regu-
lation scheme.
We observed that women had signiﬁcantly elevated
SAA levels compared with men; Lappalainen et al.
(2008) also observed a similar sex difference amongst
obese subjects [11]. Concurrent observations have
also been reported for SAA mRNA production in adi-
pose tissue [11, 13], though the reason for the gender
difference is not known. We sought to explain the
gender difference by the higher leptin and ApoA1
concentrations in women, but adjustment with these
factors did not change the result, indicating that the
divergence is related to other factors, possibly body
composition or hormonal proﬁle. Unfortunately, we
have no data available on body fat percentage or sex
hormones in our study population.
Nevertheless, hormonal contribution to SAA regula-
tion has been reported in premenopausal women using
COCs and also in postmenopausal women receiving
oestrogen replacement therapy (ERT); SAA levels
were signiﬁcantly elevated amongst those receiving
oral-conjugated estrogens [25, 26]. In addition, it has
recently been demonstrated that ERT-associated eleva-
tion in SAA was counteracted by oral administration
of an androgenic progestin, medroxyprogesterone ace-
tate [27]. In this study, we observed that premenopau-
sal women using COCs had signiﬁcantly higher SAA
levels compared with nonusers, whereas women using
levonorgestrel-releasing IUD had lower median SAA
than nonusers. Although not directly comparable, our
results lend support to these observations on hormonal
regulation of SAA. First, the higher SAA levels
amongst the COC using women were not merely sec-
ondary to their higher CRP concentrations [23] as the
difference remained unchanged after adjusting for
plasma CRP. Second, the IUD used by our study
women contained levonorgestrel which is an andro-
genic, testosterone-derived progestin [28], thus likely
to excrete anti-inﬂammatory effects analogous to med-
roxyprogesterone acetate. The mode of action of these
hormonal components most probably deals with the
ﬁrst-pass hepatic effect, as transdermal ERT has an
opposite effect on SAA levels compared with oral
ERT [25]. However, whether systemic inﬂammatory
reaction is involved in this regulation of SAA is still
somewhat uncertain [25, 26] and we were unfortu-
nately unable to evaluate the matter as we did not
measure the IL-6 or TNF-a levels in our cohort.
Whilst acute-phase SAA is almost entirely of liver
origin, mounting evidence implies that adipose tissue
is the main source of circulating SAA during the non-
acute conditions, [9, 11–13, 15]. Also, endothelial
cells, smooth muscle cells, monocytes and macro-
phages in atherosclerotic lesions have been reported
to account for the extrahepatic production of SAA, as
the presence of both SAA mRNA and protein prod-
ucts has been detected in these cell types [29–31].
Moreover, SAA is able to alter vascular proteoglycans
in a proatherogenic manner [32] and to stimulate the
production of various inﬂammatory mediators, such
as TNF-a, IL-1b, IL-8, plasminogen activator inhibi-
tor-1 and tissue factor in cultured vascular endothelial
cells, neutrophils and monocytes [9, 24, 33]. In addi-
tion, activated neutrophils can induce formation of
SAA-LDL complexes via lipoprotein oxidation in vitro
[34]. Elevation in circulating SAA has also been
related to acute cardiovascular events, with a better or
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equal prognostic value compared with CRP [5–7]. It
therefore follows that, as CRP is already a widely
used marker in prognosis of CVD [3, 7], these obser-
vations have raised the possibility that SAA could
also be a proatherogenic risk factor and not merely a
marker of systemic or local inﬂammation. However,
data are still lacking with regard to the clinical rele-
vance of minor elevation in SAA and also the cut-off
value for low-grade elevation in SAA has not been
established yet.
Our results, however, indicate that the association of
SAA, as well as that of CRP, on the early atheroscle-
rosis is mediated through BMI and serum lipids as
the associations with carotid compliance and IMT
were attenuated to the null when the multivariable
model was adjusted for BMI and serum lipids. These
results are in accordance with those of Wohlin et al.
(2007) who observed no independent association
between SAA and IMT in older men [35], yet Schil-
linger et al., (2005) reported that both SAA and CRP
are associated with the progression of active but ini-
tially asymptomatic atherosclerosis in both sexes [36].
Therefore, functional studies are required to establish
the role, if any, of SAA in atherogenesis, both in
conditions conferring a risk of atherosclerosis
per se – such as obesity – as well as in healthy and
lean individuals. Although SAA is not an independent
determinant for subclinical atherosclerosis in healthy
young adults, we suggest that it is a marker of meta-
bolic status and it remains to be discovered whether it
contributes to the pathogenesis of early atherosclerosis
via factors related to lipid metabolism. In conclusion,
the results of this study demonstrate that SAA is asso-
ciated with several metabolic risk factors in both gen-
ders regardless of BMI, and also with the use of
COCs or IUD in premenopausal women, indepen-
dently of CRP.
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Heart rate variability is independently associated
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ABSTRACT
Background Increased levels of C-reactive protein (CRP) and serum amyloid A (SAA) are associated with an
increased risk of cardiovascular disease. It is hypothesized that dysregulation of the autonomic nervous system
(ANS) leads to increased inflammation via the cholinergic anti-inflammatory pathway. Heart rate variability (HRV)
is a marker of ANS function. HRV has been shown to be associated with CRP levels. Currently, there are no
studies addressing the relationship between HRV and SAA.
Design The purpose of this study was to compare the associations between HRV, CRP and SAA in healthy
young adults. CRP and SAA concentrations and short-term HRV indices [high frequency (HF), low frequency
(LF), total spectral component of HRV, root mean square differences of successive R-R intervals, the standard
deviation of all R-R intervals and ratio between LF and HF) were measured in 1601 men and women aged 24–39
taking part in the Cardiovascular Risk in Young Finns study.
Results A significant inverse correlation (P < 0Æ05) between HRV indices and inflammatory markers was
observed. However, in linear regression analyses, only inverse association between HRV indices and CRP levels
remained significant (P < 0Æ05), while association between HRV indices and SAA levels was attenuated to the
null (P > 0Æ05) after adjusting for age, sex, body mass index, cholesterol levels, leptin and other common
traditional cardiovascular risk factors.
Conclusions Reduced HRV indices are independently associated with increased CRP levels, but not with SAA
levels. This association supports the hypothesis that dysregulation of the ANS may lead to increased inflamma-
tion early in adulthood.
Keywords Autonomic nervous system, C-reactive protein, heart rate variability, inflammation, leptin,
Serum amyloid A.
Eur J Clin Invest 2011; 41 (9): 951–957
Introduction
Heart rate variability (HRV) is the oscillation of consecutive
heart beats over time. The HRV measurement is a non-invasive
method used to assess autonomic nervous system (ANS) con-
trol of the heart [1]. Under resting conditions, the parasympa-
thetic nervous system is a more potent regulator of heart rate
(HR) while, during exercise, the sympathetic nervous system is
more important. Reduced HRV is associated with an increased
risk of cardiovascular disease (CVD) [2,3], diabetes [4] and
European Journal of Clinical Investigation Vol 41 951
DOI: 10.1111/j.1365-2362.2011.02485.x
ORIGINAL ARTICLE
hypertension [5]. In addition, many studies have also reported
the simultaneous presence of increased inflammatory parame-
ters.
Previous studies have shown that acetylcholine can suppress
the production of pro-inflammatory cytokines in vitro, while
extrinsic stimulation of the vagus nerve in vivo has been shown
to inhibit the release of pro-inflammatory cytokines and to pre-
vent inflammation [6,7]. The pathway related to ANS control of
the immune system has been termed the cholinergic anti-
inflammatory pathway [8]. Several studies have shown an
inverse relationship between HRV and inflammatory markers
levels, such as C-reactive protein (CRP) and interleukin-6, in
individuals suffering from CVD [9], as well as in healthy popu-
lations [10–13]. The current view is that reduced HRV indices
reflect an imbalance in the ANS, which results in increased
inflammation and stimulation of CRP synthesis via the cholin-
ergic anti-inflammatory pathway. This pathway represents a
possible link between ANS dysfunction, inflammation and
CVD. Inflammation has an important role in the pathogenesis
of atherosclerosis [14]. CRP has been used as a marker of
low-grade inflammation, and it has been associated with an
increased risk of CVD [15,16]. One study has reported that
reduced HRV and increased CRP levels have a synergistic
effect on the risk for CVD [17].
Like CRP, serum amyloid A (SAA) is an acute phase protein
that is associated with CVD [15,18] but not with subclinical
atherosclerosis [19]. Unlike CRP, SAA is mainly produced in
adipose tissue under noninflammatory conditions. In addition,
serum concentrations of SAA correlate strongly with adipose
mass [20,21]. It has been suggested that SAA may be a link
between obesity and inflammatory conditions [21]. Both CRP
and SAA have been shown to associate strongly with leptin
levels in noninflammatory conditions [19,22]. Also, it has been
previously demonstrated that leptin levels correlate with HRV
indices [23]. Currently, there are no studies addressing the
association between HRV indices and SAA levels, and none of
the previous studies have investigated whether the association
between HRV and inflammatory markers is independent of
leptin [10–13]. In this study, we measured short-term HRV
indices and CRP, SAA and leptin levels in a population of
healthy young adults. We sought to determine whether HRV
indices are independent of the inflammatory markers CRP
and SAA in a large population consisting of healthy young
adults.
Methods
Subjects
The study population consisted of participants in the Cardio-
vascular Risk in Young Finns study, which is an ongoing multi-
centre follow-up study involving five university city hospitals
in Finland. The study began in 1980, when 3596 participants
between the ages of 3 and 18 were randomly selected from the
national population registers. The design of this study has been
described in more detail elsewhere [24–26]. The 21-year follow-
up was conducted in 2001, when the participants were between
24 and 39 years of age. Cardiovascular risk factor measure-
ments, including body mass index (BMI), serum lipids, blood
pressure values, CRP, SAA, leptin, alcohol consumption and
smoking habits, were recorded during this follow-up. This
study was approved by local ethics committees. All
participants provided a written informed consent.
Clinical and chemical analyses
Blood pressure measurements were taken using a random zero
sphygmomanometer (Hawksley & Sons Ltd, Lancin, UK), and
the mean of three measurements was used in the analysis. BMI
was calculated from measured height and weight values. CRP,
SAA, leptin, insulin, triglycerides and total cholesterol levels
were obtained from blood plasma samples drawn during fast-
ing. Information on smoking habits, alcohol consumption, oral
contraceptive use, physical activity, pregnancy and breastfeed-
ing was collected by administering a questionnaire.
Fasting plasma CRP concentrations were analysed by using a
high-sensitive latex turbidometric immunoassay (Wako Chemi-
cals GmbH, Neuss, Germany) with a detection limit of
0Æ06 mg L)1. Serum SAA concentrations were measured with
an ELISA kit with a detection limit of < 0Æ004 mg L)1 (Human
SAA, Biosource International, Camarillo, CA, USA). Serum
leptin concentrations were analysed with a RIA (Human leptin
RIA kit; Linco Research, St. Charles, MO, USA). Other
analytical and physical examination procedures were
performed as previously reported [22,25].
HRV measurements
A single-channel chest-lead electrocardiogram (ECG), of 3 min
in length, was recorded in 2001. Prior to the recording, subjects
were comfortably seated in supine positions for a minimum of
15 min during a vascular ultrasound scan. The signals were
converted from analogue to digital with a sampling rate of
200 Hz; the respective time series of R-R intervals were gener-
ated. ECG signals were manually revised by T.K. The stationary
period was identified during 3-min period of metronome-
controlled breathing at frequency of 0Æ25 Hz and was used to
compute the time- and frequency-domain HRV indices. The
study subjects were trained to this procedure beforehand to
avoid emotional arousal. The mean duration of the analysed
stationary period was 173 s, and the mean number of analysed
R-peaks was 196. These indices were analysed by using a com-
mercial WinCPRS program (Absolute Aliens, Turku, Finland).
More detailed descriptions of these methods are described
elsewhere [27].
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The following parameters were identified from time- and
frequency-domain measurements: the high-frequency
oscillation (HF, 0Æ15–0Æ40 Hz), the low-frequency oscillation
(LF, 0Æ04–0Æ14 Hz), the total spectral component of HRV (TP),
mean root square differences of successive R-R intervals
(RMSSD) and the standard deviation of all R-R intervals
(SDNN). The ratio between LF and HF oscillations
(LF ⁄HF · 100%) was calculated. Under resting conditions,
vagal activity of cardiovascular autonomic regulation prevails
[28]. The vagal activity is the major contributor of the HF
component of spectral HRV [1]. The LF component may
represent either sympathetic modulation or combination of
both sympathetic and vagal influences. LF ⁄HF is considered to
reflect sympathovagal balance or sympathetic modulations
[1,29]. RMSSD is considered as a marker of vagal function, and
it correlates strongly with HF.
Short-term HRV indices depend on the length of the time-ser-
ies, and shorter time-series may result in less variability; there-
fore, 5-min recordings have been recommended [1]. For this
study, HRV indices were recollected from 75 subjects to com-
pare HRV indices on 3- and 5-min ECG recordings. In addition,
the reproducibility of short-term HRV indices was assessed
from 51 subjects after an average of 4Æ4 months from the first
measurement. Both the reproducibility and the comparability
of these measurements were satisfactory, and no statistically
significant differences were observed in these measurements
[27].
Statistical analysis
Electrocardiogram signals were recorded from 2151 subjects.
Ectopic beats can bias both time- and frequency-domain mea-
surements; therefore, subjects with three or more ectopic beats
(n = 87) were excluded, and recordings with less than three
ectopic beats were manually interpolated. Data recordings or
saving of the data posed some problems for 21 of the study sub-
jects. We excluded subjects who had a recent history of infec-
tion (n = 129), diabetes (n = 26) or chronic rheumatic disease
(n = 36); subjects on antihypertensive (n = 65), lipid-lowering
(n = 8), antidepressive (n = 69) or antipsychotic (n = 26) drugs;
and subjects who were pregnant (n = 62) or lactating (n = 54),
had impaired fasting glucose levels (> 6Æ0 mM, n = 62) or who
suffered from hypertension and were not on medication
(n = 12). Subjects with missing data or with one or more
exclusion criteria were not included in the analysis. The total
number of subjects included in the study was then 1601.
The data were analysed with SPSS (version 15.0; SPSS Inc.,
Chicago, IL., USA). The distributions of HF, LF, TP, LF ⁄HF,
SDNN and RMSSD indices were skewed; therefore, variables
were logarithmically (natural logarithm) transformed. In addi-
tion, natural logarithm values were used for CRP, SAA, leptin,
triglycerides and insulin levels when normal distribution was
required. The correlation between inflammatory variables and
HRV indices was estimated using the Pearson’s test. Multivari-
ate linear regression models were performed to assess the inde-
pendent effects of HRV indices as determinants of CRP and
SAA levels. HRV indices were added to the model using the
enter method; the stepwise method was used to adjust the
model to the clinical and metabolic determinants. Of the colin-
ear variables (e.g. BMI and waist–hip ratio), only those which
showed the strongest correlation with the inflammatory
variables were selected for the model. Reporting of the study
conforms to STROBE Statement [30].
Results
The characteristics of the study population are presented in
Table 1. Pearson correlations between inflammatory markers
levels, leptin and HRV indices are shown in Table 2. CRP and
SAA levels correlated significantly with HR, lnLF, lnTP,
lnSDNN and lnRMSSD indices. Additionally, SAA levels corre-
lated significantly with lnHF indices. However, CRP and SAA
levels did not correlate with the lnLF ⁄HF ratio. Leptin levels
correlated significantly with HR, lnLF, lnTP, lnLF ⁄HF, lnSDNN
and lnRMSSD.
Linear regressionmodelswere created to assess the indepen-
dent effects of these associations (Table 3). Themodelwas
adjusted for sex, age, smoking habits, diastolic blood pressure,
BMI, lnleptin, lninsulin, lntriglycerides, total cholesterol, oral
contraceptive use, physical activity index, alcohol consumption
andHR. In thismodel, CRP levels showed significant association
withHR, lnLF, lnTP, lnSDNNand lnRMSSD indices. Therewas
no statistical association between SAA levels andHRV indices.
Associations were also assess without exclusion criteria
(n = 2042). In those models, lnHF correlated significantly also
with CRP and leptin. In linear regression model, CRP had
significant association only with HR, lnLF and lnSDNN.
Otherwise, results were identical compared to analysis with
exclusion criteria.
Discussion
In this study, we have shown that HRV indices correlate with
CRP levels in a large cohort consisting of healthy young adults.
The associations remained significant after adjusting for
common CVD risk factors, such as age, sex, blood pressure,
metabolic markers and life style factors. These findings are
consistent with previous reports. Sajadieh et al. [10] were the
first to show that decreased HRV indices are associated with
increased CRP levels in healthy middle-aged and elderly sub-
jects. Sloan et al. [11] reported an inverse relationship between
HRV indices and CRP levels in a population consisting of 757
healthy subjects. Thayer and Fischer [12] reported that the
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relationship between HRV indices and CRP levels remains
significant after controlling for urine norepinephrine levels, a
marker of sympathetic ANS activity, in 611 healthy subjects.
Lampert et al. [13] showed that decreased HRV indices are
associated with high CRP levels in 264 healthy middle-aged
male twins.
An important finding of this study is that HRV indices were
found to be associated with CRP levels, independently of leptin
levels. It has been shown that leptin levels associate strongly
with CRP levels during noninflammatory conditions [22]. In
multivariable models, leptin levels appear to be the strongest
Table 1 Data characteristics
N Mean SD
Sex (% of women) 1601 52
Daily smokers (% of total) 1568 26
Oral contraceptive use (% of women) 1599 29
Body mass index (kg m)2) 1555 24Æ7 4Æ0
Waist–hip ratio 1599 0Æ84 0Æ08
Age (years) 1601 31Æ6 5Æ0
Total cholesterol (mML)1) 1601 5Æ11 0Æ93
Triglycerides (mML)1) 1601 1Æ30 0Æ82
Glucose (mML)1) 1601 4Æ98 0Æ40
Insulin (mU L)1) 1600 7Æ32 4Æ80
Systolic blood pressure (mmHg) 1592 121Æ9 13Æ8
Diastolic blood pressure (mmHg) 1592 72Æ9 8Æ6
Physical activity index 1346 16Æ2 15Æ9
Alcohol (drinks per week) 1585 6Æ3 8Æ8
Leptin (ng mL)1) 1601 10Æ26 8Æ89
CRP (mg L)1) 1601 1Æ70 3Æ43
SAA (mg L)1) 1600 22Æ23 77Æ65
HR (beat min)1) 1601 67Æ26 10Æ59
HF (ms2) 1601 1052Æ9 1557Æ7
LF (ms2) 1601 480Æ1 537Æ9
TP (ms2) 1601 2347Æ3 2419Æ1
LF ⁄HF (%) 1601 94Æ7 133Æ8
SDNN (ms) 1601 51Æ8 23Æ4
RMSSD (ms) 1601 49Æ9 32Æ6
CRP, C-reactive protein; HF, high frequency; HR, heart rate; LF, low fre-
quency; LF ⁄ HF, ratio between LF and HF · 100%; RMSSD, root mean square
differences of successive R-R intervals; SAA, serum amyloid A; SDNN,
standard deviation of all R-R intervals; TP, total spectral component of HR
variability.
Table 2 Correlation between inflammatory markers, leptin and
HR variability indices
Correlation*
lnCRP lnSAA lnLeptin
HR (beat min)1) 0Æ112† 0Æ113† 0Æ250†
lnHF (ms2) )0Æ048 )0Æ049‡ )0Æ006
lnLF (ms2) )0Æ065§ )0Æ057‡ )0Æ186†
lnTP (ms2) )0Æ074§ )0Æ054* )0Æ076§
lnLF ⁄HF (%) )0Æ005 0Æ002 )0Æ163†
lnSDNN (ms) )0Æ080§ )0Æ070§ )0Æ090†
lnRMSSD (ms) )0Æ072§ )0Æ075§ )0Æ073§
*Pearson correlation, †<0Æ0001, ‡<0Æ01, §<0Æ05.
CRP, C-reactive protein; HF, high frequency; HR, heart rate; LF, low fre-
quency; LF ⁄ HF, ratio between LF and HF · 100%; RMSSD, root mean square
differences of successive R-R intervals; SAA, serum amyloid A; SDNN,
standard deviation of all R-R intervals; TP, total spectral component of HR
variability.
Table 3 Linear relationship between inflammatory markers and
HR variability indices
Dependent Variable B SE P
CRP HR (beat min)1) 0Æ006 0Æ003 0Æ040
lnHF (ms2) )0Æ046 0Æ025 0Æ068
lnLF (ms2) )0Æ070 0Æ031 0Æ024
lnTP (ms2) )0Æ087 0Æ032 0Æ007
lnLF ⁄HF (%) )0Æ017 0Æ030 0Æ577
lnSDNN (ms) )0Æ186 0Æ066 0Æ005
lnRMSSD (ms) )0Æ108 0Æ048 0Æ024
SAA HR (beat min)1) 0Æ002 0Æ002 0Æ339
lnHF (ms2) )0Æ015 0Æ023 0Æ526
lnLF (ms2) )0Æ028 0Æ028 0Æ317
lnTP (ms2) )0Æ034 0Æ029 0Æ240
lnLF ⁄HF (%) )0Æ006 0Æ026 0Æ823
lnSDNN (ms) )0Æ088 0Æ060 0Æ143
lnRMSSD (ms) )0Æ046 0Æ044 0Æ298
Multivariate model, the effect of HR variability indices adjusted for sex,
smoking, age, diastolic blood pressure, body mass index, lnleptin, lninsulin,
lntriglycerides, total cholesterol, oral contraceptive use, physical activity
index, alcohol use and HR.
Models were performed independently to each HR variability indices.
CRP, C-reactive protein; HF, high frequency; HR, heart rate; LF, low fre-
quency; LF ⁄ HF, ratio between LF and HF · 100%; RMSSD, root mean square
differences of successive R-R intervals; SAA, serum amyloid A; SDNN,
standard deviation of all R-R intervals; TP, total spectral component of HR
variability. Bold indicates statistical significant P < 0Æ05 values.
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predictor of CRP levels. Also, it has been previously shown that
leptin levels correlate with HRV indices [23]. We also found this
association. However, other current studies have not shown a
leptin-independent association between CRP levels and HRV
indices. In this study, we showed that the association between
CRP levels and HRV indices remained significant even after
adjusting for leptin levels and other risk factors.
We also examined the association between HRV indices and
SAA levels. Both CRP and SAA are acute phase proteins, and
their physiological roles in infection are analogous. SAA is one
of the less frequently studied acute phase proteins, although
SAA levels have been shown to be associated with an increased
risk for CVD [15,18]. The correlation between HRV indices and
SAA levels was analogous to the relationship between HRV
indices and CRP levels. However, in multivariable analysis, the
association between HRV indices and SAA levels became non-
significant when adjusted for age and sex, and cardiovascular
risk factors including smoking, oral contraceptive use, physical
activity, alcohol consumption, diastolic blood pressure, BMI,
leptin, insulin, triglycerides and total cholesterol levels, while
the association between HRV indices and CRP levels remained
significant. The association between SAA levels and HRV indi-
ces was diminished after adjusting for leptin levels or diastolic
blood pressure, indicating that the possible effect of the ANS on
these inflammatory markers is different. One possible explana-
tion for this difference is that most of the vagal nervous endings
are found in the gastrointestinal tract [31]. Under noninflamma-
tory conditions, CRP is mainly produced in the liver, while
SAA is produced in adipose tissue [20,21]. Therefore, the ANS
can possibly regulate CRP levels more directly, via the choliner-
gic anti-inflammatory pathway, while the effect on SAA levels
is not direct. Reduced HRV indices have been shown to be asso-
ciated with metabolic syndrome [32] and hypertension [5], con-
ditions, which are also associated with increased inflammation.
Thus, the association between HRV indices and SAA levels
could be because of the possible effect of the ANS on both the
metabolic and vascular systems.
It is important to note that there are limitations to this study.
Because of time restrictions, only 3 min of ECG recordings were
collected. At least 5 min of recordings have been previously
recommended [1]. The mean duration of stationary R-R time
series was 173 s in our study, which should be adequate for
HRV components evaluation. Also, we have demonstrated ear-
lier that there was no statistically significant difference between
these 3-min ECG measurements when compared to 5-min
recordings, and the reproducibility of these measurements was
satisfactory [27]. However, we recognize that the amount of
subjects in the reproducibility and the comparability studies
was quite low. A single-channel chest-lead ECG was recorded
during a 3-min period of metronome-controlled breathing at
the frequency of 0Æ25 Hz. Using of controlled breathing may
have led to enhancement of HF component [29]. The HRV
index is one of several tools used to assess the ANS. Additional
methods have been used to control the sympathetic ANS. The
sympathetic ANS has been shown to modulate both pro- and
anti-inflammatory functions [31]. We were not able to control
sympathetic ANS modulation of inflammation; hence, we did
not have additional information about the study subject’s sym-
pathetic ANS activity, e.g. norepinephrine levels. Therefore, it is
also possible that the association observed here between HRV
indices and inflammation markers levels may reflect an effect
of the sympathetic ANS or a combined effect of both compo-
nents of the ANS, although LF ⁄HF, which has suggested to be
the most reliable HRV-derived marker of sympathetic ANS
activity [1], was not associated with inflammatory markers.
Blood pressure measurements were taken with a random zero
sphygmomanometer. Using this method might have lead to
inaccuracies in blood pressure measurements, because this
method has been shown to underestimate blood pressure
values [33]. Because numerous variables affect significantly on
HRV variables and inflammatory markers values, many exclu-
sion criteria were used. This lowered the number of study sub-
jects significantly (1601 vs. 2042). Therefore, we also analysed
results without exclusion criteria. This made minor changes to
results, but the main results and conclusions remained the
same. These results cannot be generalized to subjects with
hypertension, diabetes, chronic rheumatic disease pregnant
and breastfeeding women, and subjects with certain medica-
tions, because such individuals were excluded from the
analysis.
Conclusion
In summary, the present study showed that SAA and CRP lev-
els correlate analogously with HRV indices, but only the associ-
ation between HRV indices and CRP levels remains significant
after adjusting for risk factors, including leptin levels. The
independent association between HRV and CRP supports the
hypothesis that dysregulation of the ANS may lead to increased
inflammation via the cholinergic anti-inflammatory pathway in
early adulthood. Understanding these mechanisms is clinically
relevant to better manage and understand chronic inflamma-
tory diseases such as atherosclerosis in the future.
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Summary
Pentraxin 3 (PTX3) is a novel candidate immunoinflammatory marker that
has been reported to be associated with cardiometabolic risk factors and to
predict adverse outcomes in individuals with cardiovascular disease (CVD).
Despite being a member of the same pentraxin protein family as C-reactive
protein (CRP), PTX3 probably reflects different aspects of CVD pathogenesis.
In this study, we assessed plasma PTX3 correlates and determinants in the
Health 2000 Survey population, which comprised n = 403 insulin-resistant
subjects, n = 845 hypercholesterolaemic subjects and n = 311 hypertensive
subjects, all aged between 46 and 76 years. In insulin-resistant subjects the
PTX3 concentration was found to correlate directly with age, pulse pressure
and indoleamine 2,3-dioxygenase (IDO) enzyme activity and inversely with
total and low-density lipoprotein (LDL) cholesterol. In hypercholesterolaemic
subjects, the PTX3 concentration correlated directly with HDL cholesterol,
systolic blood pressure and pulse pressure, whereas in hypertensive subjects,
the PTX3 concentration correlated directly with systolic blood pressure, pulse
pressure and IDO activity. No correlation was observed between the concen-
trations of PTX3 and CRP, adiposity indicators or indicators of subclinical
atherosclerosis in any of the subject groups. PTX3 concentration variations
were attributed to variations in LDL cholesterol and IDO activity in insulin-
resistant subjects and to pulse pressure in hypercholesterolaemic and hyper-
tensive subjects. These results indicate that, in individuals at high risk of CVD,
the PTX3 concentration is associated with cardiovascular risk factors but not
with subclinical atherosclerosis.
Keywords: acute phase proteins, atherosclerosis, inflammation/inflammatory
mediators including eicosanoids
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Introduction
Immune response and inflammatory factors are known to be
involved in the development of atherosclerosis from the
point of endothelial injury to acute clinical manifestations.
According to current understanding, chronic low-grade
inflammation in the arterial wall can accelerate the accumu-
lation of asymptomatic atherosclerotic changes, whereas an
abrupt and more vigorous inflammatory activation precedes
end-point plaque rupture [1]. However, it is unclear whether
inflammatory mediators can act as causal agents in the
pathogenesis of cardiovascular disease (CVD) or whether
they merely emerge as indicators of ongoing vascular
damage. Various players of the innate immune system, such
as the traditional C-reactive protein (CRP) and a newer can-
didate of the same pentraxin family, pentraxin 3 (PTX3),
have been presented as potential atherosclerotic biomarkers,
as their low-level increase in plasma has been associated with
cardiovascular events in a number of studies [2–7].
PTX3 is an acute-phase reactant that shares structural and
functional homology with CRP, as it activates the comple-
ment system, binds microbial surfaces and apoptotic cells
and aids in their clearance [8]. However, unlike CRP, which is
synthesized mainly in the liver, PTX3 is produced at the site
of inflammation by macrophages, dendritic cells, neutro-
phils, fibroblasts, endothelial cells and smooth muscle cells
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(SMCs) [8]. Synthesized PTX3 can also be stored in neutro-
phil granules that, upon stimulation, release PTX3 rapidly
into circulation [9]. Production of PTX3 is induced by inter-
leukin (IL)-1, tumour necrosis factor (TNF)-a, oxidized
low-density lipoprotein (ox-LDL) and microbial moieties,
but is not induced by IL-6 [8]. It has been suggested that
PTX3 plays the same role in the periphery that CRP does in
circulation [10]. However, in the case of myocardial infarc-
tion (MI), the PTX3 concentration has been reported to peak
more rapidly than the CRP concentration [2], which could
indicate the higher sensitivity of PTX3 in response to vascu-
lar damage. Alternatively, the PTX3 concentration may
reflect different and uncharacterized aspect(s) of inflamma-
tion because in mouse models of atherosclerosis and MI,
PTX3 has been demonstrated to exert a cardioprotective
function [11,12].
Despite the incompletely understood role of PTX3 in vas-
cular biology, several lines of epidemiological and experi-
mental evidence imply that PTX3 could be involved
intimately in the pathogenesis of CVD. Elevated PTX3
plasma levels have been associated with adverse cardiovas-
cular outcomes [2–4,6,7], and PTX3 expression has also
been detected in atherosclerotic plaques [13,14]. Further-
more, PTX3-positive neutrophils can infiltrate atheroscle-
rotic lesions, and their presence has been observed in
coronary arterial thrombi originating from culprit lesions in
MI patients [14]. However, no consensus currently exists as
to whether plasma PTX3 is an independent risk factor in the
pathophysiology of atherosclerosis or whether it is just an
auxiliary signalling marker between vascular inflammation
and tissue repair. To determine the usefulness of PTX3 as a
marker of subclinical atherosclerosis in individuals free of
clinical CVD, we studied the relationship between plasma
PTX3 and the following factors: cardiovascular risk factors,
indices of subclinical atherosclerosis and inflammatory mea-
sures, namely CRP and indoleamine 2,3-dioxygenase (IDO)
enzyme activity.
Materials and methods
Study population
The study population was a subpopulation drawn from the
Health 2000 Survey, a large Finnish cross-sectional health
examination survey carried out from 2000 to 2001 [15]. The
overall study cohort was a two-stage stratified cluster sample
(8028 individuals) representing the entire Finnish popula-
tion aged 30 years and older. To study cardiovascular risk and
diabetes more thoroughly, a supplemental study was carried
out (sample size 1867, 82% participation rate). The partici-
pants in this study consisted of those supplementary study
subjects for whom clinical and metabolic cardiovascular risk
factor data were available. The study population consisted of
the following subject groups, based on clinical condition:
403 insulin-resistant subjects, 845 hypercholesterolaemic
subjects, 311 hypertensive subjects and 108 healthy subjects,
all aged between 46 and 76 years, and without a history of
CVD, MI, stroke or heart failure. Please see the inclusion
criteria for the subject groups in the following section (Clini-
cal and biochemical analyses). Among the 403 insulin-
resistant subjects, 355 individuals also had hypertension
and/or hypercholesterolaemia; among the 845 hypercholes-
terolaemic subjects, 521 individuals also had insulin resis-
tance and/or hypertension; and among the 311 hypertensive
subjects, 284 individuals had also hypercholesterolaemia
and/or insulin resistance. The study was conducted in five
Finnish University Hospitals. The Health 2000 Survey pro-
tocol was approved by the Epidemiology Ethics Committee
of the Helsinki and Uusimaa Hospital District. All partici-
pants gave their written informed consent.
Clinical and biochemical analyses
Height and weight were measured, and body mass index
(BMI) was calculated. Waist and hip circumferences were
measured in the standing position using the standards
created for population health studies. Waist circumference
was not measured in the supplemental study; therefore, the
waist circumference values measured for the Health 2000
Survey were used. Blood pressure was measured after at least
10 min of rest with the automatic Omron M4 manometer
(Omron Matsusaka Co., Japan; Omron Healthcare Europe
BV, Hoofddrop, the Netherlands) and the mean of three
measurements was used in the analysis. Pulse pressure was
calculated as the difference between the mean systolic pres-
sure and the mean diastolic pressure.
Current smoking, diabetes, CVD history and CVD events,
including coronary artery disease (CAD), were evaluated
with a questionnaire. Those who were current smokers were
defined as smokers, and the rest of the subjects were defined
as non-smokers. Insulin resistance was assessed according to
the International Diabetes Federation criteria [16], and
hypercholesterolaemia (LDL cholesterol >3 mmol/l or total
cholesterol >5 mmol/l) and hypertension (diastolic blood
pressure >90 mmHg and systolic blood pressure140) were
assessed according to the Finnish Current Care guidelines,
formulated on the basis of the European guidelines on car-
diovascular disease prevention [17]. Subjects were classified
as healthy based on the absence MI, CAD, heart failure,
stroke, diabetes, hyperlipidaemia, hypercholesterolaemia
and hypertension.
Venous blood samples were drawn after an overnight fast.
High-density lipoprotein (HDL) cholesterol, total choles-
terol, triglyceride and plasma glucose concentrations were
determined enzymatically with a clinical chemistry analyser
(Olympus, AU400, Hamburg, Germany). LDL cholesterol
was calculated with the Friedewald formula. Plasma insulin
concentrations were determined using a radioimmunoassay
(Phadeseph Insulin RIA, Pharmacia Sweden). Homeostasis
assessment of insulin resistance (HOMA-IR) was calculated
J. Jylhävä et al.
212 © 2011 The Authors
Clinical and Experimental Immunology © 2011 British Society for Immunology, Clinical and Experimental Immunology, 164: 211–217
according to the formula: HOMA-IR = fasting glucose
(mmol/l) ¥ fasting insulin (mU/l)/22·5 [18]. Detailed
descriptions of the methods used have been published else-
where [19]. Plasma CRP concentrations were determined
using a chemiluminescent immunometric assay (Immulite,
Diagnostic Products Corporation, Los Angeles, CA, USA).
PTX3 concentrations were determined in ethylenediamine
tetraacetic acid (EDTA)-plasma using a commercial enzyme-
linked immunosorbent assay (ELISA) kit, according to the
manufacturer’s instructions (Quantikine DPTX 30; R&D
Systems Inc., Minneapolis, USA). According to the manufac-
turer, the mean detection limit for the assay is 0·025 ng/ml
and it exhibits no cross-reactivity with either CRP or serum
amyloid P. The enzymatic activity of IDO was assessed (data
available in 759 individuals) using the plasma kynurenine/
tryptophan ratio (mmol/mmol), as described previously
[20].
Carotid artery studies
High-resolution B-mode carotid ultrasound examination of
the right carotid artery was performed according to a stan-
dardized protocol using a 7·5-MHz linear array transducer.
The examinations were performed by centrally trained and
certified sonographers at six study locations throughout
Finland. Carotid IMT measurements were performed off-
line with the use of automated image processing software,
and one researcher was responsible for reading all of the
ultrasound images. Three summary measures of the carotid
IMT were calculated: (i) the mean of the three average IMTs
of the common carotid artery (mean CCA IMT), (ii) the
mean of the three average IMTs of the carotid bulb (mean
bulb IMT) and (iii) the mean of these two means (mean
IMT). Mean IMT was used in the present study. This method
has been described in detail previously [21]. Arterial elastic-
ity was assessed as carotid artery compliance (CAC) accord-
ing to the following formula:
CAC mmHg ADC DAD PP% ,10 100 10( ) = × × ( )[ ]
where ADC is the arterial diameter change, DAD is the dias-
tolic arterial diameter and PP is pulse pressure. Arterial
diameters were calculated as the mean of three average sys-
tolic and diastolic arterial diameters.
Statistical analyses
Individuals with CRP values above 10 mg/ml were excluded
from the analyses (n = 66) due the possibility of an acute
infection. The distributions of the PTX3, CRP, insulin,
HOMA-IR and triglyceride values were skewed, hence the
variables were transformed logarithmically prior to the
analyses. Student’s t-tests and Mann–Whitney’s tests were
used to analyse differences between sexes in the test variables,
and c2 analyses with Fisher’s exact tests were used to assess
differences in smoking between sexes and prevalence of CVD
events between sexes. The correlates for plasma PTX3 were
estimated separately for each subgroup (insulin-resistant
subjects, hypercholesterolaemic subjects, hypertensive sub-
jects and healthy subjects) using Pearson’s tests. Stepwise
multivariate linear regression modelling was performed to
assess the independent determinants for plasma PTX3
concentration. Regression modelling for the determinants of
PTX3 was not, however, performed for the healthy subjects
due to the lack of statistically significant correlates for the
PTX3 concentration (Table 2). All statistical analyses were
performed using SPSS for Windows (version 17.0; SPSS Inc.,
Chicago, IL, USA) and P-values < 0·05 were considered sta-
tistically significant.
Results
The characteristics of the study population are presented in
Table 1. The majority of the variables differed significantly
between men and women; the only variables that did not
deviate between the sexes were age, LDL cholesterol level,
pulse pressure, CRP level, PTX3 level and IDO activity. Addi-
tionally, the prevalences of hypertension, hypercholestero-
laemia, CAD, heart failure and stroke did not differ between
the sexes. In insulin-resistant subjects, the PTX3 concentra-
tion correlated directly with age, pulse pressure and
indoleamine 2,3-dioxygenase (IDO) enzyme activity and
correlated inversely with total and LDL cholesterol (Table 2).
In hypercholesterolaemic subjects, the PTX3 concentration
correlated directly with HDL-cholesterol, systolic blood
pressure and pulse pressure (Table 2). In hypertensive sub-
jects, the PTX3 concentration correlated directly with sys-
tolic blood pressure, pulse pressure and IDO activity
(Table 2). No significant correlations with the PTX3 concen-
tration were observed in healthy subjects (Table 2). Smoking
was not associated with plasma PTX3 concentration
(P = 0·546). The determinants, i.e. factors that explained the
variation in plasma PTX3, were LDL cholesterol and IDO
activity in insulin-resistant subjects, and pulse pressure in
hypercholesterolaemic and hypertensive subjects (Table 3).
Discussion
In this study, we demonstrated that the plasma PTX3 con-
centration correlates with several cardiovascular risk factors
in individuals at high risk of developing CVD. In insulin-
resistant subjects plasma PTX3 correlated directly with age
and pulse pressure, and inversely with total and LDL
cholesterol. In hypercholesterolaemic subjects, we found that
plasma PTX3 correlated directly with age, HDL cholesterol,
systolic blood pressure and pulse pressure, whereas in hyper-
tensive subjects PTX3 correlated directly with diastolic blood
pressure and pulse pressure. In addition, we observed that
PTX3 correlated directly with another inflammatory marker,
IDO, in insulin-resistant and hypertensive subjects. The
factors explaining the variation in plasma PTX3 were found
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Table 1. Characteristics of the study population.
All Men Women P for difference
between sexesMean s.d. Mean s.d. Mean s.d.
Age (years) 58·21 8·03 57·90 7·75 58·47 8·246 0·223
BMI (kg/m2) 27·13 4·35 27·49 3·97 26·82 4·62 0·006
Waist circumference (cm) 93·36 13·11 99·31 11·31 88·23 12·36 <0·001
Hip circumference (cm) 102·19 9·08 101·27 7·98 102·97 9·86 <0·001
Waist-to-hip ratio 0·91 0·09 0·98 0·06 0·85 0·06 <0·001
Heart rate (beats/min) 66·51 10·14 65·49 10·51 67·35 9·75 0·002
Systolic blood pressure (mmHg) 138·47 21·71 141·63 20·46 135·71 22·41 <0·001
Diastolic blood pressure (mmHg) 84·42 10·56 87·50 10·79 81·80 9·62 <0·001
Pulse pressure (mmHg) 54·02 15·00 54·15 13·76 53·91 15·99 0·798
Total cholesterol (mmol/l) 5·59 0·94 5·50 0·96 5·66 0·91 0·002
HDL cholesterol (mmol/l) 1·58 0·43 1·43 0·38 1·71 0·43 <0·001
LDL cholesterol (mmol/l) 3·40 0·87 3·41 0·88 3·38 0·86 0·626
Triglycerides (mmol/l)* 1·20 0·90–1·60 1·30 1·00–1·80 1·10 0·80–1·50 <0·001
Glucose (mmol/l) 5·85 1·19 6·13 1·35 5·61 0·97 <0·001
Insulin (mmol/l)* 7·80 5·70–11·10 8·50 5·93–12·28 7·30 5·40–10·20 <0·001
HOMA-IR* 1·98 1·37–2·96 2·23 1·49–3·36 1·80 1·29–2·69 <0·001
CRP (mg/l)* 1·44 0·79–2·87 1·47 0·82–2·81 1·38 0·76–2·95 0·332
PTX3 (ng/l)* 1·01 0·68–1·44 1·04 0·74–1·44 0·98 0·64–1·46 0·107
IDO (kyn/tryp) 31·65 8·27 31·36 8·02 31·89 8·48 0·379
IMT (mm) 0·93 0·23 0·96 0·24 0·90 0·21 <0·001
CAC (%/10 mmHg) 0·93 0·48 0·88 0·41 0·96 0·53 0·010
Smoking (%)†
No 78·5 73·7 82·6 <0·001
Yes 21·5 26·3 17·4
Hypertension (%)†
No 71·8 71·5 72·0 0·845
Yes 28·2 28·5 28·0
Insulin resistance (%)†
No 58·1 52·4 62·7 0·001
Yes 41·9 47·6 37·3
Hypercholesterolemia (%)†
No 21·3 23·0 80·3 0·684
Yes 78·7 77·0 68·2
Diabetes (%)†
No 94·6 92·4 96·5 0·002
Yes 5·4 7·6 3·5
CAD (%)†
No 93·5 93·0 94·0 0·471
Yes 6·5 7·0 6·0
Heart failure (%)†
No 96·6 95·6 97·4 0·076
Yes 3·4 4·4 2·6
MI (%)†
No 96·0 93·9 97·7 0·001
Yes 4·0 6·1 2·3
Stroke (%)†
No 98·1 97·4 98·8 0·064
Yes 1·9 2·6 1·2
*Median values and interquartile range (IQR): Mann–Whitney’s U-test for difference between sexes. †c2 test for difference between sexes; t-test for
difference between sexes. BMI: body mass index; CAC: carotid artery compliance; CAD: coronary artery disease; CRP: C-reactive protein; PTX3:
pentraxin 3; HDL: high-density lipoprotein; HOMA-IR: insulin resistance index; IDO: indoleamine 2,3-dioxygenase (IDO) enzyme; IMT: intima-media
thickness; LDL: low-density lipoprotein; MI: myocardial infarction; s.d.: standard deviation.
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to be LDL cholesterol and IDO in insulin-resistant subjects
and pulse pressure in hypercholesterolaemic and hyperten-
sive subjects, although these factors accounted for only 1·1–
5·7% of the variation in the PTX3 levels. Interestingly, no
statistically significant correlations for plasma PTX3 were
observed in healthy subjects. Moreover, the PTX3 concentra-
tion did not correlate with indicators of subclinical athero-
sclerosis, IMT and CAC or with CRP and adiposity
indicators in any of the subject groups.
The association of the PTX3 concentration with cardi-
ometabolic risk factors has been documented previously. In
subjects with metabolic syndrome, Zanetti et al. (2009)
observed that plasma PTX3 correlated directly with triglyc-
eride levels and inversely with HDL cholesterol levels [22],
whereas Yamasaki and colleagues (2009) have reported
inverse correlations between plasma PTX3 and triglyceride
levels and between plasma PTX3 and BMI [23]. Negative
findings on the relationships between the levels of all plasma
lipids and PTX3 in rheumatic and non-rheumatic patients
with CVD have also been presented [24,25]. Intriguingly,
Alberti et al. (2009) detected expression of PTX3 in adipose
tissue from obese and lean subjects and reported that the
age- and sex-adjusted expression of PTX3 in visceral adipose
tissue correlated with BMI, HDL, HDL/LDL ratio, triglycer-
ides, CRP, fibrinogen and adiponectin [26]. They did not,
however, find a correlation between the levels of adipose
Table 2. Pearson’s correlations for (log)pentraxin 3 (PTX3).
Insulin-resistant
subjects
Hypercholesterolaemic
subjects
Hypertensive
subjects
Healthy
subjects*
n = 403 n = 845 n = 311 n = 108
r P r P r P r P
Age 0·105 0·034 0·085 0·013 0·103 0·070 0·033 0·734
Body mass index (kg/m) -0·059 0·236 -0·058 0·093 0·034 0·546 -0·069 0·475
Waist circumference (cm) -0·014 0·783 -0·017 0·613 0·028 0·621 0·032 0·744
Hip circumference (cm) -0·037 0·464 -0·009 0·805 0·074 0·192 -0·035 0·722
Waist-to-hip ratio 0·021 0·680 -0·019 0·574 -0·030 0·604 0·068 0·485
Heart rate (beats/min) -0·023 0·652 0·038 0·273 0·079 0·167 -0·060 0·541
HDL cholesterol (mmol/l) 0·017 0·737 0·080 0·019 0·058 0·310 -0·048 0·623
LDL cholesterol (mmol/l) -0·139 0·006 -0·061 0·079 0·040 0·487 -0·107 0·273
Total cholesterol (mmol/l) -0·102 0·040 -0·012 0·721 0·063 0·270 -0·156 0·106
(log)Triglycerides (mmol/l) 0·034 0·498 -0·012 0·722 0·001 0·987 -0·019 0·844
Glucose (mmol/l) 0·041 0·408 0·053 0·126 0·018 0·748 0·074 0·448
(log)Insulin (mmol/l) 0·082 0·102 0·032 0·360 0·103 0·069 0·070 0·474
(log)HOMA-IR 0·081 0·103 0·042 0·225 0·091 0·110 0·079 0·414
Systolic blood pressure (mmHg) 0·089 0·073 0·117 0·001 0·143 0·012 0·159 0·102
Diastolic blood pressure (mmHg) 0·017 0·733 0·062 0·073 0·025 0·666 0·168 0·083
Pulse pressure (mmHg) 0·111 0·025 0·126 <0·001 0·171 0·003 0·110 0·261
(log)CRP (mg/l) 0·041 0·413 -0·006 0·868 0·041 0·467 0·083 0·390
IDO 0·161 0·010 0·010 0·828 0·152 0·035 0·031 0·795
Carotid IMT (mm) 0·057 0·260 0·041 0·243 0·032 0·578 0·044 0·656
Carotid artery compliance (%/10 mmHg) -0·051 0·339 -0·062 0·090 -0·085 0·155 0·038 0·707
Statistically significant correlations (P < 0·05) are shown in bold type. *Subjects excluded for CVD, MI, stroke, heart failure, insulin resistance,
hyperlipidaemia or hypertension. BMI: body mass index; CAC: carotid artery compliance; CRP: C-reactive protein; PTX3: pentraxin 3; HDL:
high-density lipoprotein; HOMA-IR: insulin resistance index; IDO: indoleamine 2,3-dioxygenase (IDO) enzyme; IMT: intima-media thickness; LDL:
low-density lipoprotein.
Table 3. Independent determinants for plasma (log)pentraxin 3 (PTX3) in a stepwise linear regression model.
Determinats
Insulin-resistant subjects Hypercholesterolaemic subjects Hypertensive subjects
n = 403 n = 845 n = 311
B s.e. P B s.e. P B s.e. P
LDL cholesterol -0·054 0·019 0·005
Pulse pressure 0·002 0·001 0·019 0·003 0·001 0·007
IDO 0·004 0·002 0·015
R2 = 0·057 R2 = 0·011 R2 = 0·025
The model included age, LDL cholesterol, total cholesterol, glucose, insulin, HOMA-IR, systolic blood pressure, diastolic blood pressure, pulse
pressure and IDO as dependent variables. HOMA-IR: insulin resistance index; IDO: indoleamine 2,3-dioxygenase (IDO) enzyme; LDL: low-density
lipoprotein; s.e.: standard error.
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tissue-derived PTX3 expression and LDL cholesterol,
glucose, insulin or blood pressure. In contrast, Bosutti et al.
(2007) demonstrated that plasma LDL-cholesterol is associ-
ated with PTX3 mRNA levels in adipose tissue and white
blood cells in non-diabetic pacemaker-implanted patients
[27].
Results on the associations of PTX3 with CRP [4,7,25,28]
and sex [6,7,23] also seem to be contradictory. With regard
to age, however, there seems to be a consensus that advancing
age is associated with higher PTX3 levels [7,23–25], a notion
that was also verified in our study among insulin-resistant
and hypercholesterolaemic subjects.
Even though the potential role of PTX3 in vascular
biology and CVD has been studied intensively, the causalities
between PTX3 levels and cardiovascular outcomes are still
unclear. Similarly, the functional role of PTX3, if any, in
atherogenesis has not been established. Nevertheless, PTX3
has been reported to be associated with cardiac events in
heart failure patients [4,6] and in hospitalized AMI patients
[2,3,7] and the PTX3 concentration has also been demon-
strated to be associated with all-cause and cardiovascular
mortality among ostensibly healthy subjects [25]. Addition-
ally, recent mouse studies have proposed that PTX3 could
have an atheroprotective role [11,12], potentially ascribed to
its relationship with HDL cholesterol [29]. In keeping with
the protective capability of PTX3, Deban and colleagues
(2010) reported that, in both localized and systemic inflam-
matory conditions, PTX3 can act as a negative feedback
mediator by dampening excessive neutrophil recruitment,
thereby limiting inflammation [30]. Our novel observation
that plasma PTX3 correlates directly with IDO activity in
insulin-resistant and hypertensive subjects could similarly
reflect the immunosuppressive function of PTX3 because
IDO, a product of antigen-presenting cells, is a known
immunoinflammatory down-regulator of type 1 T helper
cell responses [31]. Currently, however, the relationship
between elevated plasma PTX3 levels and acute cardiovascu-
lar events and PTX3’s putative suppressive or protective role
are unclear.
As a limitation of this study, it must be acknowledged that
in our study the subject groups, especially the healthy sub-
jects, were rather small, and the observed correlations
between plasma PTX3 and cardiovascular risk factors were,
although significant, somewhat weak. Consequently, it
appears that in our population, PTX3 plasma levels were
determined largely by factors other than the traditional CVD
risk factors, as our regression models explained only a minor
part of the variation in the PTX3 concentration. Addition-
ally, the frequency of subjects with a diagnosed CVD in our
study population was too low to carry out statistical analysis
on plasma PTX3 levels among these subjects.
Analogously to the results of Zanetti et al. (2009) [22], we
observed no correlation between cardiometabolic risk
factors and plasma PTX3 in the group of healthy subjects,
indicating that plasma PTX3 may not be a suitable risk indi-
cator in healthy subjects. Similarly, the lack of correlation
between plasma PTX3 and subclinical CVD indicators in all
the subject groups in this study, as well as in a recent study by
Miyaki et al. (2010), suggests that plasma PTX3 might not
reflect early atherosclerotic changes. Nevertheless, a direct
correlation between PTX3 levels and IMT was observed in
elderly hypertensive patients by Yano et al. (2010) [32],
whereas Yilmaz et al. (2009) demonstrated an independent
association between PTX3 levels and endothelial dysfunc-
tion in diabetic renal disease patients [33]. Moreover, Jenny
et al. (2009) have shown that plasma PTX3 correlates directly
with the ankle-brachial blood pressure index, but not with
IMT, in CVD-free individuals [25].
Taken together, the results of this study indicate that,
although plasma PTX3 levels were not associated with sub-
clinical atherosclerosis, they correlated with several cardio-
vascular risk factors in individuals at high risk of developing
CVD. Further research is required to validate the use of
plasma PTX3 as an auxiliary and/or adiposity- and CRP-
independent risk marker in CVD-free individuals.
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Summary
Human cytomegalovirus (CMV) infection is associated with a higher risk of
cardiovascular disease in immunocompromised organ transplant patients. It
has been linked with the pathogenesis of elevated arterial blood pressure.
However, controversy exists as to whether CMV infection is associated with
endothelial function, and little is known about its role as a potential risk factor
for early atherosclerosis development at a young age.We aimed to discover if
CMV antibody titres are associated with early vascular changes (carotid
intima-media thickness, carotid artery distensibility and brachial artery flow-
mediated dilation), blood pressure elevation or other traditional cardiovas-
cular risk factors.CMV antibody titres weremeasured in 1074 women and 857
men (aged 24–39 years) taking part in the Cardiovascular Risk in Young Finns
study. CMV antibody titres were significantly higher in women compared to
men. In men, high CMV antibody titres were associated directly with age
(P < 0·001) and systolic (P = 0·053) and diastolic (P = 0·002) blood pressure
elevation, and associated inversely with flow-mediated dilation (P = 0·014). In
women, CMV antibody titres did not associate with any of the analysed
parameters. In a multivariate regression model, which included traditional
atherosclerotic risk factors, CMV antibody titres were independent determi-
nants for systolic (P = 0·029) and diastolic (P = 0·004) blood pressure eleva-
tion and flow-mediated dilation (P = 0·014) in men. High CMV antibody
titres are associated independently with blood pressure and brachial artery
flow-mediated dilation in young men. This association supports the hypoth-
esis that common CMV infection and/or an immune response to CMV may
lead to impaired vascular function at a young age.
Keywords: atherosclerosis, blood pressure, cytomegalovirus, flow-mediated
dilation, risk factors
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Introduction
Human cytomegalovirus (CMV) is a member of the herpes
virus family. It is a widely spread virus, and up to 40% of
people acquire the infection during their first year of life [1].
The prevalence increases progressively with increasing age,
and more than 90% of senior citizens are CMV seropositive
[2]. Women are known to have higher CMV seroprevalence
than men [2]. Additionally, the seroprevalence is higher
among people with low socio-economic status (SES) [2]. In
most immunocompetent people, the primary CMV infec-
tion is mild or even asymptomatic. CMV infection is
typically a clinical problem in immunocompromised people,
including patients with congenital infections or immu-
nodeficiency syndrome, as well as patients receiving organ
transplants [1].
CMV infection is associated with various chronic inflam-
matory diseases, including cardiovascular disease (CVD),
autoimmune diseases and certain cancers [1]. The role of
CMV as a risk factor for CVD is controversial. CMV infec-
tion has been shown to increase the risk of cardiac allograft
vascular disease and graft rejection in immunocompromised
organ transplant patients [3]. The use of anti-viral treatment
with ganciclovir has been shown to decrease the risk
of allograft vascular disease in transplant patients [4,5]. In
immunocompetent people, the association between CMV
infection and an increased risk of CVD is less clear. Sig-
nificant associations have been reported between CMV
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seropositivity and CVD risk [6,7], and also between high
CMV antibody titres and increased CVD risk [8,9].However,
negative associations have also been reported [6,10,11]. Few
relatively small studies exist that have shown an association
between CMV and early atherosclerotic changes; none the
less, CMV has been shown to be associated with endothelial
function [12,13] and increased carotid intima-media thick-
ness (IMT) [14]. Not all reports are unanimous, however
[15,16]. Interestingly, recent publication has shown that
essential hypertension is associated with increased CMV
DNA copy number and CMV-encoded microRNA expres-
sion [17]. Also, CMV infection has been linked with the
pathogenesis of increased arterial blood pressure via stimu-
lation of renin and cytokine production and contributes to
increased blood pressure values in mice [18].
Recent studies have linked high cytomegalovirus anti-
body titres with cardiovascular disease and total mortality
among older people [19–21]. Therefore, we hypothesized
that CMV antibody titres, rather than seropositivity, might
be more relevant markers of deleterious effects of CMV
infection in young adults. In this study, we sought to iden-
tify if intense humoral CMV-specific immunity, measured
by CMV antibody titres, is associated with early vascular
changes, IMT, carotid artery distensibility (Cdist), brachial
artery flow-mediated dilation (FMD), blood pressure values
or other traditional CVD risk factors in young healthy
adults.
Materials and methods
The study population consisted of participants in the Car-
diovascular Risk in Young Finns study, which is an ongoing
multi-centre follow-up study in five university hospitals in
cities with medical schools in Finland. The study began in
1980, when 3596 participants between the ages of 3 and 18
years were selected randomly from the national population
registers. The study design has been presented in more detail
elsewhere [22,23]. The 21-year follow-up was conducted in
2001, when the participants were between 24 and 39 years of
age. Cardiovascular risk factor measurements, including
body mass index (BMI), waist circumference, serum lipids,
blood pressure values, levels of C-reactive protein (CRP),
SES (occupation and education), alcohol consumption and
smoking habits, were recorded during this follow-up. The
study complies with the Declaration of Helsinki. The study
was approved by local ethics committees and subjects gave
informed consent.
Blood pressure measurements were taken using a random
zero sphygmomanometer (Hawksley & Sons Ltd, Lancin,
UK), and the mean of three measurements was used in the
analysis. BMI was calculated from the measured height and
weight. Waist circumference and hip circumference were
measured, and the waist–hip ratio was calculated. Data
regarding occupation, education, smoking habits, alcohol
consumption and physical activity were gathered via
questionnaires. Measurements of plasma lipids, glucose and
insulin were performed by fasting plasma, as described
previously [22]. CRP concentrations were analysed with a
high-sensitivity latex turbidimetric immunoassay (Wako
Chemicals GmbH, Neuss, Germany) with a detection limit
of 0·06 mg/l. CMV IgG antibody titres were analysed using a
commercial enzyme immunoassay (Enzygnost Anti-CMV/
IgG; Siemens Healthcare Diagnostics Products GmbH,
Marburg, Germany). According to the manufacturer, the
test sensitivity was 99·3% and the specificity was 98·2%.
Seropositivity for CMV was defined as a serum anti-CMV
immunoglobulin (Ig)G titre of !230.
Carotid ultrasound measurements were performed using
a Sequoia 512 high-resolution ultrasound system (Acuson,
Mountain View, CA, USA). Subjects were instructed to avoid
smoking, high-calorie meals, coffee and other caffeine drinks
on the day of the ultrasound measurements. Subjects also
were instructed to avoid vigorous exercise and alcohol con-
sumption on the previous evening of the measurements.
Cdist, which depicts the ability of the large arteries to expand
under cardiac pulse pressure, was assessed from the formula
Cdist = ([Ds–Dd]/Dd)/(Ps–Pd), where Ds is the systolic diam-
eter, Dd is the diastolic diameter, Ps is the systolic blood
pressure and Pd is the diastolic blood pressure [24]. Mean
IMT was derived from a minimum of four measurements of
the posterior wall of the left carotid artery (at ~10 mm proxi-
mal to the bifurcation) [24]. To assess brachial FMD, the left
brachial artery diameter was measured both at rest and
during reactive hyperaemia. Increased flow was induced by
inflation of a pneumatic tourniquet placed around the
forearm to a pressure of 250 mmHg for 4·5 min, followed by
release. Three measurements of arterial diameter were per-
formed at end-diastole at a fixed distance from an anatomic
marker at rest and at 40, 60 and 80 s after cuff release. The
vessel diameter in scans after reactive hyperaemia was
expressed as the percentage relative to the resting scan. The
average of three measurements at each time-point was used
to derive the maximum FMD (the greatest value between 40
and 80 s) [25].
CMV antibody titres were measured successfully in 2133
subjects.We found that 648 subjects were seronegative (<230
antibody titres) and that 1485 subjects were seropositive
(!230). Subjects with missing data on smoking, education,
BMI, waist circumference, waist–hip ratio, blood pressure,
insulin, alcohol consumption, IMT and/or Cdist values were
not included in the analysis. Therefore, the total number of
subjects included in the study was 1931 subjects (1074
women and 857 men). The subjects were then divided into
four quartiles according to CMV antibody titres. CMV anti-
body titres were parameterized with a dummy variable com-
paring the highest quartile (Q4), with the bottom three
quartiles combined (Q1–Q3). A t-test was used for normally
distributed variables and the Mann–Whitney U-test
was used for skewed variables (triglycerides, insulin and
CRP). The c2 test was used for categorized variables. A
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multivariable linear regression model was used to assess
CMV significance as an independent determinant for blood
pressure values and FMD. Log10-transformed values were
used for skewed variables. All analyses were also repeated in
a subcohort consisting of only CMV seropositive subjects.
Results
In our study cohort, there were significantly (P = 0·003)
more seropositive women (72·3%) than seropositive men
(65·9%). Additionally, there were significantly (P < 0·001)
more women with CMV antibody levels over 14 000 titres
compared to men (72·5% versus 27·5%). Because of the
strong sex difference in our study sample, all analyses were
performed separately in men and women, including the
quartile division.
Characteristics of the study subjects according to sex and
CMV antibody titre quartiles are presented in Table 1. In
men, high CMV antibody titres were associated significantly
with diastolic blood pressure (P = 0·002) and were associa-
ted borderline significantly with systolic blood pressure
(P = 0·053) compared to all other men. In men, age was also
associated with the highest CMV antibody titre quartile
(P < 0·001). There were no significant associations between
other traditional CVD risk factors (anthropometric, lipid,
metabolic, inflammatory or lifestyle factors) and high CMV
antibody titres. In men, subjects with high CMV antibody
titres had significantly lower FMD values (P = 0·013). IMT
and Cdist values did not differ significantly between CMV
antibody titres. In women, there were no significant associa-
tions between CMV antibody titres and early markers of
atherosclerosis. However, there was a trend between high
CMV antibody titre and higher FMD values (P = 0·070).
A multivariable regression model was used to analyse
whether CMV antibody titres are independent determinants
for blood pressure and FMD. In men, high CMV antibody
titres were associated independently with systolic blood
pressure (P = 0·029) and diastolic blood pressure (P = 0·004)
after adjusting for age, BMI, HDL cholesterol, triglycerides,
insulin, CRP, smoking, occupational status and alcohol
consumption (Table 2). In men, high CMV antibody titres
were also associated independently and inversely with
FMD (P = 0·014) after adjusting for age, baseline brachial
diameter, BMI, systolic blood pressure, HDL cholesterol,
triglycerides, insulin, CRP, smoking, occupational status
and alcohol consumption (Table 3). In women, high CMV
Table 1(a). Baseline characteristics of women according to cytomegalovirus immunoglobulin (Ig)G antibody titrers.
Characteristics
Cytomegalovirus IgG antibody titre quartiles
*P-value
1 2 3 4
<230 titre
(n = 297)
290–9 300
titre (n = 234)
9 400–15 000
titre (n = 289)
16 000–46 000
titre (n = 254)
Age (years)* 31·2 (4·9) 30·8 (5·0) 32·4 (5·0) 32·1 (4·7) 0·120
Smokers, % daily‡ 16·2 20·3 20·4 21·3 0·413
Occupational status, % manual‡§ 21·0 25·9 21·7 25·0 0·424
Education, % comprehensive school‡ 6·7 7·8 10·4 8·3 0·990
Body mass index (kg/m2)* 23·9 (4·1) 24·0 (4·4) 24·4 (4·3) 24·5 (4·6) 0·200
Waist circumference (cm)* 77·7 (10·3) 77·8 (10·6) 79·9 (11·2) 79·6 (11·7) 0·166
Waist–hip ratio* 0·79 (0·06) 0·78 (0·06) 0·80 (0·06) 0·80 (0·06) 0·145
Systolic blood pressure (mmHg)* 115·3 (12·2) 116·4 (12·2) 116·9 (11·6) 115·2 (12·8) 0·288
Diastolic blood pressure (mmHg)* 71·3 (8·2) 71·4 (9·1) 72·4 (8·1) 71·2 (8·9) 0·360
Total cholesterol (mmol/l)* 5·00 (0·84) 5·03 (0·88) 5·07 (0·91) 5·05 (0·96) 0·780
HDL cholesterol (mmol/l)* 1·40 (0·29) 1·44 (0·29) 1·38 (0·30) 1·38 (0·30) 0·302
LDL cholesterol (mmol/l)* 3·09 (0·73) 3·08 (0·75) 3·18 (0·75) 3·16 (0·82) 0·453
Triglycerides (mmol/l)† 1·00 (0·80–1·30) 1·00 (0·80–1·30) 1·00 (0·75–1·40) 1·00 (0·78–1·30) 0·591
Glucose (mmol/l)* 4·8 (0·5) 4·8 (0·6) 4·9 (0·8) 4·8 (1·1) 0·453
Insulin (mU/l)† 6·0 (5·0–8·0) 6·0 (4·0–8·0) 7·0 (5·0–9·0) 6·0 (4·0–9·0) 0·766
C-reactive protein (mg/l)† 0·77 (0·30–1·90) 1·00 (0·38–2·50) 0·84 (0·33–2·22) 0·80 (0·34–2·29) 0·941
Physical activity index*|| 17·7 (15·9) 16·2 (13·6) 15·8 (15·6) 16·4 (14·5) 0·886
Alcohol (no. drinks per week)* 3·4 (4·3) 4·2 (5·5) 3·7 (4·9) 3·9 (7·9) 0·763
IMT (mm)* 0·56 (0·08) 0·57 (0·09) 0·58 (0·09) 0·58 (0·08) 0·221
Cdist (%/10 mmHg)* 2·38 (0·81) 2·32 (0·71) 2·30 (0·76) 2·33 (0·76) 0·996
FMD (%)*# 8·49 (4·55) 8·73 (4·43) 8·72 (4·60) 9·24 (4·52) 0·070
*Mean values and standard deviation, t-test for difference between highest CMV antibody titrers compared to other groups. †Median values and
interquartile range (IQR), Mann–Whitney U-test for difference between highest CMV antibody titres compared to other groups. ‡Percentages and c2
test for difference between highest CMV antibody titres compared to other groups. §Data missing for 136 participants. ||Data missing for 231
participants. #Data missing for 62 participants. HDL: high-density lipoprotein; LDL: low-density lipoprotein; IMT: carotid intima-media thickness;
Cdist: carotid artery distensibility; FMD: flow-mediated dilation.
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antibody titres were not associated independently with FMD
(P = 0·112).
We also carried out a subanalysis in CMV seropositive
subjects. In men, high CMV antibody titres were associated
with age (P = 0·001), systolic blood pressure (P = 0·020),
diastolic blood pressure (P = 0·001), alcohol consumption
(P = 0·050) and FMD (P = 0·033). High CMV antibody titres
remained a significant determinant for systolic blood pres-
sure (P = 0·021), diastolic blood pressure (P = 0·005) and
FMD (P = 0·022) in the multivariable model. In seropositive
women, no significant associations were found between
CMV antibody titres and the risk factors or markers of early
atherosclerosis.
Discussion
In this study, we showed that high CMV antibody titres are
associated independently with blood pressure values and
associated inversely with FMD in young men. To our
knowledge, there are no prior studies demonstrating an
association between CMV antibody titres and blood pressure
in humans. Recently, in a Chinese cohort, Li et al. have
shown that plasma CMV DNA copy number is associated
with hypertension [17]. Additionally, they showed that
CMV-encoded microRNA, hcmv-miR-UL112, was highly
expressed in hypertensive patients. Further they showed that
hcmv-miR-UL112 could target interferon regulatory factor
1, which is related to up-regulation of angiotensin II type 2
receptor [26]. This pathway is one plausible pathological
mechanism between CMV infection and increased blood
pressure. An association between CMV infection and
increased arterial pressure has also been shown in mice [18].
Cheng et al. showed that CMV infection induced renin
expression in a dose-dependent manner in mouse and
human cells and that increased angiotensin-II, interleukin
(IL)-6, tumour necrosis factor (TNF)-a and monocyte
chemotactic protein-1 (MCP-1) levels were identified in
mouse serum. Both IL-6 and TNF-a levels have been shown
to correlate with increased blood pressure values [27,28].
The association shown in this study between high CMV
antibody titres and with blood pressure values in young men
supports the possible relationship between CMV infection
and blood pressure. Because renin, angiotensin-II, IL-6,
TNF-a and MCP-1 levels were not measured in this study,
we were not able to evaluate whether this association
depends on these factors. However, CRP concentrations,
Table 1(b). Baseline characteristics of men according to cytomegalovirus (CMV) immunoglobulin (Ig)G antibody titres.
Characteristics
Cytomegalovirus IgG antibody titre quartiles
P-value
1 2 3 4
<230 titre
(n = 292)
240–5 400
titre (n = 139)
5500–10 000
titre (n = 206)
11 000–35 000
titre (n = 220)
Age (years)* 30·8 (4·8) 31·6 (4·9) 31·5 (5·0) 33·0 (5·1) <0·001
Smokers, % daily‡ 23·4 39·6 30·6 28·2 0·796
Occupational status, % manual‡** 42·5 43·3 45·8 43·5 0·934
Education, % comprehensive school‡ 7·2 11·5 5·3 5·9 0·451
Body mass index (kg/m2)* 25·8 (4·1) 25·5 (3·8) 25·3 (3·6) 26·1 (4·0) 0·126
Waist circumference (cm)* 89·9 (11·4) 89·6 (10·5) 88·7 (10·0) 90·2 (10·7) 0·374
Waist–hip ratio* 0·89 (0·06) 0·90 (0·07) 0·89 (0·06) 0·90 (0·06) 0·347
Systolic blood pressure (mmHg)* 129·2 (13·2) 127·5 (12·1) 128·1 (11·9) 130·8 (16·4) 0·053
Diastolic blood pressure (mmHg)* 74·5 (8·8) 73·9 (8·1) 74·0 (7·8) 76·8 (10·8) 0·002
Total cholesterol (mmol/l)* 5·12 (0·99) 5·27 (1·11) 5·26 (0·96) 5·25 (1·00) 0·536
HDL cholesterol (mmol/l)* 1·16 (0·27) 1·17 (0·28) 1·17 (0·28) 1·15 (0·27) 0·282
LDL cholesterol (mmol/l)* 3·34 (0·90) 3·45 (0·97) 3·45 (0·88) 3·45 (0·88) 0·478
Triglycerides (mmol/l)† 1·20 (0·90–1·70) 1·30 (0·90–1·90) 1·20 (0·90–1·80) 1·30 (0·90–1·80) 0·460
Glucose (mmol/l)* 5·2 (0·5) 5·3 (1·6) 5·2 (0·5) 5·2 (0·5) 0·850
Insulin (mU/l)† 6·0 (4·0–9·0) 6·0 (4·0–9·0) 6·0 (4·0–9·0) 7·0 (4·3–9·0) 0·329
C-reactive protein (mg/l)† 0·56 (0·29–1·25) 0·70 (0·26–1·51) 0·52 (0·27–1·33) 0·62 (0·30–1·43) 0·236
Physical activity index*,†† 18·3 (18·3) 13·1 (15·0) 15·3 (16·9) 15·1 (16·7) 0·436
Alcohol (no. drinks per week)* 8·2 (9·3) 10·6 (12·9) 8·5 (8·3) 7·6 (10·0) 0·123
IMT (mm)* 0·59 (0·10) 0·59 (0·09) 0·60 (0·10) 0·59 (0·11) 0·811
Cdist (%/10 mmHg)* 2·04 (0·67) 1·99 (0·64) 2·03 (0·65) 1·94 (0·66) 0·086
FMD (%)*‡‡ 7·17 (3·96) 6·96 (4·03) 7·23 (4·42) 6·36 (3·69) 0·013
*Mean values and standard deviation, t-test for difference between highest CMV antibody titrers compared to other groups. †Median values and
interquartile range (IQR), Mann–Whitney U-test for difference between highest CMV antibody titres compared to other groups. ‡Percentages and c2
test for difference between highest CMV antibody titres compared to other groups. **Data missing for 126 participants. ††Data missing for 91
participants. ‡‡Data missing for 79 participants. HDL: high-density lipoprotein; LDL: low-density lipoprotein; IMT: carotid intima-media thickness;
Cdist: carotid artery distensibility; FMD: flow-mediated dilation.
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which are considered to be indicators of systemic low-grade
inflammation, were available from the present cohort. We
found that CRP concentrations did not differ between CMV
antibody titre quartiles and that the association between
CMV antibody titres and blood pressure values was not
attenuated after adjustment with CRP.However, it is possible
that CMV may mediate other inflammatory pathways than
CRP. Based on the works of Li et al. and Cheng et al., it can be
speculated that the activation of the renin–angiotensin
system (RAS) is possibly an underlying mediator behind
these findings. It is possible that high CMV antibody titres
are indicators of frequent reactivation of CMV or reinfection
with new strains of CMV, leading to stronger immunity in
these individuals. CMV activity may lead to an increased
RAS activation, leading to arterial constriction via the influ-
ence of angiotensin-II, a mechanism that possibly explains
the observed increased blood pressure values in this study.
The association between CMV infection and endothelial
function has been reported previously in relatively small
study populations, but the findings have not been consistent.
In a population consisting of paediatric heart transplant
patients (n = 50), Simmond et al. demonstrated that
decreased FMD is associated with CMV replication after
transplantation [12]. In a middle-aged population (mean
age 38 years), which consisted of diabetic and non-diabetic
subjects (n = 157), Grahame-Clarke et al. showed that CMV
seropositivity was associated with impaired vascular func-
tion measured by venous occlusion plethysmography with
bradykinin and glyceryl trinitrate [13]. Additionally, CMV
infection has been shown to cause arterial dysfunction in a
mouse model [29]. However, negative findings have also
been reported in small cohorts, which consisted of young
Japanese men (n = 81) [16] and young Canadian men
(n = 65) [15]. In our study we demonstrated for the first
time, in a large cohort of young men (n = 657), that high
Table 2. Determinants of systolic and diastolic blood pressure in a multivariate linear regression model in men (n = 730).
Blood pressure Risk variable b" s.e. P-value
Systolic Age (years) 0·026" 0·101 0·800
Body mass index (kg/m2) 0·868" 0·161 <0·001
HDL cholesterol (mmol/l) 3·215" 2·027 0·113
Triglycerides (mmol/l) 7·840" 2·955 0·008
Insulin (mU/l) 6·898" 2·553 0·007
C-reactive protein (mg/l) 1·452" 1·092 0·184
Smoking (daily) -3·147" 1·098 0·004
Non-manual occupation -2·438" 0·991 0·014
Alcohol (no. drinks per week) 0·087" 0·049 0·075
High CMV antibody (titre) 2·367" 1·084 0·029
R2 = 0·181
Diastolic Age (years) 0·385" 0·063 <0·001
Body mass index (kg/m2) 0·431" 0·099 <0·001
HDL cholesterol (mmol/l) 3·895" 1·252 0·002
Triglycerides (mmol/l) 8·742" 1·825 <0·001
Insulin (mU/l) 5·387" 1·577 0·001
C-reactive protein (mg/l) 0·928" 0·674 0·169
Smoking (daily) -2·114" 0·678 0·002
Non-manual occupation -2·151" 0·612 <0·001
Alcohol (no. drinks per week) 0·095" 0·030 0·002
High CMV antibody (titre) 1·927" 0·669 0·004
R2 = 0·275
High CMV antibody (titre); CMV antibody titres were parameterized with a dummy variable comparing the highest quartile with the bottom three
quartiles combined. HDL: high-density lipoprotein; CMV: cytomegalovirus.
Table 3. Determinants of flow-mediated dilation in a multivariate
linear regression model in men (n = 657).
Risk variable b" s.e. P-value
Age (years) 0·004" 0·032 0·929
Baseline brachial diameter (mm) -2·828" 0·361 <0·001
Body mass index (kg/m2) 0·236" 0·054 <0·001
Systolic blood pressure (mmHg) -0·025" 0·013 0·050
HDL cholesterol (mmol/l) 0·355" 0·641 0·580
Triglycerides (mmol/l) -0·098" 0·945 0·917
Insulin (mU/l) -0·209" 0·819 0·799
C-reactive protein (mg/l) -0·093" 0·346 0·787
Smoking (daily) -0·273" 0·351 0·436
Non-manual occupation -0·386" 0·313 0·219
Alcohol (no. drinks per week) -0·019" 0·016 0·231
High CMV antibody (titre) -0·844" 0·343 0·014
R2 = 0·118
High CMV antibody (titre); CMV antibody titres were parameter-
ized with a dummy variable comparing the highest quartile with the
bottom three quartiles combined. HDL: high-density lipoprotein;
s.e.: standard error.
Cytomegalovirus, blood pressure and FMD
313© 2012 The Authors
Clinical and Experimental Immunology © 2012 British Society for Immunology, Clinical and Experimental Immunology, 167: 309–316
CMV antibody titres were associated independently with
endothelial function. In vitro, CMV infection has been
shown to activate the P38-mitogen-activated protein kinase
(MAPK) signalling pathway and up-regulate phosphatase
and tensin homologue [30,31]. Via this pathway, endothelial
nitric oxide synthase is inhibited and reduced nitric oxide
(NO) production leads to endothelial dysfunction [32,33].
The association between CMV and endothelial dysfunction
has been hypothesized further to be one possible pathologi-
cal mechanism of hypertension [33]. This mechanism is
a possible explanation for the demonstrated association
between CMV and reduced FMD in our study, and it is also
a possible alternative explanation for the demonstrated asso-
ciation between CMV and increased blood pressure. In this
study, high CMV antibody titres were not associated with
IMT or Cdist. Previously, in a cohort consisting of middle-
aged subjects, high CMV antibody titres were shown to be a
risk factor for increased IMT [14]. One possible explanation
for this discrepancy between the results could be the age
difference between the cohorts. Possible deleterious effects of
CMV immune response on IMT may not be currently
detectable in young adult ages.
In this study, CMV antibody titres were significantly
higher among women, an observation that has also been
seen in other populations [2]. Interestingly, high CMV anti-
body titres were not associated with decreased FMD values
or with increased blood pressure values in women. Thus, it
might be possible that CMV infection leads to dissimilar
immune responses and subclinical manifestations in women
and men. Zhu et al. found that the association of an immune
response to CMV and the risk of coronary artery disease
differed between the sexes [34]. In their study, coronary
artery disease risk was increased among women who had
humoral antibodies against CMV but not in those women
who had only a cell-mediated immune response to CMV. In
men, there was no difference between different immune
responses and coronary artery disease risk. Our work also
supports the hypothesis that immune responses to CMV
may differ between the sexes. Zhu et al. proposed that the
differences in the findings between the sexes may be due to
the association found between CMV and CRP in men, but
not in women. In our study, CMV antibody titres were not
associated with CRP.All in all, we did not find any significant
implications for high CMV antibody titres in young women.
Based on our current knowledge, we do not have an expla-
nation for the observed sex-related differences in our results.
The role of CMV as a risk factor for CVD is controversial.
A great deal of previous studies investigated the role of CMV
seropositivity as a risk factor for CVD indices [6,7,10]. Few
studies have investigated the role of CMV antibody titres
[8,9,11]. Regardless of the approach, both negative and posi-
tive associations have been reported. Numerous mechanisms
have been reported on how CMV infection may lead to the
development and exacerbation of atherosclerosis. CMV has
been shown to infect human endothelial cells [35] and leu-
cocytes [36]. Infection of these cells leads to neutrophil
transendothelial migration [37], smooth muscle cell migra-
tion [38], intracellular adhesion molecule expression and
leucocyte adhesion [39]. Conversely, it has been demon-
strated that CMV-independent TNF-a production can
induce CMV reactivation [40]. Thus, the alternative expla-
nation could also be the reverse causality. High CMV anti-
body titres might be a result of immunoresponses stimulated
by pathological changes independent of CMV.
In this study, the subjects with high CMV antibody titres
were compared to those with moderate, low or seronegative
CMV antibody titres, whereas the traditional set-up has been
to compare seropositive and seronegative subjects. The latter
set-up may be problematic due to the high prevalence of the
virus in humans. More than half of humans have serological
evidence of CMV infection and it is also possible that there
are some seronegative cases that have had prior CMV infec-
tion without leaving detectable serological evidence. This
methodology raises the question of how an almost ubiqui-
tous infection could be a sole risk factor. Along these lines,
we used a set-up where subjects with high CMV antibody
titres were compared to other subjects. This strong antibody-
specific immunity against CMV could be the result of
various factors: severe primary infection, recent infection,
reinfections of CMV with a different strain, frequent reacti-
vations of the virus in the body or non-viral-related indi-
vidual differences in immunity. The advantage of this set-up
is that these subjects certainly have a strong CMV-specific
humoral immune response, but conversely, we do not know
what mechanism may have caused it. Further studies are
needed to differentiate the aetiology of strong CMV-specific
immune response. Because our study cohort was ethnically
homogeneous, the generalizability of our results is limited to
white European subjects. It is also important to remember
that observational studies cannot establish causality.
In conclusion, this study showed that high CMV antibody
titres associate directly with blood pressure and inversely
with FMD in young men. These associations were not found
in women. Our results support the idea that this common
virus could be a risk factor for unfavourable changes in the
cardiovascular system at an early age.
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